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Abstract 
Background: Globally there is no consensus on haemoglobin (Hb) parameters that 
define maternal anaemia. Therefore it is difficult to distinguish physiological anaemia 
of pregnancy from anaemia associated with pathology. Low maternal iron status is 
associated with adverse outcomes, although the evidence is difficult to interpret.  
Non-anaemic iron deficiency requires prevention and treatment, before end stage 
iron deficiency anaemia.  Increases in serum ferritin (SF) secondary to inflammation, 
gives misleading results of iron stores if not tested with C-reactive protein (CRP). 
Given the complexities, how do Lead Maternity Carer (LMC) midwives in New 
Zealand manage anaemia and iron deficiency, without a clinical guideline? 
Methods: In this descriptive study, quantitative data was retrospectively collected 
from September-December 2013, from LMC midwives (n=21) and women (n=189), in 
one New Zealand area.  Main outcomes assessed were women’s iron status. Anaemia 
was defined as Hb <110g/L in the first trimester, <105g/L in subsequent trimesters, 
and <100g/L postnatally. Iron deficiency was defined as SF <20 µg/L, if CRP<5mg/L. A 
secondary analysis of iron status and body mass index (BMI) was undertaken. 
Results: Of the 186 women who had Hb testing at booking, 46% did not have ferritin 
tested concurrently. Of the 385 ferritin tests undertaken, 86% were not tested with 
CRP. Despite midwives prescribing iron for 48.7%, and recommending iron for 16.9% 
of second trimester women, 47.1% had low iron status before birth. Only 22.8% had 
Hb testing postpartum, including 65.1% (of 38) with blood loss >500mls. Results of a 
secondary analysis showed a significant difference (p=.05) between third trimester 
ferritin levels in women with BMI ≥ 25 (Md SF 14 µg/L) and BMI < 25 (Md SF 18 µg/L). 
Conclusions: Inconsistent testing of ferritin made it difficult to assess maternal iron 
status, especially without concurrent testing of CRP. Midwives may not understand 
and recognise the progression from iron sufficiency to end-stage iron deficiency 
anaemia. Even without further research this small study may indicate the need for 
improved education for midwives, and a clinical guideline. More complex studies on 
the prevalence in New Zealand, BMI and iron status, and maternal outcomes 
especially in the postpartum period, are warranted.  
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Glossary of terms 
Absent iron stores:  very low or absent iron stores, insufficient for erythropoeisis, i.e. 
SF < 12 µg/L. 
Anaemia: Low haemoglobin levels (defined as: first trimester Hb <110g/L, second 
trimester Hb < 105g/L, third trimester Hb < 105 g/L, early postpartum Hb <100g/L). 
Anaemia of chronic disease (ACD), or anaemia of inflammation: A type of functional 
iron deficiency where, due to the presence of inflammation, hepcidin decreases iron 
uptake in the gut and limits the amount of iron available in the body for 
erythropoeisis. 
Body Mass Index (BMI): a measure of body fat based on weight and height in kg/m². 
Complete blood count (CBC): single test which in New Zealand includes haemoglobin 
count, white cell count, and RBC indices i.e. MCV, MCH, and Hct. 
C-reactive protein (CRP): acute phase protein and measure of inflammation if CRP 
>5mg/L. 
Erythropoeisis: production of red blood cells, in the bone marrow of adults. 
Haematocrit (Hct): the number of RBCs packed by centrifuge in a given volume of 
blood. 
Haemoglobin (Hb):  the iron containing protein in RBCs that binds to oxygen, for 
oxygen transport to the tissues. 
Haemoglobinopathy (HbP): general term for haemoglobin abnormalities i.e. sickle 
cell disease and thalassaemia. 
Hepcidin: liver hormone and master regulator of iron metabolism.  
Iron deficiency (ID): low iron stores (defined as: SF < 20 µg/L, or SF <50 µg/L if CRP 
>5mg/L). 
Iron deficiency anaemia (IDA): low iron stores and anaemia. 
Iron sufficiency: non-anaemic and non-iron deficient. 
KNOV: The Royal Dutch Organisation of Midwives. 
Lead Maternity Carer (LMC): primary maternity care provider, chosen by the woman, 
to provide continuity of care from early pregnancy until 6 weeks after the birth.  
Low birth weight (LBW):  neonates weighing less than 2500 gms. 
Mean cell volume (MCV): size of the red blood cells. 
Mean cell haemoglobin (MCH): average weight or mass of haemoglobin. 
Non-anaemic iron deficiency (NAID): normal haemoglobin, and low or absent iron 
stores (SF <20 µg/L, or SF <50 µg/L if CRP >5mg/L). 
Over the counter oral iron (OTC): includes liquid/tablet iron supplements, 
multivitamins and minerals, and herbal preparations. 
Red blood cells (RBCs): or erythrocytes carry oxygen, nutrients and wastes to and 
from the tissues. 
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Serum ferritin (SF):  a multifunctional acute-phase protein that measures iron stores, 
and inflammation. 
Sickle cell disease: genetic blood disorder resulting in abnormally shaped red blood 
cells. 
Small for gestational age (SGA): neonate weighing less than the 10th percentile. 
Thalassaemia: genetic blood disorder, resulting in mild or severe microcytic anaemia, 
and possible iron overload.  
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Chapter One: Introduction and Background 
Introduction 
There are no national guidelines In New Zealand for the diagnosis and treatment of 
maternal anaemia, non-anaemic iron deficiency (NAID) and iron deficiency anaemia 
(IDA). So how do New Zealand midwives, the main providers of primary maternity 
care, manage low maternal iron status in pregnancy and the postpartum period? This 
thesis reports on a study that describes a snapshot of New Zealand Lead Maternity 
Carer (LMC) midwives current practice in the diagnosis and treatment of maternal 
anaemia and iron deficiency, as little is known about actual practice in this clinical 
area. The research design used was a retrospective descriptive study, utilising 
quantitative data on midwives’ practice, and haematological and clinical outcomes of 
women in their care. In addition to contributing to a body of knowledge about 
maternal anaemia and iron deficiency, from a unique New Zealand midwifery 
perspective, the main objective of this study was to clarify whether there is a need 
for a midwifery, or multi-disciplinary guideline, to inform practice and improve care 
of mothers and babies. 
New Zealand’s maternity care system is recognised internationally as a unique model 
that promotes normal birth, by promoting primary midwifery care (Grigg & Tracy, 
2013). The model is based on the partnership between the woman and the midwife. 
The midwife provides primary care as an autonomous practitioner within her scope 
of professional practice (Guilliland & Pairman, 1995). Under section 88 of the New 
Zealand Public Health and Disability Act 2007 (Ministry of Health (MOH), 2007) 
women can choose a midwife, general practitioner doctor, or obstetric specialist as 
their LMC to provide care throughout pregnancy, birth and the postnatal period. In 
2012 the majority of women (88.8%) registered with midwives as their LMCs (MOH, 
2015). 
The midwifery profession in New Zealand draws on the theory of evidence-based 
practice as the framework that guides practice. One of the challenges of the 
theoretical perspective of evidence based practice is closing the gaps between 
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knowledge, education and practice (Spiby & Munro, 2010).  However the evidence 
around maternal anaemia and iron deficiency is surprisingly complicated and 
contentious. 
As primary maternity care providers, New Zealand LMC midwives provide continuity 
of care from early in pregnancy, to up to six weeks postpartum.  LMC midwives assess 
women’s iron status throughout pregnancy, give dietary advice, and prescribe or 
recommend oral iron treatment options, if indicated. But there are difficulties in 
diagnosing anaemia and iron deficiency as internationally there is no clear consensus 
regarding diagnostic criteria. This makes it problematic for midwives to distinguish 
normal physiological anaemia of pregnancy from anaemia requiring treatment, or 
anaemia associated with underlying pathology.  
Globally, poor maternal iron status has been associated with increased mortality, 
morbidity and adverse outcomes for mothers, babies and infants. These adverse 
outcomes are controversial and challenging to evaluate because of the multi-factorial 
nature of anaemia, and the heterogeneity of studies that make it difficult to pool 
data for meta-analyses (National Blood Authority (NBA), 2015). There is clear 
evidence however, that maternal anaemia is associated with a high utilisation of 
hospital resources and a nine-fold increase in blood transfusion (James et al., 2008).  
But the overarching question of whether there is evidence that iron supplementation 
improves outcomes for women and babies remains difficult to elucidate (and beyond 
the scope of this study), and requires more research (Barroso et al., 2011; Crowther, 
2010; Jans, 2012; Wiegerinck & Mole, 2012).  
Although the current study focuses on primary midwifery care, medical research and 
scientific data have provided most of the evidence on anaemia and iron deficiency. 
Therefore, the background and literature review are informed by a wide range of 
disciplines as well as midwifery, including: obstetrics, pharmacology, haematology, 
neonatology, paediatrics, pathology, nutrition, public health and epidemiology.   
To provide a context for this study, the background includes overviews on global 
prevalence, iron metabolism, and the effects of low maternal iron status.  This 
background is detailed because of the complexity of the essential role of iron; an 
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element that is fundamental to life, that affects the development and functioning of 
every bodily system. It is therefore important to have some understanding of why, 
and to what extent low maternal iron status is a problem, if we are to diagnose and 
treat anaemia and iron deficiency. These overviews include what is known about 
maternal anaemia and iron deficiency in New Zealand, from an evidence-based 
midwifery perspective. 
Research problem 
On the surface, maternal anaemia is “seemingly straightforward”, but there are large 
gaps between evidence and practice (Amelink-Verburg, Herschderfer, Offerhaus & 
Buitendijk, 2010, p. 28), and the clinical issues are complex. This study began with the 
idea of exploring the overarching question of how do midwives in New Zealand 
distinguish normal physiological anaemia of pregnancy from anaemia requiring 
treatment, or anaemia associated with pathology? A clear definition of anaemia is 
fundamental in making this distinction. However the boundaries between 
physiological and pathological anaemia in pregnancy are not well understood or 
defined. The Royal Dutch Organisation of Midwives (KNOV) sought to address these 
issues with the introduction in 2000 of a primary care evidence-based midwifery 
guideline on anaemia for low risk women (Amelink-Verburg et al., 2010). This 
guideline is particularly relevant to this study, given the similarities between the New 
Zealand and the Dutch models of maternity care. 
The rationale for the KNOV anaemia guideline was therefore partly motivated by the 
fact that “there is no global consensus on the definition of anaemia and Hb cut-off 
points vary” (Amelink-Verburg et al., 2010, p. 27). The World Health Organisation’s 
(WHO) 1968 definition of anaemia in pregnancy as a haemoglobin (Hb) of less than 
110g/L is the most often cited, although considered statistically flawed (McMahon, 
2010) as it does not distinguish differences between races (Pasricha, Drakesmith, 
Black, Hipgrave & Biggs, 2013). This limits the applicability of the WHO anaemia 
definition to the Australasian population (NBA, 2015).  
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The research question, aims and objectives 
Without  clinical guidance it is unclear how New Zealand primary care midwives 
actually manage maternal iron status in practice. Therefore the study’s research 
question was: “what is LMC midwives’ practice around management of women’s 
Hb<110g/L and/or serum ferritin <20mcg/L, during pregnancy and postpartum?”  
The overall aim of the research was to ascertain whether there may be a need for a 
consensus statement or guideline for New Zealand midwives, in the diagnosis and 
treatment of maternal anaemia, NAID and IDA. As well as beginning to address the 
lack of New Zealand research on maternal iron status, the specific study objectives 
were: 
 To ascertain levels of consistency of New Zealand LMC midwives’ testing and 
diagnosis of maternal anaemia and iron deficiency.  
 To describe New Zealand LMC midwives’ practice around recommending or 
prescribing iron supplementation in relation to iron status and gestation.  
The exploratory nature of this study contributes to the small body of global 
midwifery research on maternal iron status, from a unique New Zealand midwifery 
perspective based on continuity of care (Grigg & Tracy, 2013). 
Background 
Physiology of iron metabolism   
An overview of iron metabolism is an important background to this study. In addition 
to the traditional understanding of iron metabolism, new knowledge has deepened 
our understanding of the complexities  of how iron  is absorbed and used in the body, 
especially in the presence of inflammation. Understanding the physiology of iron is 
fundamental if midwives are to accurately diagnose and treat anaemia and iron 
deficiency, and recognise the factors that affect iron status in pregnancy and 
postpartum.     
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It is well known that the primary function of iron is  the synthesis of haemoglobin for 
transport of oxygen to all the tissues in the body. Iron is also absolutely essential for 
all cell growth and body systems (Barut & Harma, 2009), including neural and 
cognitive development and function in the young and adult brain (Bodnar, Cogswell 
& McDonald, 2005; Morton et al., 2014). Iron is also a component of certain enzymes 
needed for catecholamine neurotransmitter function, and for the production of 
adenosine tri-phosphate for cell respiration and energy (Jordan, 2010).  
Dietary iron is absorbed and eliminated by mucosal cells in the gut wall and 
transported to plasma where it is bound to the transport protein transferrin. Dietary 
sources of non-haem ferric iron (found in grains, fruits and vegetables), are converted 
to ferrous iron, as only ferrous and haem iron are available for absorption (Elias, 
2007; Milman, 2006). Haem iron is found in fish, meats and poultry. Iron absorption 
is physiologically promoted by depleted or absent iron stores, increased 
erythropoiesis during pregnancy, and by blood loss around the time of birth (Milman 
2006). Erythropoiesis is the production of red blood cells (RBCs) in the bone marrow 
(Rosto, 2009), and is totally dependent on iron. 
In the last decade, knowledge of iron metabolism has significantly changed with the 
discovery of the liver hormone hepcidin; as the master regulator of systemic 
bioavailabilty of iron in humans (Koenig, Tussing-Humphreys, Day, Cadwell & 
Nemeth, 2014). In the presence of acute or chronic infection or inflammation, 
hepcidin regulates body iron by decreasing iron uptake in the gut, as well as 
decreasing availability of iron in the body for erythropoiesis (Koenig et al., 2014; 
Wang, Knovich, Coffman, Torti & Torti, 2010). This defence mechanism is presumed 
to have developed to restrict iron’s availability for pathogens and micro-organisms to 
grow (Friedman et al., 2012; Wang et al., 2010).  
Approximately 70% of the body’s iron is in haemoglobin, the oxygen carrying 
substance on RBCs (Rosto, 2009); 3% is in myoglobin an intramuscular oxygen store 
(Jordan, 2010). The remainder of iron is predominantly stored within ferritin, in the 
reticuloendothelial tissue cells in the bone marrow, the liver, spleen and gut (Koenig 
et al., 2014). This intracellular iron is stored as an iron core within the hollow, 
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spherical glycoprotein ferritin molecules (WHO, 2011), that protect the cells from the 
toxicity of free iron (Milman, 2006). A single iron core within a ferritin molecule may 
contain up to 4000-4500 iron atoms (WHO, 2011). When body iron reserves are 
small, the iron is present in ferritin. With larger iron reserves, ferritin is condensed to 
haemosiderin which can be visualised in bone marrow biopsy (Wang et al., 2010). 
Non-anaemic iron deficiency and iron deficiency anaemia  
Iron deficiency is on the spectrum ranging from iron sufficiency to iron deficiency 
anaemia (Pavord et al., 2012). From normal body iron stores (iron sufficiency), 
depletion progresses to deficient, then absent iron stores. An absence of iron stores 
for erythropoiesis forces haemoglobin (functional iron) to be used up for the limited 
production of red blood cells, resulting in IDA. Iron deficiency anaemia is therefore, a 
depletion or absence of iron stores with a low Hb. The decrease in Hb is preceded by 
depletion of iron stores, and is the end stage, and most severe form of iron deficiency 
(Pavord et al., 2012).    
In general, anaemia can result from decreased production of RBCs, increased 
destruction of RBCs, or blood loss (Smith, 2010). During pregnancy, iron deficiency is 
the most common cause of anaemia (Haider et al., 2013; Pasricha, 2012). However 
anaemia, NAID and IDA are often multi-factorial and may be difficult to diagnose due 
to co-existing conditions such as: infections, inflammation, parasitic diseases (e.g. 
malaria and hookworm), micronutrient deficiencies (e.g. folic acid and vitamin B12), 
inherited haemoglobinopathies (e.g. thalassaemia and sickle cell disease), gastro-
intestinal and menstrual blood loss in premenopausal women (Goonewardene, 
Shehata & Hamad, 2012; Pasricha et al., 2010). Because of the decreased 
bioavailability and sequestering of iron, secondary to acute or chronic infections or 
inflammation, anaemia of inflammation is now recognised as the second most 
prevalent cause of anaemia, after iron deficiency (Friedman et al, 2012).  
Diagnoses of anaemia and IDA are further complicated by the normal physiological 
changes of pregnancy and haematological values (Jordan, 2010). A greater increase in 
plasma volume (40-50%) compared to the red cell mass increase (≤30%) results in 
normal physiological haemodilution and anaemia of pregnancy (Baddock, 2015). 
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Normal physiological haemodilution of pregnancy reduces blood viscosity, thereby 
increasing placental and fetal perfusion and oxygenation, whilst also minimising the 
risks of stasis and thrombosis (Walsh et al., 2011; Ziaei, Norrozi, Faghihzadeh & 
Jafarbegloo, 2007).  
Frye (2007) states the normal haemoglobin drop in pregnancy of 20g/L by 28-30 
weeks gestation is an excellent indicator of expanded blood volume, although this 
drop is not quantified so precisely elsewhere in the literature. Conversely, extreme 
haemo-concentration with Hb>145g/L in early pregnancy, or Hb > 132 g/L mid 
pregnancy may herald fetal growth restriction, or even demise (Rasmussen, Bergsjo, 
Jacobsen, Harem & Bakketeig, 2005; Ziaei et al., 2007). There is considerable 
individual variation in the degree of haemodilution, with the nadir of haemoglobin 
estimated to be between 24-28 (Graves & Barger, 2001) or 24-32 weeks gestation 
(Milman, 2006).  
Iron requirements in pregnancy and postpartum 
Pregnancy, birth and lactation dramatically increase the demand for iron due to the 
increased demands of the fetoplacental unit and increased maternal red cell mass 
(Bhandall & Russell, 2006). Estimates of the total demand throughout pregnancy 
range from 800-1000mg (Barut & Harma, 2009) to 1200mg (McMahon, 2010).  
Requirements for absorbed iron increase through pregnancy from 0.8mg/day in the 
first trimester to 7.5mg/day in the third trimester, an average requirement of 
4.4mg/day (Milman, 2006).  
Although iron demands increase, iron absorption also increases from 30% (James, 
Steer, Weiner & Gonik, 2006) to 70 % (Jordan, 2010), in response to decreasing iron 
stores. Women with ample iron reserves have less of an increase in iron absorption 
(Milman 2006). However, few women enter conception with sufficient iron stores to 
meet the extra iron demands of pregnancy (McMahon, 2010). 
The growing fetus  receives iron  even when the mother is iron deficient (Barut & 
Harma, 2009). Fetal iron demands are greatest in the third trimester (McMahon, 
2010), when there is a transfer of iron from the mother’s iron stores to her baby to 
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establish good neonatal iron stores (Monti, 2004). There is strong evidence that 
delayed cord clamping at birth, also improves neonatal iron status (Andersson, 
Hellstrom-Westas, Andersson, & Domellof, 2011).  
Blood loss at delivery further exacerbates the demand for iron. Barut and Harma 
(2009) estimate that 7% of vaginal deliveries have an estimated blood loss (EBL) of 
≥1000mls, with 23% of caesareans associated with an EBL of 1000-1500ml. In the 
study area, the District Health Board 2014 statistics are lower with 5.9% of vaginal 
births, and 9.0% of caesareans associated with EBL ≥1000mls.  
In the postpartum period, plasma volume decreases, primarily via diuresis. In the first 
two months postpartum, a significant amount of iron is returned to body stores from 
the erythron mass (McMahon, 2010). For postpartum women, breastfeeding 
removes about 1gm of iron per day, but this iron demand is partly mitigated by 
lactational amenorrhoea (Pasricha et al., 2010). These processes result in a 
substantial rise in haemoglobin levels over this time (James et al., 2006; Friedman et 
al., 2012). 
Effects of low maternal iron status 
Anecdotally, and in the literature,  some midwives debate  the evidence of adverse 
effects of low iron status on pregnancy and postpartum, and the benefits of iron 
supplementation (Amelink-Verburg et al., 2010; Jans, 2012; Graves & Barger, 2001; 
Grigg, 2015).  Some New Zealand midwives may therefore, be less pro-active in their 
approach to preventing or managing anaemia, and iron deficiency in pregnancy. 
Evidence does indicate that the effects of iron deficiency, even without anaemia, 
causes tissue enzyme malfunction and functional impairment (WHO, 2001). This 
brings in to focus NAID as an important clinical issue requiring prevention and 
treatment in pregnancy and postpartum (Goonewardene et al., 2012; Grigg, 2015; 
Pavord et al., 2012).  
A recent UK study (Daru et al., 2015) examined the views and opinions of 148 
midwives, obstetricians, anaesthetists and haematologists, on NAID in pregnancy. 
The study found that all clinicians were interested in testing for NAID as a target 
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condition, if proven to be effective at improving maternal and neonatal outcomes. 
Daru et al.’s (2015) finding highlights an underlying question posed in this study: if it 
is important to diagnose and treat anaemia and iron deficiency in pregnancy, why is 
the evidence so difficult to decipher? 
At a population and individual level, the causes of anaemia and iron deficiency are 
often multi-factorial, and associated with other pregnancy risks such as poor 
nutrition and low socio-economic status (Pasricha et al., 2013; Pavord et al., 2012). It 
is difficult to clearly establish adverse outcomes related to low iron status due to the 
heterogeneity of clinical trials on iron interventions.  The ranges of the variables 
studied in clinical trials are heterogenous and very wide, i.e: different haemoglobin 
and serum ferritin parameters, interventions including different doses and routes of 
administration, populations, study sizes and outcomes (NBA, 2015). The 
heterogeneity of randomised clinical trials (RCTs) has, therefore, made the outcomes 
difficult to pool in meta-analyses such as the Cochrane Collaboration (Dodd, Dare & 
Middleton, 2009; Reveiz, Gyte, Cuervo, 2007).  
A Cochrane review (Dodd et al., 2009) is also critical of the over-emphasis on 
haematological indices in studies on maternal iron status, rather than clinical or 
maternal outcomes. This over-emphasis has resulted in a substantial body of 
evidence on the positive effects of iron therapy on the so called soft values (i.e. 
laboratory values), whilst the evidence of effects on hard values, or clinical outcomes 
is much smaller (Milman, 2012a). The discussion below is an overview of the 
evidence of specific risks associated with maternal anaemia and iron deficiency. As 
Pasricha (2012) succinctly says “it is important not to confuse no evidence of an 
effect, with evidence of no effect” (p.143). 
 Quality of life, fatigue, cognition and postnatal depression 
Iron deficiency impacts directly on cognitive function in the adult and infant brain 
(Bodnar et al., 2005; Morton et al., 2014). Reduced iron in the brain alters iron 
containing enzymes, neurotransmitter function, cellular and oxidation processes 
(Beard et al., 2005), infant brain development (Morton et al., 2014), and thyroid 
hormone metabolism (Bodnar et al., 2005). Anaemia and iron deficiency are 
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therefore physiologic factors that are associated with maternal depression; 
contributing to fatigue, apathy and inability to concentrate (Corwin, Murray-Kolb, & 
Beard, 2003).     
There are strong recommendations in the literature for good quality research on low 
maternal iron status,  psychological functioning and quality of life (QOL), (Allen, 2000; 
Barroso et al., 2011; Dodd et al., 2009; James et al., 2008; Makrides, Crowther, 
Gibson & Skeaff, 2003; Milman, 2012b). However, very few studies have been 
undertaken. Many psychosocial factors influence maternal depression, including child 
care stress, infant temperament, low self esteem and poor social support (Corwin et 
al., 2003; Waldie et al., 2015). The lack of research may reflect the difficulties of 
analysing subjective and multidimensional risk factors, variables and outcomes, as 
well as the sensitivity of tools such as the Edinburgh Postnatal Depression Score 
(EPDS) and SF26 to measure QOL (Ross et al., 2003).  
A recent study of 5664 pregnant women in New Zealand, found that one in eight 
(11.9%) women were depressed during pregnancy, with EPDS scores >12 (Waldie et 
al., 2015). These women were also more likely to eat poorly and smoke (Waldie et al., 
2015). In comparison, the prevalence of minor postnatal depression (PND) in the USA 
is estimated at 19%, and major PND at 12% (Corwin et al., 2003). The New Zealand 
Perinatal Maternal Mortality Review Committee Report (PMMRC, 2015) found that 
maternal suicide is the most common indirect cause of maternal mortality in New 
Zealand, with 21 women taking their lives during pregnancy and postpartum, from 
2006-2013. Investigating this has become a priority for the PMMRC (2015). There is 
no prevalence data on maternal anaemia and iron deficiency in New Zealand (Morton 
et al., 2014). However, there may be an un-studied association between the high 
rates of depression, maternal suicide, and poor iron status in New Zealand. 
A study of 81 poor South African mothers demonstrated a significant association 
between postpartum IDA, depression and stress with the association more evident at 
nine months than ten weeks postpartum (Beard et al., 2005). This suggested a 
cumulative effect of both iron deficiency and environmental factors such as fatigue, 
poverty and hunger. There was a 25% improvement in depression and stress scales in 
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the women who received 125mg iron/day, despite ongoing environmental stresses 
(Beard et al., 2005).  
As part of the same larger study, Perez at al. (2005) found that at ten weeks 
postpartum, anaemic mothers were less responsive and more controlling of their 
infants. At nine months postpartum, mothers with IDA were significantly less 
engaged in goal setting and more negative towards their babies. In contrast, the 
anaemic mothers who received 125mg iron/day were more like the non-anaemic 
women in terms of being positive and responsive towards their infants at nine 
months. Infants of the mothers with IDA scored worse on developmental tests at ten 
weeks and nine months of age. Thus the negative cumulative effect of postpartum 
IDA on maternal-infant interactions was significantly exacerbated by poverty (Perez 
et al., 2005).  
Beard et al. (2005) and Perez et al., (2005) questioned whether delayed infant 
development was also related to infants’ iron deficiency, secondary to poor maternal 
iron status in pregnancy. Although this question was beyond the scope of Beard et al. 
(2005) and Perez et al. (2005), their results suggested that low maternal iron status 
contributed to both environmental and biological factors that negatively affects 
infant development.  
Anaemia, iron deficiency and breastfeeding    
Anaemic mothers with postpartum symptoms of depression and/or fatigue may miss 
or misinterpret their newborn infant’s cues from very early on (Corwin et al., 2003). 
Interpretation of infants feeding cues is essential for the establishment of 
breastfeeding. The association between low maternal iron status and missing infants’ 
cues may therefore, have adverse affects on lactation and breastfeeding in multiple 
ways. A small Canadian study of 85 mothers, found that women with a low 
haemoglobin (<95g/L) on day two postpartum were significantly more likely to 
discontinue breastfeeding before four months of infants age (P<0.02) than non-
anaemic women (Rioux, Sovoie & Allard, 2006).  
The WHO recommends exclusive breastfeeding (EBF) for the first six months of life, 
to reduce infant mortality and improve recovery from common childhood illnesses. 
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However, there are some concerns about prolonged EBF in developing countries with 
a high prevalence of maternal and infant anaemia. In their study of 183 infants, 
Meinzen-Derr et al. (2006) found that maternal anaemia is associated with a 3-fold 
increased risk of infant anaemia (p=0.03). At nine months, a lower infant 
haemoglobin was associated with longer duration of EBF among anaemic mothers 
(p=0.003). These findings warrant further research (Meinzen-Derr et al., 2006). 
Fetal and infant development 
Iron is essential for fetal brain development (Andersson et al., 2011), and to a large 
extent the iron status of a newborn depends on the iron status of the mother in 
pregnancy (Milman, 2012a). However the risk of iron deficiency is highest in the first 
6-18 months of life (Pasricha, 2012). Anaemia and iron deficiency in infants and 
young children are associated with impaired motor development, long lasting 
behavioural and cognitive delays (Andersson et al., 2011).  
In the fetus, most iron is transferred from the mother after 30 weeks gestation, 
which corresponds with peak maternal iron absorption (Allen, 2000). When maternal 
iron status is poor, there is an increase in the number of placental transferrin 
receptors to take up more iron. However, there is evidence that this system is 
insufficient to maintain iron transfer to the fetus when the mother is iron deficient 
(Allen, 2000). Recent evidence demonstrates that pregnant women with lower 
hepcidin levels (due to an absence of inflammation) transfer more iron to their fetus 
compared to mothers with detectable hepcidin levels (Koenig et al., 2014). These 
mechanisms for maternal-fetal iron transfer are complex.  
A review prior to the discovery of hepcidin in 2000, that did not analyse ferritin 
levels,  found no significant association between maternal haemoglobin at or near 
term, and haemoglobin concentration in cord blood, except for rare cases of severe 
maternal anaemia (Allen, 2000). This was also a result of a New Zealand study (Emery 
& Barry, 2004) comparing the haemoglobin concentration in cord blood of non-Maori 
(n=93) and Maori participants (n=31) (p=0.95). However Maori mothers had 
significantly lower (undefined) haemoglobin levels (p=0.002), but not ferritin levels 
(p=0.02), than non-Maori mothers (Emery & Barry, 2004). Emery and Barry (2004) did 
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not account for the effect of increased maternal serum ferritin levels in the presence 
of inflammation. 
Morton et al. (2014) studied maternal and perinatal predictors of newborn iron 
status, as part of the Growing up in New Zealand (GUiNZ) study. The authors found 
that the mean umbilical cord haemoglobin (n=131) was highest in neonates of 
European mothers (164 g/L), compared to Pacific neonates (150 g/L) (p=0.05). Seven 
per cent of all the newborns had iron deficiency, 2% were anaemic, and none had 
IDA. Cord blood samples with evidence of inflammation (n=5, CRP >5mg/L or serum 
ferritin >370 µg/L) were excluded from the study. The mean BMI of the women in the 
study was higher (26.9) compared to the mean (25.4) in the cohort of 6822 women in 
the GUiNZ study. Although Morton et al. (2014) state that there is a cumulative 
adverse effect on newborn iron status with multiple maternal co-morbitities, 
especially obesity and diabetes, the extent of this association is unclear and warrants 
further research. This study does provide an indication of the prevalence of neonatal 
iron deficiency in New Zealand.   
Low iron status, birth weight and pre-term birth. 
The associations between low iron status, prematurity and neonatal birth-weight are 
often discussed in the literature. Although normal physiological haemodilution of 
pregnancy optimises placental perfusion, severe anaemia and low iron status, in the 
first trimester especially, results in fetal growth restriction (Graves & Barger, 2001; 
Walsh et al., 2011). The benefits of early recognition of poor iron status, and early 
prevention or treatment are generally recommended. Iron supplementation started 
early in pregnancy has the best effect on the length of gestation, birth weight and the 
development of the fetus (Milman, 2012b; Pena-Rosas, De-Regil, Dowswell & Viteri, 
2012). However, causal relationships of clinical outcomes related to a low 
haemoglobin have not been clearly established (Jans, 2012; Rasmussen, 2001). Meta-
analyses of RCTs show there is a general paucity of studies reporting clinical 
outcomes, and interpretation of those studies is limited by the heterogeneity in 
design, intervention, setting and outcome measurements (Dodd et al, 2009; Reveiz et 
al., 2007).  
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Most studies on outcomes associated with iron status are observational, and more 
controlled experiments are required (Rasmussen, 2001). However because it would 
be unethical not to treat anaemic women, it is difficult to conduct prospective 
randomised trials to examine the efficacy of iron supplementation (Allen, 2000). A 
meta-analysis of both observational studies and randomised trials, with a different 
methodological approach to Cochrane Collaboration methods, found a strong 
association between anaemia and a higher risk of low birth weight (LBW) (RR 0.81, CI 
0.71 to 0.93), especially when diagnosed in the first and second trimester (OR 1.29, CI 
1.09 to 1.53) (Haider et al., 2013).  
Some studies from developed and developing countries have demonstrated an 
association between iron status, prematurity and birth-weight. An often cited, 
randomised trial of 4,926 pregnant Nepalese women, who received daily 
supplements of 60mg of ferrous iron and folic acid from 11 weeks, resulted in a 
significant 16% (RR=0.84, CI 0.72 to 0.99) reduction in the prevalence of LBW 
neonates (Christian et al., 2003). Follow-up of 3761 of the children in the Nepalese 
trial demonstrated that at seven years the children’s development had improved, 
and the mortality rate was 31% less compared to children of women not 
supplemented with iron and folic acid antenatally (Christian et al., 2009).  
Another often cited study in the United States of America (USA) of 513 low income 
women demonstrated that a daily supplement of 65mg ferrous iron decreased the 
frequency of LBW (4% vs. 17%, p=0.003) and prematurity (3% vs. 10%, p=0.017) 
compared to the placebo group (Cogswell, Parvanta, Ickes, Yip & Brittenham,  2003). 
Furthermore, a large Chinese study of 5828 women also demonstrated that antenatal 
supplementation with iron, significantly decreased the risk of early preterm birth 
(PTB <34 weeks) (p=0.031), and early neonatal mortality by 54% (RR 0.46, CI 0.21 – 
0.98) compared to the non-iron supplemented group (Zeng et al., 2008). 
Although the optimal range for haemoglobin has not been established (NBA, 2015) it 
appears to fit a U-shaped curve (Pena-Rosas et al., 2012). There is evidence that high 
haemoglobin levels in pregnancy, defined variously as an Hb >130g/L at sea level 
(Pena-Rosas et al., 2012), >132 g/L (Ziaei et al., 2007), or >145g/L (Milman, 2006), are 
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associated with adverse outcomes, especially maternal hypertension, low birth 
weight and premature births.  
An Iranian study of 727 pregnant women with high haemoglobin levels (Hb >132 g/L) 
in the second trimester, surprisingly gained ethics approval to test the outcome of 
supplementing the case group with 50mg of ferrous iron throughout the rest of 
pregnancy (Ziaei et al., 2007). Results showed that the small for gestational age (SGA 
i.e. < 10th percentile) birth rate, and number of women with hypertensive disorders 
increased significantly in the case group (p=0.035 and p=0.05 respectively). The 
physiological explanation for these results was iron-induced macrocytosis, increasing 
blood viscosity to a point that utero-placental blood flow was impaired, placental 
perfusion decreased, with an increased risk of placental infarction (Ziaei et al., 2007). 
The authors of this study concluded that routine iron supplementation of non-
anaemic women is not rational and may be harmful.  
Maternal mortality and morbidity associated with anaemia 
The primary function of iron in the body is the formation of haemoglobin in red blood 
cells, for delivery of oxygen to the tissues. But at what point is oxygen delivery to the 
tissues compromised by low haemoglobin, in the context of normal physiological 
haemodilution of pregnancy? Whilst some midwives (Graves & Barger, 2001) are 
critical of the medical community for pathologising lower haemoglobins in 
pregnancy, they acknowledge the difficulty of trying to assess the lower threshold 
beyond which adequate oxygen delivery to cardiac tissues is compromised. Similarly, 
Jans (2012) says the risk of an anaemic woman being predisposed to circulatory 
problems following a postpartum haemorrhage is theoretical, and circulatory 
problems can only be expected when Hb < 40-50 g/L. 
From a medical perspective, a Hb <70g/L requires urgent medical treatment 
(Goonewardene et al., 2012), and may warrant a blood transfusion (NBA, 2015). An 
Hb <40g/L is an emergency with the risk of congestive heart failure, sepsis or death 
(Goonewardene et al., 2012). Pavord et al. (2012) say little is known about the Hb 
threshold under which mortality increases, although this may be as high as 89 g/L, 
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which was associated with a doubling of the risk of maternal death in a 1958 British 
study (Brabin, Hakimi & Pelletier, 2001).  
Postpartum haemorrhage (PPH) is a leading cause of global maternal mortality, 
especially in developing countries where the risk of dying in pregnancy and childbirth 
is 50-100 times greater than for women in developed countries (Brabin et al., 2001). 
Worldwide, almost 600,000 women die each year as a result of complications relating 
to pregnancy and birth (Brabin et al., 2001).  Postpartum anaemia is closely linked to 
anaemia in pregnancy, and aggravated by blood loss (Milman, 2011). However there 
are many causes of anaemia (e.g. nutrient deficiencies, malaria, 
haemoglobinopathies, and haemolytic anaemias) that contribute to the overall 
pathology of anaemia, in addition to blood loss (Brabin et al., 2001; Goonewardene 
et al., 2012; Pasricha, 2012). For these reasons, the reduction in prevalence of 
maternal anaemia has been the focus of global public health strategies such as the 
Safe Motherhood initiative (Brabin et al., 2001).  
In New Zealand, 3.4% of the maternal mortality rate is related to PPH (Perinatal 
Maternal Mortality Review Committee (PMMRC), 2015). From 2006-2013, three 
women died in New Zealand due to blood loss. Excessive blood loss (>1999mls) is the 
leading cause of severe acute maternal morbidity (SAMM) in New Zealand, 
accounting for 44.9% (44 of 98) of SAMM intensive care admissions or ‘near misses’, 
from 2011-2012 (Lawton et al., 2014). Almost half of these (n=20) were found to be 
preventable due to factors such as clinician delay, or failure to diagnose significant 
blood loss. Third trimester anaemia is not stated as a preventable factor in Lawton et 
al.’s (2014) report, although anaemia is recognised as a risk factor for lowered 
tolerance to blood loss (NBA, 2015; Milman, 2012b).  
The associations between maternal anaemia, mortality, morbidity and the use of 
blood transfusions are not well researched by intervention studies (NBA, 2015), 
because of ethical and logistical reasons (Brabin et al., 2001). In observational 
studies, anaemia as ‘all cause’ for mortality or morbidity is difficult to establish due to 
the multi-factorial nature of anaemia (Allen, 2000; Goonewardene et al., 2012). For 
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example, anaemia poses other risks such as increased risk of infection or sepsis, 
which further contribute to morbidity and mortality (Brabin et al., 2001). 
Global prevalence  
Anaemia is defined by the WHO as a severe health problem if the prevalence exceeds 
40%, a moderate problem if prevalence is 20-39.9%, and a mild problem if the 
prevalence is 5-19.9% (Pasricha, 2012). It is challenging to extrapolate the prevalence 
of anaemia, from the prevalence of iron deficiency (Goonewardene et al., 2012; 
Haider et al., 2013). Previously, many agencies have considered anaemia and iron 
deficiency synonymously. But this is flawed as there are many other causes of 
anaemia other than iron deficiency, that contribute significantly to the overall burden 
of anaemia (Pasricha, 2012).  
The multi-factorial nature of anaemia may partly explain the differences in estimates 
of global prevalence of anaemia and IDA. The WHO estimates the worldwide 
prevalence of anaemia in pregnant women is 41%, compared to 6% pregnant women 
in the USA (Pasricha, 2012). One United Kingdom (UK) study found that 24.4% of 
women were anaemic at some stage antenatally (Barroso et al., 2011). 
Approximately 10% of women in the USA have postpartum anaemia (James et al., 
2008), although Bhandal and Russell (2006) suggest higher rates  of up to 30% in the 
UK; a prevalence rate also confirmed in Barroso et al.’s (2011) study. Comparison of 
prevalence data is also inherently complicated by the different diagnostic cut off 
values used for maternal anaemia and iron deficiency, by various agencies, 
researchers and reviewers.  
The contribution of iron deficiency to the prevalence of anaemia also varies markedly 
in different populations (Pasricha, 2012). In recent UK Guidelines on the management 
of iron deficiency in pregnancy, it is estimated that 30-40% of pregnant women in the 
developed world have NAID (Pavord et al., 2012). A Dublin study on the occurrence 
of maternal NAID, reported one third of 492 pregnant women had low iron stores 
(defined as SF<20µg/L) at booking, increasing to 50% at 36 weeks gestation (Walsh et 
al., 2011).  Milman et al. (2012a) compare a 25-30% prevalence of IDA in pregnancy 
in prosperous Western societies, with a prevalence of 52% amongst pregnant women 
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in developing countries. The distinction between developed and developing 
countries, when considering prevalence of anaemia, may be even less clear in 
countries with rapidly changing proportions of migrant populations. Major ethnic 
disparities exist for migrants in relation to access to health care, and health 
outcomes, including pregnancy outcomes (Jans, 2012). The extent to which this might 
also apply to the growing migrant population in New Zealand, is unknown.  
Anaemia is nonetheless described as ‘common’ with a high, albeit inexact prevalence, 
based on surveillance data and results of RCTs (Makrides et al., 2003). However the 
commonness of anaemia and iron deficiency as complaints of pregnancy, are 
debated by some midwives as being elusive and overstated (Amelink-Verburg et al., 
2010; Graves & Barger, 2001).    
With the prevalence of anaemia and iron deficiency difficult to ascertain, surrogate 
measures have been utilised to estimate prevalence in certain populations. For 
example, KNOV initially estimated the prevalence of anaemia for pregnant women in 
the Netherlands as indicated by a 72% use of iron medications; recognising a 
potential for over supplementation that inspired the formation of the anaemia 
guideline for midwives (Amelink-Verburg et al., 2010). A large USA study (James et al. 
2008) based the prevalence of anaemia in 254,248 pregnant and postpartum women 
on pregnancy related hospital diagnosis codes on discharge, unverified by laboratory 
results. Nearly one in five women had a diagnosis of anaemia. Whilst the authors 
stated the actual prevalence may have been underestimated, the diagnosis of 
anaemia in hospitalized women was associated with “a 9-fold increase in blood 
transfusion (p < 0.0001), 33% longer average length of stay (p < 0.0001), and 50% 
higher average total cost per hospitalisation (p < 0.0001)” (James et al. 2008, p.1279). 
Maternal anaemia and iron deficiency in New Zealand 
The increased hospital costs associated with a diagnosis of anaemia and obstetric 
bleeding may apply similarly to the New Zealand maternity health care setting. The 
NZ Maternity Clinical Indicators (MOH, 2011) report the rate of blood transfusions as 
an indicator for significant estimated blood loss across District Health Boards (DHB). 
In 2011, the national rate for blood transfusion was 1.6% for women giving birth 
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vaginally, and 3.3% for women giving birth by Caesarean section (MOH, 2011). 
Although these rates give no real clue to the overall prevalence of anaemia, the rate 
of blood transfusion could be interpreted as a diagnosis by proxy, of clinically severe 
anaemia. The decision to transfuse blood is not only based on volume of blood loss, 
but also on a woman’s haemodynamic stability, and iron status before and after birth 
(NBA, 2015).  
To date, there is no published prevalence data for maternal anaemia or iron 
deficiency in the general Australasian populations (Pasricha, 2012). However one 
DHB has undertaken an audit of twelve months of laboratory results to estimate the 
prevalence of anaemia, NAID and IDA amongst the women birthing in the tertiary 
level hospital (R. Seigne, personal communication, February, 2014). Unpublished data 
from the 4726 women showed the rate of anaemia, NAID and IDA was 4.3%, 19.7% 
and 0.4% in the first trimester, and 19.7%, 54% and 13.4% (respectively) in the 
second trimester. The proportion of NAID and IDA was likely to be underestimated as 
only 40% of women had serum ferritin tested in the first trimester, and 85% in the 
second trimester. 
Almost all women in New Zealand have their haemoglobin level checked, as part of 
the routine antenatal blood tests, which includes the complete blood count. In New 
Zealand the complete blood count automatically includes white cell count 
differentials, red cell indices (i.e. mean cell volume (MCV), mean cell haemoglobin 
(MCH), haematocrit (Hct)) and haemoglobin levels.   This is usually requested by an 
LMC midwife, who provides primary maternity care for the majority (88.8%) of New 
Zealand women (MOH 2012). However, general practitioner doctors also request the 
first antenatal bloods especially if women visit them to confirm pregnancy.  
Many midwives also test antenatal serum ferritin to assess iron stores, although this 
is not done routinely.  Oral iron is not prescribed routinely for pregnant women in 
New Zealand and Australia, but rather based on individual need (Gibbons & Wratten, 
2015). New Zealand midwives prescribe oral iron within their autonomous scope of 
practice. Anecdotally, there appears to be a variable range of midwifery practice 
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around diagnoses, prevention and treatment of maternal anaemia and iron 
deficiency, in New Zealand. 
Evidence based midwifery, midwifery research, midwifery guideline development 
With a similar philosophy and level of autonomy comparable to New Zealand 
midwives, midwives in the Netherlands have formulated a guideline for the 
management of anaemia in pregnancy. No such guideline exists for New Zealand 
midwives. Internationally, KNOV are the only professional body of midwives to have a   
formal guideline on the management of maternal iron status. 
Although midwives tend to support the position that anaemia of pregnancy is a 
normal physiological process, there is a shortfall of midwifery research and guidance 
on how to distinguish physiological anaemia of pregnancy, from anaemia requiring 
treatment. Amelink-Verburg et al. (2010) describe the evolving meaning of evidence-
based midwifery as incorporating midwifery values with views of women, combined 
with evidence found in the scientific literature. However, the lack of midwifery 
research on maternal iron status raises questions, asked by Spiby and Munro (2010), 
of midwives’ degree of engagement in the full cycle of research activity that 
generates the basis for evidence-based midwifery practice. This issue was echoed by 
midwifery leaders Dixon (2014) and Campbell (2013), who recently challenged New 
Zealand midwives to become fully engaged as primary researchers, rather than 
assistants, as a basis for midwifery guideline development.  
Spiby and Munro (2010) also challenged the philosophical, midwifery concepts of 
supporting ‘normality’ by a conceptual shift of working towards achieving 
‘optimality’, and utilising a wide range of literature and evidence from different 
sources. This multi-disciplinary argument could be applied to evidence on maternal 
iron status. Despite the abundance of scientific literature on anaemia and iron 
deficiency in pregnancy, so many questions remain. As Crowther (2010) asks “what 
can midwives add to this with their understanding and holistic approach to care?” (p. 
49). As a midwifery researcher, my response to these questions and challenges is to 
design and undertake clinical research to begin to unravel some of the complexities 
surrounding maternal iron status in New Zealand.  
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Significance of the study 
The clinical issues around maternal anaemia and iron deficiency are immense, 
complex and contentious, especially amongst midwives. This is primarily because of 
the blurred line between normal physiological anaemia of pregnancy, and anaemia 
requiring treatment. Without a clear and current understanding of iron metabolism, 
it is not possible to accurately interpret laboratory tests, prescribe or recommend 
iron appropriately. Although anaemia is seen as common in pregnancy, the actual 
prevalence in New Zealand is unknown. It was necessary to explore the evidence on 
adverse outcomes associated with anaemia and iron deficiency in pregnancy and 
postpartum, as part of this study; to describe the extent to which low maternal iron 
status is problematic for mothers and their infants, despite the limited research in 
some areas, and heterogeneity of research in others. Without this background of 
explaining why low iron status is a problem, there is little value in focusing on 
diagnosis and management. 
This study is significant because it describes how the participant midwives in this New 
Zealand study currently diagnose and manage anaemia and iron deficiency in 
pregnancy and postpartum, without clear clinical guidance. There are no studies in 
New Zealand or internationally, that have done this. Midwives in the Netherlands 
have led the way with anaemia research, particularly regarding haemoglobinopathies 
(Jans, 2012), and the development of an anaemia guideline in 2000 (Beentje & Jans, 
2011; Amelink-Verburg et al., 2010). The midwifery leaders in the Netherlands who 
developed the guideline remain sceptical that anaemia is a problem in terms of 
adverse outcomes (Amelink-Verburg et al., 2010; Jans, 2012), although a survey of 
Dutch midwives’ opinions indicates that some disagree (Offerhaus, Fleuren & 
Wensing, 2004).   
Some midwives have published opinions in articles (Graves & Barger, 2001), and 
books (Frye, 2007), and every midwifery text book has a section on maternal 
anaemia. Latterly these discussions have included iron deficiency, such as in the 
required reading for midwifery students in New Zealand by Pairman, Pincombe, 
Thorogood and Tracy (2015). Still, the diagnosis of anaemia and iron deficiency is 
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unclear. This study starts to close the gap between evidence and practice, in the 
primary care management of maternal anaemia and iron deficiency, paving the way 
for more complex studies in New Zealand in the future.  
Overview of the thesis 
There are five chapters in this thesis that describe LMC midwives primary care 
management of iron status in pregnancy and postpartum. Chapter One has explained 
the research problem, question and aims. This includes background physiology of 
iron metabolism, effects of maternal anaemia and iron deficiency, global prevalence, 
and guideline development. In Chapter Two, the Literature Review explores the 
evidence around diagnosis and management of low iron status in pregnancy and 
postpartum, emphasising the recent focus in the literature on iron deficiency. Areas 
of consensus are clarified, whilst discrepancies, controversies and gaps in the 
evidence, literature and practice are highlighted to specifically guide the design of 
this study. Chapter Three outlines the research design including justification and 
explanation of the descriptive methodology, and methods. Chapter Four presents the 
study results, including secondary analysis of the association between low iron status 
and body mass index. Chapter five discusses the results in relation to the literature, 
whilst exploring the implications of the study, areas of research, and the study’s 
strengths and limitations. 
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Chapter Two: Literature Review 
Introduction and overview 
Whilst Chapter one broadly explored the current understanding of the physiology 
and effects of anaemia and iron deficiency in pregnancy and postpartum, the 
literature review focuses on diagnosis and management. The international literature 
was reviewed to explore current knowledge and recommended practice in relation to 
diagnosis and treatment of low maternal iron status. This involved looking at global 
public health strategies, national guidelines and individual therapeutic approaches, 
from a primary midwifery care perspective.  
Specifically, the literature was investigated to find out what guidance exists, and 
what evidence it is based on. As researcher, I have taken the position that low 
maternal iron status is problematic and associated with adverse maternal and infant 
outcomes, although the evidence is difficult to elucidate as discussed in Chapter One. 
Given the controversies and challenges around low maternal iron status, the 
literature was also investigated for studies that described how care providers actually 
manage this.   
No observational or descriptive studies focusing on midwives’ management of 
maternal anaemia and iron deficiency were found in the literature. However, one 
observational study, from a multi-disciplinary perspective was found: “Prevalence of 
maternal anaemia and its predictors: a multi-centre study” from the UK (Barroso et 
al., 2011). The aim of Barroso et al. (2011) was to observe current practice around 
identification and management of antenatal and postnatal anaemia. Their multi-
centre study of 2103 women also reported on the prevalence of anaemia. The 
outcome of my literature review informed the design of this study; to describe 
current practice around New Zealand LMC midwives diagnosis and management of 
anaemia and iron deficiency in pregnancy and postpartum, as little is known in this 
area. 
 
Page 24 
 
Search strategy 
The literature search for this study was commenced in 2013, until completion in 
2015. This included database searches on Pub Med, CINAHL (Cumulative Index to 
Nursing and Allied Health), Joanna Briggs Institute and the Cochrane Database of 
Systematic Reviews. Keywords were: anaemia, iron deficiency, pregnancy and 
postpartum. Maternity guidelines, reports from the Ministry of Health, textbooks, 
and references from published works were also searched. Although literature from 
the last ten years was preferred, there were some older often cited seminal 
references and reports, and several older but still very relevant articles.   
Screening and Diagnosis 
Screening with risk factors  
Before testing or treatment is undertaken, women can be screened for risk factors 
associated with developing anaemia and iron deficiency in pregnancy. Many risk 
factors have been identified:  multiple pregnancy (McMahon, 2010),  increased 
multiparity (Barroso et al., 2011), short time interval between births (Allen, 2000; 
Barroso et al., 2011), teenage pregnancies (Alwan et al., 2011; Barroso et al., 2011; 
Brabin et al., 2001), vegan or poor diet (Jans, 2012), smoking (Rasmussen, Bergso, 
Jacobsen, Haram & Bakketeig, 2005), high BMI (Friedman et al., 2012; Koenig et al., 
2014), history of bleeding (James et al., 2008), low socio-economic status (Beard et 
al., 2005; Bodnar et al., 2005; Perez et al., 2005), non-white ethnicity (Barroso et al., 
2011; James et al., 2008), haemoglobinopathies (Brabin et al., 2001; Jans, 2012), and 
chronic disease or infection (Koenig et al., 2014; Pasricha et al., 2013; Wang et al., 
2010). Screening with risk factors for low maternal iron status can be undertaken at a 
population or individual level.  
The concept of screening needs clarification. In 1968 the WHO defined screening as 
“the presumptive identification of unrecognized disease by the application of tests 
[or risk factors]...which can be applied rapidly to sort out apparently well persons 
who probably have a disease from those who probably do not” (p. 139), with a view 
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to early detection of conditions that would benefit from early treatment or 
intervention.  
The extent to which New Zealand midwives screen for low maternal iron status is 
unknown. Jans (2012), states that midwives generally take a more holistic approach 
to screening for anaemia,  compared to a more medical technical approach. Some 
midwives may intuitively or knowingly screen women with risk factors, prior to 
testing or supplementation. Some midwives may screen for low iron status based on 
symptoms, or a combination of both. Crowther (2010) for example, encourages 
midwives to work with women on their iron status at each visit to genuinely find out 
how they are, and Frye (2007) discusses women’s ‘vitality gauge’ as an indicator of 
anaemia, regardless of haemoglobin levels.   Although fatigue is the most common 
symptom of anaemia and iron deficiency, symptoms are usually non-specific unless 
the anaemia is severe (Pavord et al., 2012).  
In the literature review, only two guidelines were found that stated specific maternal 
risk factors as a screening tool for identifying women at higher risk of anaemia and 
iron deficiency in pregnancy. The KNOV 2000 guideline on anaemia (in Jans, 2012), 
and the UK guidelines on the management of iron deficiency in pregnancy (Pavord et 
al., 2012), both clearly identify risk factors that guide management for prevention of 
low maternal iron status. This includes additional testing for at risk women, and is 
summarised in Table 1, alongside other guidelines and recommendations.  
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Table 1: Comparison of guidelines, recommendations,  and  definitions  of anaemia and iron deficiency in pregnancy and postpartum  
Organisation First trimester  Second trimester  Third trimester  Postpartum  General recommendations  
Health Pathways 
(2015)  
All women, test CBC*: 
If Hb* <110 g/L & 
MCV* <80, test ferritin 
ID*: SF*<20 µg/L 
Test CBC: if Hb <105 
g/L & MCV <80, test 
ferritin  
ID: SF<20 µg/L 
Test CBC: if Hb <105 
g/L & MCV <80, test 
ferritin  
ID: SF<20 µg/L 
None stated  Mild (undefined) NAID*:  
→  65-200mg oral iron 
 Mod (undefined) NAID:  
→  100-200mg oral iron 
New Zealand College 
of Midwives (2005) 
 All women, test CBC  None stated Consider CBC No parameters stated None stated 
NICE Guidelines  
(2014, 2015) 
Offered screening for 
anaemia. If Hb <110 
g/L, investigate & 
consider iron 
supplementation 
if Hb <105 g/L at 
28wks, investigate & 
consider iron 
supplementation 
No parameters 
stated 
If woman persistently 
fatigued, or if has had 
PPH, check Hb. If low 
treat according to 
local policy 
No routine supplementation 
RANZCOG (2013) All women, test CBC. 
Particular note of MCV 
as indicator of 
underlying HbP*  
Test Hb at 28 wks. 
No parameters stated 
No parameters 
stated 
No parameters stated None stated 
Royal Netherlands 
Organisation of 
Midwives (KNOV in 
Jans, 2012)  
All women, test CBC  
Hb<114.5 g/L under 13 
wks 
 
Repeat CBC at 20 wks 
for at risk groups § 
Hb<110 g/L at 14-17 
wks 
Hb<104.8 g/L at 18-21 
wks 
Hb<101.6g/L at 22-37 
wks 
CBC for all women at 
30 wks 
Hb<101.6g/L at 22-
37 wks 
Hb<104.8g/L after 38 
wks 
 
Hb<104.8g/L at 1-5 
wks 
Hb<116.1g/L at 6 wks 
All women: check 
postpartum Hb at 4-6 
weeks 
If EBL >1000mls: check 
Hb  at 7-10 days, and 6 
weeks  postpartum 
All women:  
 No ferritin testing 
 Test MCV if Hb low: 
o If MCV 80-100→no 
treatment 
o If MCV 70-80→ 200mg 
oral iron 
o If MCV <70 or ≥100→ 
refer to GP 
All women: check Hb 3-6 wks 
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Organisation First trimester  Second trimester  Third trimester  Postpartum  General recommendations  
after start of treatment 
UK Guidelines  
(Pavord et al., 2012) 
CBC for all women at 
booking 
Hb<110 g/L 
ferritin testing for high 
risk women only¶ 
SF<30 µg/L 
CBC for all women at 
28wks 
Hb<105 g/L 
SF<30 µg/L  
 
Hb<105 g/L 
SF<30 µg/L  
 
Check Hb if 
EBL>500mls, or 
uncorrected anaemia 
antenatally, or if 
symptomatic 
Hb<100 g/L  
 All women given dietary 
advice 
 Routine supplementation 
not recommended 
 NAID →65mg iron 
 IDA* → 100-200mg iron 
US Centre for  
Disease Control 
(1998) 
Hb<110 g/L at 12 wks 
SF<12 µg/L 
Hb<105 g/L at 24 wks 
SF<12 µg/L 
Hb<114g/L at 36 wks 
SF<12 µg/L 
Hb<120g/L at 4-6 
weeks.  
Test Hb & Hct if:  3rd 
trimester anaemia, 
excessive blood loss, 
or multiple births 
Routine 30 mg/day oral iron 
for all pregnant women  
World Health  
Organisation (1968) 
Hb<110 g/L 
SF<15 µg/L 
Hb<110 g/L 
SF<15 µg/L 
Hb<110 g/L 
SF<15 µg/L 
Hb<100 g/L  ferritin best measure of 
iron stores 
 ferritin not tested 
routinely 
 ferritin tested in at risk 
populations  
*Abbreviations: complete blood count (CBC); general practitioner (GP); haemoglobin (Hb); haemoglobinopathy (HbP); iron deficiency (ID); iron deficiency anaemia (IDA); mean cell 
volume (MCV); non-anaemic iron deficiency (NAID); serum ferritin (SF). 
§ KNOV risk factors: teenage pregnancies, pregnancies within 12 months of birth, poor nutrition, multiple pregnancy, haemoglobinopathies (e.g. thalassaemia). 
¶ UK Guideline risk factors: current or previous anaemia, teenage pregnancies, pregnancies within 12 months of birth, parity ≥3, recent history of bleeding, high risk of bleeding, 
Jehovah’s witnesses, haemoglobinopathies (e.g. thalassaemia). 
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The KNOV and UK guidelines are clear and comprehensive, unlike other guidelines 
and recommendations. For example, recommendations in The New Zealand College 
of Midwives Handbook for Practice (NZCOM, 2005) are very limited. Also, there is no 
clear strategy for New Zealand midwives to identify risks factors for low maternal 
iron status, or how to manage them, despite some discussion on risk factors in the 
compulsory textbook Midwifery: preparation for practice (Hunter & Gunn, 2015). 
Screening for risk factors of anaemia appears integral to the identification and 
management of maternal iron status. Yet, it is unknown whether or not New Zealand 
midwives are more pro-active in their management of women who have risk factors 
for anaemia and iron deficiency. Therefore demographic and clinical data on 
women’s potential risk factors was collected for the study. 
Haemoglobin and identifying anaemia  
Internationally, there are few comprehensive guidelines on the management of 
maternal anaemia and iron deficiency (Table 1). A comparison of the different 
approaches and diagnostic parameters for anaemia highlights the major issues. 
Where guidelines do exist, most are short on detail. Most importantly, the diagnostic 
criteria differ significantly between guidelines.  
Because of physiological haemodilution, pregnant women need different parameters 
to define normal haemoglobin values (Jans, 2012). However, the boundaries between 
physiological and pathological anaemia of pregnancy are not well understood or 
defined (Pena-Rosas & Viteri, 2006). Consequently, there is no global consensus on 
the various cut-off points used to define anaemia (Amelink-Verburg et al., 2010), as 
illustrated in Table 1. The perception that healthy women with normal physiological 
anaemia of pregnancy were being over-diagnosed and over-treated for anaemia, 
motivated the Dutch midwives to develop their first evidence based guideline. This 
may be an important issue for New Zealand midwives too. 
Statistically, anaemia is defined as a haemoglobin level less than two standard 
deviations below the mean, or <5th percentile, for a matched healthy population 
(Pavord et al., 2012). Without a large population study in New Zealand, normal and 
abnormal haemoglobin values are unknown here. The most often cited 1968 WHO 
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definition of anaemia in pregnancy, as a haemoglobin concentration <110g/L (Table 
1), is considered by some to be arbitrarily chosen (Milman, 2006), statistically flawed 
due to population sampling errors (McMahon, 2010), and not applicable to the 
Australasian population (NBA, 2015). Nonetheless, the global WHO definition is 
recognised as necessary for comparisons of prevalence, and effects in different 
populations (Goonewardene et al., 2012).  
The USA Centre for Disease Control (CDC, 1998) criteria for anaemia in pregnancy as 
Hb<105 g/L (Table 1), is considered a reasonable alternative to the WHO definition, 
as it takes into account haemodilution of pregnancy (Paterson et al., 1994 ; Pavord et 
al., 2012). However Graves and Barger (2001) also question the validity of the CDC 
parameters, as they are based on aggregated data from four European studies of 
iron-supplemented women. Neither the WHO or CDC parameters distinguish cut-offs 
for race, although ranges of haemoglobin do vary by race, possibly because of ethnic 
differences in the prevalence of haemoglobinopathies (e.g. thalassaemia or sickle cell 
disease) (Pasricha et al., 2013). From their midwifery perspective, Graves and Barger 
(2001) suggest parameters for defining anaemia in normal healthy pregnant women 
may be much lower. 
Dutch midwives based their 2000 anaemia guideline on gestation dependent 
reference values, stated in mmol/L and converted to g/L in Table 1. The lowest KNOV 
parameter for defining anaemia is an Hb < 101.6g/L at 22-37 weeks gestation. These 
gestation specific criteria are based on two studies that Jans (2012) states are well 
known in the Netherlands. However, despite an extensive literature search, and 
direct email contact with S. Jans, and a Dutch Obstetrician, these studies were not 
available.  KNOV’s guideline may therefore be based on old or low quality evidence.  
Nonetheless, authors of the KNOV guideline consider it a small revolution, as the 
lower haemoglobin reference values are based on the 5th percentile as the normal 
value (Beentje & Jans, 2011), compared to other higher cut-off values such as the 
WHO definition (Amelink-Verburg et al., 2010).  
Interestingly, a study of Dutch midwives’ adherence to the KNOV guideline found 
that 31% of midwives considered the haemoglobin cut off values too low (Offerhaus 
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et al., 2004). Critics of the KNOV guideline consider the lower haemoglobin cut off 
values leads to under-detection of IDA, and failure to detect anaemia sufficiently 
early enough in pregnancy (Jans, 2012). Twenty-one percent of Dutch midwives also 
consider the period between the KNOV recommendation of testing haemoglobin at 
twelve and thirty weeks gestation, for low risk women, as too long; further leading to 
under-detection of anaemia and iron deficiency, especially for immigrant women 
(Offerhaus et al., 2004). 
Diagnostic parameters aside, a low haemoglobin concentration indicates anaemia but 
not the cause. The role of blood tests is to diagnose logically, beginning with the most 
common cause for abnormally low haemoglobin levels (iron deficiency), then explore 
more complex pathologies as the clinical picture fits (Crowther, 2010), e.g. folate or 
B12 deficiencies, haemoglobinopathies,  chronic bleeding, infection or inflammation. 
Although haemoglobin is considered the simplest, least invasive test used to screen 
and diagnose anaemia (James et al., 2006), the low cost and ease of measuring 
haemoglobin concentration have also made it the most ubiquitous (Graves & Barger, 
2001).  
Haemoglobin concentration is often used as a pseudo-marker for iron deficiency or 
iron status in pregnancy (Milman, 2006). However Walsh et al. (2011) demonstrated 
that as a single test, the WHO cut off of Hb<110g/L has a proven sensitivity of only 
5% for iron deficiency (SF <20µg/L), and only 8% for absent iron stores (SF <12µg/L), 
effectively missing over 90% of absent iron stores.  Haemoglobin alone is therefore a 
poor measure of iron status, as the Hb is the last red cell indice to drop before end 
stage iron deficiency anaemia (IDA) (Mei et al., 2005; Pasricha, 2012; Walsh et al., 
2011).  
In Ireland, Barrosso et al. (2011) observed that 88.7% of the 2103 women studied had 
their Hb tested as part of the CBC at booking. In total, 19.1% (n=402) of the women 
were anaemic at booking or in the second trimester. A significant number of these 
women remained anaemic in later pregnancy (30%), and 24% had postnatal anaemia. 
A small proportion of the women in the study who were found to be anaemic in the 
first and second trimester, had their ferritin levels checked (20% and 12% 
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respectively) (Barroso et al., 2011). Without a measure of iron stores, practitioners 
cannot discern where a woman sits on the spectrum from iron sufficiency to non-
anaemic iron deficiency (NAID), and IDA. This had important implications for this 
study in terms of observing how midwives in New Zealand identified low iron status, 
without a measure of iron stores. So do LMC midwives rely on haemoglobin as a 
single measure of maternal iron status?  The specific haemoglobin and serum ferritin 
parameters used to define anaemia and iron deficiency in this study are explained in 
Chapter Three on Research Design. 
                               Serum ferritin and identifying iron deficiency 
As with haemoglobin levels, there is no clear consensus on serum ferritin parameters 
that define iron deficiency or absent iron stores (Table 1). There is also a range of 
approaches in the guidelines and recommendations to serum ferritin testing. These 
range from not testing ferritin, to a risk based approach, to routine (universal) testing 
for all women. Ferritin is also a complex multi-functional molecule that requires an 
additional test to accurately measure iron stores in the presence of inflammation. 
Because there are no clear recommendations or guidelines for New Zealand 
midwives on the testing of iron deficiency in pregnancy, the literature on the 
parameters and different approaches to testing are explored below.  
Serum ferritin screening for iron deficiency early in pregnancy is widely 
recommended to provide a baseline, and enable early commencement of iron 
therapy (Breymann, Honegger, Holzgreve & Surbek, 2010; Crowther, 2010; Elias, 
2007; Milman et al., 2006; Milman, 2012a; Pasricha, 2012; Walsh et al., 2011). So it is 
somewhat surprising that the UK Guideline for the Management of Iron Deficiency in 
Pregnancy (Pavord et al., 2012) does not support the approach of universal screening 
of serum ferritin in pregnancy. However, Pavord et al. (2012) do recommend testing 
‘at risk’ women (Table 1). Women without risk factors for anaemia are not tested for 
iron deficiency, unless they are from areas with a particularly high prevalence of at 
risk women (Pavord et al., 2012).    
The UK approach considers unselected routine screening with serum ferritin as an 
expensive use of resources (Pavord et al., 2012). The UK approach may also be 
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following recommendations from the WHO, although this is not implicitly stated.    
From a global public health perspective, the WHO (2011) also does not recommend 
universal serum ferritin screening in pregnancy. The WHO only recommends ferritin 
testing in pregnancy, prior to iron supplementation, if the population prevalence of 
anaemia is <20% (Pasricha, 2012).  
In the study area, clinical guidance for local general practitioner doctors on primary 
care management of anaemia and iron deficiency in pregnancy (Health Pathways, 
2015), does not recommend routine serum ferritin testing unless MCV <80fL (Table 
1). Health Pathways (2015) is included in this literature review because local LMC 
midwives access the website, and the Health Pathways approach may soon be 
adopted by other DHBs (J. Spring, personal communication, November 14, 2015). The 
extent to which midwives use Health Pathways (2015) is unknown. 
The KNOV guideline, including the 2008 revision, does not recommend midwives test 
serum ferritin as a measure of iron stores at all. Instead KNOV utilises MCV to 
diagnose anaemia (Jans, 2012), with no emphasis on iron deficiency as a clinical issue. 
Midwives in the Netherlands only test serum ferritin to differentially diagnose IDA 
from haemoglobinopathies (Beentje & Jens, 2011). It was clearly important for this 
study to look carefully at how ferritin is assessed. Therefore, the evidence for the 
different approaches is discussed below. 
Various serum ferritin cut-off values for the definition of iron deficiency in pregnancy 
are debated (Milman et al., 2006; Pavord et al, 2012). This complicates diagnosis for 
New Zealand midwives, especially in the absence of a guideline. Serum ferritin is 
nonetheless recommended as the most accurate, accessible, current measure of iron 
stores (Pairman et al., 2015; Pasricha et al., 2013; Pavord et al., 2012; Wang et al., 
2010; WHO, 2011).  Serum ferritin <15µg has shown a specificity of 98% and 
sensitivity of 75% for iron deficiency, defined by the invasive gold standard of no 
stainable bone marrow iron; and at <30µg a specificity of 85% and sensitivity of 90% 
(Walsh et al., 2011).  
Unlike haemoglobin, serum ferritin is not affected by smoking or altitude (WHO, 
2011). Serum ferritin is a stable glycoprotein unaffected by recent iron ingestion 
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(Pavord et al., 2012), but levels are subject to daily fluctuations of 15-20% (Crowther, 
2010).    As well as being cheap and cost effective, Crowther (2010) considers serum 
ferritin testing a valuable arsenal for New Zealand midwives to avoid over-prescribing 
of iron in pregnancy. Serum ferritin should also be considered valuable to avoid 
under-prescribing of iron in pregnancy. 
However, ferritin is a complex and multi-functional molecule (Wang et al., 2010), 
with some limitations in the diagnosis of iron deficiency. Serum ferritin levels are 
affected by haemodilution of pregnancy, and drop in pregnancy because less ferritin 
is produced (Milman, 2006) as the iron stores are mobilised (Pavord et al., 2012).  By 
32 weeks gestation, serum ferritin has progressively decreased to 50% of pre-
pregnancy levels, increasing mildly in the third trimester (Pavord et al., 2012). The 
WHO (2011) states that a drop in serum ferritin does not necessarily imply functional 
iron deficiency. Functional iron deficiency occurs when despite adequate stores, iron 
cannot be mobilised for erythropoiesis (Pasricha et al., 2010).  
The main disadvantage of serum ferritin is that it is also an acute phase protein, and 
levels increase during any overt or covert inflammation (Thurnham et al., 2010; 
WHO, 2011). There are many possible causes of inflammation: acute and chronic 
infections (e.g. malaria), liver disease, arthritis, malignancy, increased alcohol intake 
and obesity (Friedman et al., 2012; Gartner et al., 2013; Koenig et al., 2014; Nel, 
Kruger, Baumgartner, Faber & Smuts, 2015; Wang et al., 2010). Other pro-
inflammatory states specific to pregnancy are implantation (Mor, Cardenas, 
Abrahams & Guller, 2011), normal and operative birth (Lee at al., 2014), and pre-
eclampsia (Koenig et al., 2014). These pro-inflammatory states are associated with 
elevated ferritin levels due to inflammation. 
Recent advances in the understanding of iron physiology have increased knowledge 
of the multiple causes, and mechanisms, of anaemia and functional iron deficiency in 
the presence of inflammation. In 2000 the liver hormone hepcidin was discovered. 
Hepcidin regulates body iron by decreasing iron uptake in the gut and limiting 
utilisation of iron for erythropeiesis, when inflammation is present (Koenig et al., 
2014; Wang et al., 2010). This sequestering of iron results in increased ferritin levels, 
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and degrees of functional iron deficiency, or anaemia of chronic disease (ACD), also 
called anaemia of inflammation.  
This makes ferritin levels difficult to interpret and misleading due to the potential for 
false normal or high ferritin results (Pasricha, 2012). Anaemia of chronic disease is 
now recognised as the second most prevalent cause of anaemia, after iron deficiency 
(Friedman et al, 2012; Munoz, Breymann, Garcia-Erce, Comin & Bisbe, 2007). 
Anecdotally, the mechanisms of functional iron deficiency and inflammation are not 
understood by all midwives in New Zealand. Table 2 (adapted with permission from 
Pasricha et al. (2010)) provides an overview on interpretation of laboratory tests for 
iron status. 
Table 2*: Overview of interpreting laboratory blood test results to assess iron 
status 
Diagnosis Haemoglobin Mean cell volume  
and mean cell 
haemoglobin 
Serum ferritin 
µg/L 
 
Non-anaemic iron deficiency 
(NAID) 
Normal Normal or low < 15-30 
Iron deficiency anaemia (IDA) Low Low (or normal in 
early IDA) 
< 15-30  
Anaemia of chronic disease 
(ACD) or inflammation 
Low Normal (maybe 
mildly low) 
Normal or 
elevated (elevated 
ferritin does not 
imply elevated 
iron stores) 
IDA with coexistent chronic 
disease or inflammation 
Low Low Low or normal, 
but usually <60-
100 µg/L  
Thalassaemia minor Low (or normal) Low (or normal) Normal or 
elevated 
*Source: adapted with permission from the Medical Journal of Australia and Pasricha et al. 2010 
 
Because of the effect of inflammation on ferritin levels, it is widely recommended 
that serum ferritin is tested alongside another inflammatory marker, C-reactive 
protein (CRP). Although midwives can order CRP tests (District Health Boards Shared 
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Services, 2013), anecdotally it appears that midwives do not order CRP alongside 
serum ferritin. Currently, laboratories do not routinely analyse CRP with serum 
ferritin, so CRP testing is dependent on individual laboratory practice.  
C-reactive protein is a correcting factor that indicates the need to adjust the 
diagnostic parameters for iron deficiency upwards, when inflammation is present i.e. 
CRP >5mg/L (Gartner et al., 2013; McMahon, 2010; Nel et al., 2015; Thurnham et al., 
2010; WHO, 2011). C-reactive protein levels appear to be independent of pregnancy 
and gestational age (Pavord et al., 2012). Recommended adjustment to the serum 
ferritin cut-off value that defines iron deficiency, in the presence of inflammation, 
varies from 30µg/L (Nel et al., 2015; Thurnham et al., 2010; WHO, 2011), to 50µg/L 
(Goonewardene et al., 2012), and up to 70µg/L (Wang et al., 2010). Given that the 
WHO (2011) recommends serum ferritin as the best current measure of iron stores, it 
has become a research priority to establish alternative methods and thresholds for 
interpreting ferritin, in the presence of various phases of inflammation (Cheng et al., 
2013; Gartner et al., 2013; Moschonis, Chrousos, Lionis, Mougios & Manios, 2012; 
Nel et al., 2015; Thurnham et al., 2010).  
In the immediate postpartum period there is also an increased chance of false normal 
or high ferritin levels, due to oxidative stress and inflammatory responses following 
birth.  Milman (2011) suggests that serum ferritin can be accurately tested at one 
week postpartum, because women have reached a haemodynamic steady state with 
the disappearance of haemodilution. Ferritin naturally increases in response to this, 
rather than inflammation, and at one week will most likely accurately reflect body 
iron status (Milman, 2011). Alternatively, Breymann et al. (2010) says there is no 
value in taking postpartum ferritin levels at all to diagnose iron deficiency, because of 
inflammation. Iron stores as well as Hb should be tested antenatally, and post partum 
iron stores subsequently assumed (Breymann et al., 2010).  
New Zealand midwives may be unaware of the importance of these aspects in the 
differential diagnosis of iron deficiency and IDA in pregnancy and postpartum. The 
affect of inflammation on iron stores is described in the literature, but not in the 
observational study of current practice by Barroso et al. (2011). Furthermore, the 
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evidence around the interplay between ferritin and inflammation is not available for 
midwives in New Zealand in a form that clearly guides midwives’ clinical practice. 
Although approaches to serum ferritin testing vary (universal vs. risk based), ferritin is 
still widely accepted as the best measure of iron stores, by all but the Dutch 
midwives. Because of the complexities around testing and interpreting serum ferritin, 
it was apparent from the literature review that this study should include an analysis 
of CRP testing, alongside analysis of serum ferritin testing for iron stores. 
Mean cell volume  
Anecdotally, many New Zealand midwives may not be interpreting MCV when 
assessing iron status. According to the Health Pathways (2015) guideline, general 
practitioners in the study area only test serum ferritin if microcytic anaemia is 
indicated by a low MCV (<80fL) (Table 1).    The Royal Australian and New Zealand 
College of Obstetricians and Gynaecologists (RANZCOG, 2013) has no guidance for 
testing serum ferritin for iron stores, but does recommend interpreting MCV to assist 
in the diagnosis of anaemia, although parameters are undefined (Table 1).   
Conversely, the Dutch midwives’ anaemia guideline emphasises MCV, with specific 
parameters (Table 1). Dutch midwives say that MCV testing distinguishes 
physiological anaemia from anaemia (Offerhaus et al., 2004) and IDA (Jans, 2012). 
The advantages and disadvantages of MCV testing are considered below. 
The KNOV guideline considers MCV advantageous because it is less affected by 
haemodilution. It is a sensitive, cheap and easily available test (Offerhaus et al., 
2004). Dutch midwives test MCV only if the Hb result is low i.e. Hb < 5th percentile 
(Table 1). If MCV<80 fL, oral iron is prescribed. If MCV <70 fL, or >100 fL, the woman 
is referred to the general practitioner. So unlike in New Zealand, where MCV is 
routinely tested alongside haemoglobin as part of the CBC, Dutch midwives have to 
re-test to get a MCV result. 
The MCV gives information on the average size of the RBC. Red blood cells in the 
normal MCV 80-98fL range are normocytic. Mean cell volume <80fL indicates 
microcytic (small) RBCs, associated with iron deficiency and thalassaemia (Table 2). In 
mild cases of iron deficiency the MCV may not fall below normal (Pavord et al., 2012).  
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However a low or falling MCV is still suggestive of iron deficiency, regardless of the 
haemoglobin level (McMahon, 2010).  
Iron deficiency anaemia is referred to as microcytic, hypochromic anaemia because 
of the small, pale RBCs or erythrocytes (Miller & Wilkes, 2015). An MCV >100 fL 
indicates macrocytic RBCs, associated with other forms of anaemia e.g. B12 and/or 
folate deficiencies (megaloblastic, macrocytic anaemia) (Goonewardene et al., 2012). 
Macrocytosis is also associated with alcoholism, liver disease, hypothyroidism and 
cancer (Crowther, 2010). In  anaemia of inflammation (or ACD), the RBCs are usually 
normocytic (Friedman et al., 2012; Pasricha et al., 2010). To further complicate 
things, some people have both anaemia of inflammation  and IDA, which tends to 
present as microcytic anaemia, with normal or high serum ferritin (Friedman et al., 
2012; Pasricha et al., 2010) (Table 2). This can be difficult to diagnose 
(Goonewardene et al., 2012). 
A study on adherence to the KNOV 2000 anaemia guideline found 49% of Dutch 
midwives found it difficult not to prescribe iron if a woman has a low Hb but 
acceptable MCV, saying the KNOV parameters leads to under-detection of IDA 
(Offerhaus et al., 2004). Authors of the KNOV guideline say the standard is based on 
an extensive literature review, sufficient to substantiate and facilitate change 
(Amelink-verburg et al., 2010). However, there does not appear to be evidence in the 
literature to support or reject this emphasis on MCV. There were a number of 
published studies on MCV, Hb and anaemia from the 1970s, but nothing recently. 
Unlike serum ferritin, the value of MCV as an effective single indicator alongside Hb 
to detect iron deficiency, has not been widely studied (Mei et al., 2005).  
The KNOV anaemia guideline’s reliance on MCV to diagnose iron deficiency may have 
limited usefulness or sensitivity as MCV is slower to reflect low or reducing iron 
stores, than other tests (Thomas et al., 2013). A low MCV with a low Hb may 
accurately reflect IDA (Table 2), but the diagnosis is occurring at the final stage of iron 
depletion when iron stores may be absent, and it may be too late and too difficult to 
treat with oral iron therapy. Although MCV is a useful diagnostic tool alongside 
haemoglobin, the scope of this study limited the inclusion of MCV in the main 
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analysis.  However, MCV was examined in a sub-group of the study cohort with 
laboratory results suggestive of anaemia of inflammation, or thalassaemia (low 
haemoglobin and high ferritin).  
Other biochemical tests for iron status 
There are many other biochemical tests for iron deficiency, each measuring a 
different aspect of iron physiology (Mei et al., 2005). Discussion of the literature on 
these biochemical tests is beyond the scope of this study. Traditional diagnostic tests 
within the CBC are the red cell indices: haematocrit (Hct), MCV (as discussed above), 
mean cell haemoglobin (MCH) and reticulocyte counts.  
The reticulocyte count is the first to increase when erythropoises is stimulated 
(Notebaert et al., 2007). The MCH indicates the amount of haem pigment in each 
RBC. A normal MCH range of 25-34µg, indicates a normochromic RBC (Crowther, 
2010). Pale anaemic RBCs are hypochromic.  The haematocrit is the percentage of 
RBCs in the plasma volume, which complements measurements of haemoglobin. 
Values <0.33 may be diagnostic of anaemia in pregnancy (WHO, 2001). A high Hct 
>0.45 may indicate dehydration or decreased plasma volume associated with 
hypertension or pre-eclampsia (CDC, 1998; Frye, 2007).  
New Zealand midwives routinely request the CBC, however it is uncertain how much 
understanding or emphasis is placed on interpreting the red cell indices. Although 
this study did not analyse women’s red cell indices other than haemoglobin, the 
haematocrit and MCVs of a small sub group of women with high haemoglobin levels 
was of clinical interest in the study. 
Management and Treatment 
There are a range of approaches to preventing and treating anaemia and iron 
deficiency in pregnancy and postpartum, from primary care approaches of dietary 
advice and oral iron, to secondary/tertiary care strategies of intravenous iron or 
blood transfusions. Whilst the process of prescribing or recommending oral iron 
appears simple, there are many things to consider. It is unclear how much influence 
midwives have on women’s iron status, as women themselves are also responsible 
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for improving their diet and taking supplements when needed. The women’s 
contribution is beyond the scope of this study. However midwives’ primary care 
approach to testing and management is arguably a major influence on iron status in 
pregnancy; helping to reduce adverse outcomes associated with maternal anaemia 
and iron deficiency, as well as the risks and costs associated with blood transfusions 
and intravenous iron.  
Dietary recommendations 
There is a consensus in the literature that dietary advice and oral iron are the first 
lines of treatment for anaemia in the first and second trimesters, or throughout 
pregnancy when anaemia is mild (Barut & Harma, 2009; Breymann et al., 2010; Dodd 
et al., 2009; Pasricha et al., 2010). However, only KNOV (Jans, 2012) and the UK 
(Pavord et al., 2012) guidelines incorporate dietary advice in their recommendations 
(Table 1). 
Good nutrition is an important preventative measure, but not an effective treatment 
for iron deficiency (Pavord et al., 2012) or IDA (Beentje & Jens, 2011). A UK study of 
the oral iron intake (diet and supplements) of 1274 pregnant women, found that iron 
intake was higher in vegetarians, older mothers and women with a university degree 
(Alwan et al., 2011). Iron intake was significantly less in women who smoked, had a 
long term illness or lower socio-economic status (Alwan et al., 2011). The finding that 
vegetarians were less likely to have a low iron intake (odds ratio = 0.5, 95% 
confidence interval: 0.4, 0.8) is counter to popular belief, and contradicts the Dutch 
midwives’ recommendation that vegetarianism is a risk factor in pregnancy.  
Much of the literature on dietary iron focuses on how to limit inhibitors, and 
encourage iron absorption. Vitamin C improves bioavailability of iron. Similarly, 
consuming small amounts of haem (meat) iron with non-haem iron converts ferric to 
ferrous iron, a more soluble and absorbable form of iron (Elias, 2007). Inhibitors of 
iron absorption are tannin, calcium in milk products such as cheese, polyphenols in 
coffee and tea, phytate in whole grains, cereals and breads, oxalic acid in spinach and 
beetroot (Milman, 2006), and antacids (Monti, 2004). However, as Pavord et al. 
(2012) say “education and counselling regarding diet may improve iron intake and 
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enhance absorption but the degree of change achievable, especially in poorer 
individuals, remains in question” (p. 592). 
Oral iron supplementation 
Oral iron is not prescribed routinely for pregnant women in New Zealand and 
Australia (Miller & Wilkes, 2015). Although LMC midwives prescribe oral iron within 
their scope of practice, there is no clear guidance as to how much iron to prescribe 
and at what point. The only clear guidance is for obstetric referral and/or 
consultation when haemoglobin is <90g/L, and not responding to treatment (MOH, 
2012).    Midwives in New Zealand are advised to determine “the amount of 
supplementation required on an individual-needs basis according to the woman’s 
blood results, the woman’s diet and the gestation of the pregnancy” (Hunter & Gunn, 
2015, p. 872). Hunter and Gunn (2015)  point to National Women’s Hospital (2013) 
Guidelines, and UK Guidelines (Pavord et al., 2012), however the haemoglobin 
parameters and approach to oral iron supplementation in these guidelines differ. This 
may be confusing for midwives. It follows then, that this study wanted to explore 
how New Zealand midwives manage oral iron supplementation in practice. 
In the UK, pregnant women are no longer routinely supplemented with iron. Studies 
have shown that the UK population is generally well nourished and the incidence of 
anaemia, iron deficiency and IDA is lower than in the past, although still a significant 
problem (Alwan et al., 2011; Pavord et al., 2012). Evidence of the benefits of iron 
therapy on clinical and functional outcomes is explored in Chapter One. Importantly 
though, because meta-analyses of trials on iron supplementation are inconclusive 
(Dodd et al., 2009; Pena-Rosas et al., 2012; Reveiz, Gyte & Cuervo, 2010), some argue 
that iron supplementation should be stopped altogether (Wiegerinck & Mole, 2012). 
Nonetheless, women and infants in less-developed countries, where the high 
prevalence of maternal anaemia and iron deficiency constitutes a serious public 
health issue, do benefit from routine supplementation (Brabin et al., 2001; 
Goonewardene et al., 2012; Pasricha et al., 2013).   
Despite the controversies in the evidence, oral iron is still recommended as the first 
line treatment option for anaemia, NAID and IDA because it is cheap, safe and 
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effective (Pavord et al., 2012). Care must be taken, however, to establish the 
underlying cause of IDA before commencing treatment (Pasricha et al., 2010). The 
choice of treatment depends on the cause (Breymann et al., 2010). For example, 
nutritional iron deficiency benefits from oral iron supplementation but anaemia of 
inflammation, or ACD,  may not because the iron is unable to be absorbed and 
utilized in the body for erythropoeisis (Friedman et al., 2012; Koenig et al., 2014).     
How much iron to give is also contentious. There is a move in the literature away 
from regimes of high daily doses of oral iron supplements, towards lower dose 
approaches starting earlier in pregnancy.  Evidence from research demonstrates 
efficacy and reduced side effects with lower oral iron doses, or intermittent higher 
dose approaches, commenced early in pregnancy (Makrides et al., 2003; Milman et 
al., 2006).  The benefits of these approaches are thought to improve women’s ability 
to take iron more consistently (McMahon, 2010).   
An often cited study of 301 healthy Danish pregnant women evaluated the effect of 
daily oral iron prophylaxis of  20, 40, 60 and 80mg doses of elemental iron (Milman et 
al., 2006). The study groups were stratified according to their serum ferritin levels at 
inclusion. There were no significant differences in iron status between women taking 
40 to 80mg iron/day, but in women taking 20mg iron/day their iron status during 
pregnancy and postpartum was significantly lower (Milman et al., 2006).  
Although the scope of this study did not include examining dosages of oral iron 
supplementation, the Danish study by Milman et al. (2006) is still useful because of 
the distinction between higher and lower dose oral iron. This study was therefore 
designed to describe approximately whether midwives were prescribing higher dose 
iron, or recommending lower dose over the counter (OTC) iron. In New Zealand, for 
example, two commonly prescribed iron tablets contain 105mg (Ferrous sulphate) 
and 65mg (Ferrous fumarate) of elemental iron, compared to a popular OTC iron 
(Thomsons organic iron) with 24mg of elemental iron.  
Barroso et al. (2011) also observed practice around prescribing iron in relation to test 
results and found that of the 402 women found to be anaemic in the first or second 
trimester, only 49.3% had documented evidence of iron prescription. Similarly, this 
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study was designed to observe practice around iron supplementation in relation to 
women’s gestation and iron status; with the added distinction between prescribing 
(higher dose iron), or recommending (lower dose) iron. 
Consumption of oral iron is often problematic because of the high rate of mostly 
gastro-intestinal (GI) side effects (10-40%) that leads to a high rate of non-compliance 
(Barut & Harma, 2009). Common side effects are nausea and constipation. Other side 
effects include diarrhoea, abdominal pain, vomiting, general malaise and epigastric 
pain. Side effects are dose-related (Bhandall & Russell, 2006). Compliance rates for 
oral iron are also affected by the length of treatment required to replenish iron 
stores i.e. 3-6 months after normal Hb is restored (Singh, Fong & Kuperan, 1998). 
However, studying factors that influence women’s compliance rates with oral iron 
was beyond the scope of this study. 
The potential for over-supplementing oral iron was also a consideration in this study. 
Toxicity is generally not considered to be a concern as iron absorption is regulated by 
iron stores (Elias, 2007). But more recent evidence recognises that higher oral iron 
doses may have a toxicological effect, or oxidative damage associated with excessive 
pooling of intestinal iron (McMahon, 2010).  The risk of damage to intestinal 
epithelium is due to the continuous presence of relatively small amounts of excessive 
iron (Pavord et al., 2012), and iron-generated free radicals (Milman et al., 2006). The 
placenta is also particularly susceptible to free radical damage because it is highly 
vascular and rich in mitochondria. Markers of oxidative stress have been found to be 
significantly elevated in placentas of women who supplement regularly with iron 
(Pavord et al., 2012). High doses of oral iron may also lead to potential toxicity as 
high haemoglobin levels are associated with adverse fetal and maternal outcomes, as 
discussed in Chapter One. Because of the potential for over and under-prescribing 
iron, the study was designed to analyse haemoglobin and ferritin levels when 
midwives prescribed or recommended oral iron. 
The literature around dosages and side effects of oral iron was explored to broaden 
understanding of the overall effects of oral iron supplementation. In the last decade, 
knowledge of iron metabolism and the physiological effects of low and high dose iron 
Page 43 
 
supplements has increased. Because it was not known how LMC midwives in New 
Zealand approach iron supplementation, the study was designed to find out how 
often midwives prescribed iron, or recommended over the counter iron. These 
actions were designed to be recorded in relation to women’s iron status and 
gestation, to determine if midwives were prescribing appropriately, according to 
international evidence and guidelines.  
Postpartum anaemia, blood transfusion and intravenous iron  
The literature on postpartum anaemia was explored to understand the relationship 
between late pregnancy, and postnatal iron status. This included treatments or 
interventions for severe postpartum anaemia. This relationship was the initial 
motivation for this study. Anecdotally, it appears that a significant number of 
anaemic women present in labour, with a lower threshold for requiring blood 
transfusion or intravenous (IV) iron in the postnatal period.  
Birth can be a time of significant blood loss. Women who approach birth with 
significant anaemia, iron deficiency or IDA may be physiologically less tolerant of 
blood loss (Milman, 2012b; NBA, 2015). Accordingly, improvements in low antenatal 
iron status, decreases the use of postpartum blood transfusions (Milman, 2011; NBA, 
2015; Pavord et al., 2012; Walsh et al., 2011).  
Most women with post partum anaemia, NAID or IDA will benefit sufficiently from 
regular oral iron so that blood transfusion or intravenous iron are not required  
(McMahon, 2010). However, oral iron is not considered sufficiently effective, nor the 
response to treatment rapid enough, to treat moderate to severe postpartum 
anaemia or IDA (Barut & Harma, 2009; Singh et al., 1998). Decisions on management 
of haemorrhagic anaemia, take in to account the volume of blood loss, signs and 
symptoms, pre-partum haemoglobin levels, as well as antenatal iron stores 
(Breymann et al., 2010).  
There is no defined threshold below which RBC’s are indicated, as the decision to 
transfuse is made on an individual basis (Breymann et al., 2010). A blood transfusion 
may be indicated with an Hb of < 70g/L, but may not be required if the woman is 
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well-compensated (NBA, 2015). Outside of the massive obstetric haemorrhage 
situation, audits indicate that postpartum blood transfusions are over utilised (NBA, 
2015; Pavord et al., 2012). This is despite increased costs (James et al., 2008), risks of 
transfusion induced sensitisation, e.g. wrong blood, infection, acute lung injury (Barut 
& Harma, 2009; Breymann et al., 2010; Notebaert et al., 2007), and the potential 
future risk of fetal haemolytic disease (NBA, 2015; Pasricha et al., 2010; Pavord et al., 
2012).  Therefore, while blood transfusions have clear clinical benefits, there are 
significant risks, costs and disadvantages associated with them. 
Intravenous iron may be used as an alternative or adjunct to blood transfusion 
(Munoz et al., 2007). Second generation formulations of IV iron (iron sucrose and iron 
polymaltose), are being superseded by third generation (ferric carboxymaltose), with 
large (1000mg) total dose iron formulations, and a fifteen minute infusion time. With 
proven efficacy and safety, and advantages in administration (Breymann, Gliga, 
Bejenariu & Strixhova, 2007; Christoph et al., 2012; Frossier, Collingwood, Hodyl & 
Dekker, 2014; Van Wyck, Martens, Seid, Baker & Mangione, 2007), ferric 
carboxymaltose (ferinject) has recently been adopted for use in New Zealand 
hospitals, and some outpatient settings. This study gathered data on blood 
transfusions and IV iron to look at the link between these interventions and primary 
care management of maternal iron status, although this was not a main study 
objective or outcome. 
Summary of literature review 
The clinical issues around testing, diagnosis and management of anaemia and iron 
deficiency in pregnancy and postpartum, are complex for many reasons. There is no 
consensus on the definition of maternal anaemia. The often cited 1968 WHO 
definition of an Hb <110g/L is criticised for not sufficiently taking in to account 
normal haemodilution of pregnancy, and for not reflecting variance in different 
populations such as in Australasia. Similarly, there are inconsistent definitions of iron 
deficiency in the literature, with little in the way of clinical guidance for New Zealand 
midwives.  
Page 45 
 
Globally, there are only two comprehensive guidelines on the management of 
maternal iron status: UK guidelines on the management of iron deficiency in 
pregnancy (Pavord et al., 2012), and the KNOV Anaemia in Primary Care Midwifery 
Practice guideline (Jans, 2012). These guidelines are very different, with different 
parameters. However they both use evidence-based risk factors to guide the 
approach to testing, and they both emphasise dietary advice as a routine 
preventative strategy. The Dutch midwives emphasise MCV testing alongside 
haemoglobin testing, whereas other guidelines and literature focus on the red cell 
indices i.e. Hct and MCV as adjuncts to haemoglobin testing.   
Although serum ferritin is widely recommended as the best measure of iron stores, 
an accurate interpretation of iron stores requires concurrent testing with another 
inflammatory marker, CRP, to adjust the ferritin cut-off in the presence of 
inflammation. The best parameter for interpreting ferritin in the presence of 
inflammation is unclear, and the focus of recent research. Without correct laboratory 
testing of serum ferritin, midwives may be incorrectly interpreting misleading results. 
In the absence of an evidence-based guideline midwives may not be aware of the 
complexities and challenges in testing and diagnosing of maternal anaemia and iron 
deficiency.   
In terms of prevention and treatment of low maternal iron status, the evidence 
supports low dose oral iron started early in pregnancy for prevention (and to improve 
compliance), or higher (possibly intermittent) doses for treatment. It is beyond the 
scope of this study to examine dosages of oral iron, although a distinction is made 
between lower over the counter oral iron, and higher dose iron prescriptions. Beyond 
these primary care strategies, the literature supports a reduction in the use of blood 
transfusions, and better utilisation of intravenous iron where anaemia is moderate to 
severe, especially postpartum. Women who are anaemic or iron deficient as they 
approach birth, have a lower tolerance for blood loss, and are more likely to have low 
iron status postnatally.  
This literature review explored the gaps in knowledge and practice around diagnosis 
and management of maternal iron status, from a midwives' practice point of view. 
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Because so little is known about actual practice in New Zealand, this study is a 
starting point for identifying how LMC midwives, as primary maternity care providers 
test and diagnose anaemia and iron deficiency in pregnancy and postpartum. 
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Chapter three: Research Design 
Introduction, aims and objectives 
This research was undertaken to explore primary care midwifery management of 
maternal anaemia and iron deficiency in New Zealand by LMC midwives. The study 
examined the practice of LMC midwives as the study participants, by retrospectively 
investigating the data of their clients who were anaemic and/or iron deficient at 
some point during pregnancy or postpartum. The women’s retrospective data 
comprised a form of birth cohort, or closed cohort; followed from the study onset 
forward, often at set intervals, up to a fixed end date (Vandenbroucke et al., 2007).  
Primary care midwifery notes were reviewed and baseline information was obtained 
about the study cohort. The primary care notes are the hard-copy clinical notes 
where the midwife enters the woman’s medical and obstetric history, all primary 
care episodes and visits, and ongoing information such as birth summaries, 
consultation letters, laboratory, and ultrasound results. A copy of the primary care 
notes are also held by the woman. Each woman’s iron status was retrospectively 
identified for each trimester and postpartum, up to discharge from midwifery care. 
Clinical data and information on the midwives’ management of anaemia and iron 
deficiency was obtained from the primary care notes, from booking as baseline, to 
discharge. Further details of the design are described below. 
The research was stimulated by the overarching question as to whether there may be 
a need for a guideline to guide New Zealand midwives’ identification and 
management of maternal anaemia and iron deficiency. The research question was: 
“what is LMC midwives’ practice around management of women’s Hb<110g/L and/or 
serum ferritin <20mcg/L, during pregnancy and postpartum?” Specific study 
objectives were: 
 To ascertain levels of consistency of New Zealand LMC midwives’ testing and 
diagnosis of maternal anaemia and iron deficiency.  
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 To describe New Zealand LMC midwives’ practice around recommending or 
prescribing iron supplementation in relation to iron status and gestation.  
The exploratory nature of this study contributes to the existing but small body of 
global midwifery research on maternal iron status, from a unique New Zealand 
perspective. 
Research Approach/Methodology 
A descriptive study was undertaken with the main objective being an “accurate 
portrayal of characteristics of people, situations or groups, and/or the frequency with 
which certain phenomena occur” (Polit & Beck, 2008, p.752).  Descriptive research 
falls under the broader category of observational, non-experimental research. 
The descriptive methodology of this study was used to describe the phenomenon in 
the more or less natural setting, with no attempt to manipulate variables, or establish 
cause and effect, as described by Jirowong, Johnson and Wetch (2011). The 
phenomenon being investigated was the primary care midwifery management of 
maternal anaemia and iron deficiency, because little is known about actual practice 
in New Zealand.  
The value of observational or descriptive studies in clinical practice is endorsed by 
Strengthening and Reporting of Observational Studies in Epidemiology (STROBE) 
(Vandenbrouke et al., 2007). The STROBE guideline states that valuable evidence for 
health care practices requires knowledge about aetiology, pathogenesis, diagnosis 
and prognosis of diseases. This evidence is acquired from randomised trials about 
treatments and interventions. However, most  clinical or public health knowledge 
comes from observational research, with about 90% of research papers published in 
clinical speciality journals describing observational research (Vandenbrouke et al., 
2007).     
The research methodology in this study is non-experimental, observational and 
quantitative. Descriptive data was collected on the study population of LMC 
midwives, and data from women they cared for who were identified retrospectively 
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(by the LMCs) as having been anaemic and/or iron deficient at any point during 
pregnancy or postpartum period. The results may help direct more complex studies 
in the future, thereby beginning to address the lack of research on maternal iron 
status, specific to New Zealand. 
Research Methods 
A data collection tool was developed to record data from written entries in the 
women’s maternity notes and laboratory results. This was a form of chart review, and 
although chart review is a convenient source of data, the complexities of obtaining 
high quality data are sometimes overlooked (Allison et al., 2000). The tool was 
therefore designed with methodological rigour to enhance validity and reliability.  
Quantitative data was collected on a number of variables from the midwives and 
women, but no attempt was made to manipulate variables or establish cause and 
effect. The approach focused primarily on the description of midwives’ practice. The 
key study variables were haemoglobin, serum ferritin and whether midwives 
prescribed or recommended iron. Analysis of co-relations between the variables 
planned to ask questions about decision making of midwives. For example, “at what 
stage of pregnancy are midwives more likely to prescribe iron supplements?” or “is 
there an association between midwives’ caseloads or experience, and prescribing or 
recommending iron supplementation to women?”  
Setting  
Originally it was planned to undertake the research in two New Zealand regions. 
However for pragmatic reasons, and given the size and scope of the study the 
decision was made to undertake the research in one area only. This is a recognised 
limitation of the study as the population demographics vary markedly between the 
two main North and South Islands of New Zealand. Generalisability of the results may 
have been affected by this. The study is set in a South Island urban area that has four 
primary care maternity facilities and a large tertiary level hospital, with an annual 
birth rate of approximately 6000 babies. 
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Participants, sampling and recruitment 
Recruitment of the LMC midwives in the study group was via snowballing or network 
sampling methods following a presentation at a New Zealand College of Midwives 
(NZCOM) meeting. The sampling method of midwives was non-probability, self-
selected and purposive as described by Polit and Beck (2008). Only LMC midwives 
were included in the study because they are the predominant providers of primary 
maternity care in New Zealand.  
The study group of midwives were considered homogenous as they have similar 
characteristics that “ensures similarity of extraneous variables” such as similar 
training (Jirowong et al., 2011, p. 142). The disadvantage of homogeneity in the 
sample group is that it limits generalisation to other groups (Jirowong et al., 2011) or 
health professionals, such as family doctors or general practitioners. 
Following ethics approval from Victoria University of Wellington (Appendix A), and 
the DHB (Appendix B), recruitment of LMC midwives began in May 2014 with a 
presentation at a NZCOM meeting. Participant information sheets (Appendix C) were 
circulated and contact details of interested midwives recorded. The proposed 
research was positively received, with midwives identifying a need for research on 
maternal anaemia and iron deficiency. The presentation was followed up by notices 
in local NZCOM newsletters. The participant information sheet was posted on the 
regional NZCOM Facebook page where a number of midwives reported seeing the 
study information for the first time.   Interested midwives were followed up by phone 
and email to verbally confirm participation. Participant recruitment continued until 
the completion of data entry at the end of October 2014.  
In the phone and email conversations it was clearly explained to midwives that the 
study aimed to simply describe midwives management of anaemia and iron 
deficiency where little is known, as there is no recognised standard to measure 
practice against. This was not an audit. It was also explained that the ethics approval 
gained under the Human Ethics Policy (Victoria University of Wellington, 2014) was in 
accordance with the Privacy Act (Office of the Privacy Commissioner, 1993). As the 
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researcher, I would only be looking at, and gathering clinical data related to iron 
status.  
For pragmatic reasons, not all women cared for by the participating midwives during 
the study period were included in the study, although this would have enabled 
estimates of prevalence of maternal anaemia and iron deficiency in New Zealand.   
Women who were not anaemic or iron deficient at any point in pregnancy and/or 
postpartum were excluded. This was the only exclusion criteria, as the purpose of the 
study was to review midwives’ management of low maternal iron status. All women 
giving birth within the study period of September to December 2013 with an Hb of 
<110g/L and/or serum ferritin of <20 µg/L at any time throughout pregnancy and the 
postnatal period were included. Data was collected from four key decision points: the 
first trimester booking visit, second and third trimester, and postpartum, with 
laboratory results and midwives’ management recorded at each point.  
Study size 
Although the external validity of an observational study is strengthened by a 
predetermined sample size, based on sample size calculations, the importance of 
sample size determination depends on the context of the study (Vandenbroucke at 
al., 2007).   Early in the design phase, it was decided that due to the size and scope of 
the study, the aim was to sample as many midwives as possible within the time 
frame. The study aimed for a sample size of 20-30 midwives in one New Zealand 
area, where approximately two hundred LMCs practice. It was estimated that each 
midwife would provide data on approximately 10-20 women, potentially resulting in 
200-600 cases. The final study size was 21 LMC midwives, and a cohort of 189 
women. 
Design of data collection tool 
Design of the tool went through several phases. After the tool was pre-tested twice 
by two LMC participant midwives, it was changed to an electronic version with no 
hard copy. During this time the data entry plan changed from prospective entry by 
midwives, to retrospective entry by the researcher on to a Microsoft Excel computer 
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generated spreadsheet. This spreadsheet was developed with assistance from a 
specialised DHB programmer and health statistician.  
The advantage of entering data directly on to a computerised instrument is that it 
reduces opportunities for error, especially for larger complex projects with 20-30 
variables, or more than 50 charts to abstract data from (Allison et al., 2000). Although 
time-consuming for one person, this was considered an advantage in enhancing the 
internal validity of the tool, by minimising inter-observer error and reducing 
measurement bias. Immersion in the data, from inputting to analysis, can also 
enhance the quality of data analysis as the researcher knows the data and can 
scrutinize the data for typical and extreme cases, as well as sub-groups (Polit & Beck, 
2010). However one individual ‘abstractor’ working in isolation can also be a 
disadvantage in gathering high quality data because of abstractor assumption and 
interpretation (Allison et al., 2000). So to enhance the tool’s reliability and 
repeatability, factors affecting internal validity are explained in more detail below.  
Quantitative, retrospective data was gathered from the case notes on midwives’ and 
women’s demographic data, laboratory results, midwives’ documentation on their 
management of maternal iron status, and on a small number of postpartum 
outcomes (i.e. birth-weight, gestation at birth, and blood loss). Data on laboratory 
results were also collected online from the DHB to access results missing in hard-copy 
in the clinical notes. This included collection on data regarding inter-laboratory 
differences in testing of serum ferritin.  
Demographics 
Midwives’ demographic data was gathered from a short paper questionnaire of 
seven closed, self-coded questions, including multiple choice questions. These 
midwifery characteristics included: age, years of practice, ethnicity, work setting, 
caseload, practice arrangements and qualifications. Midwives’ demographic data was 
compared to demographic data from the national Midwifery Workforce Survey 
(MCNZ, 2012) to ascertain representativeness of the sample group.  
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Demographic data on the women included: parity, age, ethnicity, time frame 
between pregnancies, smoking and BMI. Women’s demographic data was compared 
with maternal demographic profiles from 2012, in the Report on Maternity (MOH, 
2015).  Although quality of diet and socio-economic status are both strongly 
associated with iron status in pregnancy, they were not included in the baseline 
demographics of women, due to the complexity in measuring these factors within the 
limited scope of study. Some data was gathered on maternal risk factors (i.e. age, 
parity and time interval between births), but these were not analysed in the end due 
to limited size and scope of the study.  
Mode of administration 
After the participating midwives had determined which women met the inclusion 
criteria, a time and place was arranged for handing over of the primary care clinical 
notes to the researcher. These notes were different to the hospital notes, which were 
not accessed for this study. Privacy and confidentiality of the midwives, and 
anonymity of the women and their clinical information, was maintained at all times. 
The clinical notes were locked in storage when not in use. Data was entered on the 
researcher’s password protected computer, and backed up on a hard drive and 
locked away securely. Maternity notes were returned to the midwives as soon as 
data entry was completed. Midwives were de-identified by allocating them a 
number, linked to their group of women from the beginning of data collection. The 
women were never named, in the collection of their data. Women’s national health 
index (NHI) identifiers were entered initially on the Excel spreadsheet, and changed 
to a case number when entered onto the Statistical Package of Social Sciences 
Software (SPSS) spreadsheet. Both the midwife participants and the women’s data 
and test results, were de-identified, becoming anonymous very early in the research 
process.  
Quantitative variables  
The study variables that were collected for the first, second and third trimester 
included: haemoglobin, serum ferritin, CRP, gestational age at testing, reasons for not 
testing, and midwives’ management including: dietary advice, over the counter iron, 
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iron prescription, and referral (or transfer of care) to a specialist for intravenous iron 
or blood transfusion. Postpartum variables also included gestation at birth, birth-
weight, peri-partum blood loss and timing of tests. Not all outcome variables were 
included in the analysis, i.e. gestation at birth and birth weight.  Data was collected in 
the rawest form and entered as continuous variables, or coded categorical variables. 
The level of measurement for some variables was reorganised into categories after 
the initial data collection, and during statistical analysis. 
Haemoglobin was the key variable that defined anaemia. The inclusion criteria of 
Hb<110g/L was selected because it is the WHO (1968) parameter for diagnosing 
anaemia in pregnancy, that is still maintained (NBA, 2015), and most often cited. The 
WHO parameter of Hb<110g/L may not also sufficiently account for haemodilution 
beyond the first trimester of pregnancy (Pavord et al., 2012). However, CDC (1998) 
definition of anaemia in pregnancy as Hb<105 g/L, is considered a reasonable 
alternative to the WHO definition, as it takes into account haemodilution of 
pregnancy (Paterson et al., 1994; Pavord et al., 2012). Therefore, this study defined 
anaemia in the second and third trimester as Hb<105 g/L. Postpartum anaemia was 
defined as Hb <100 g/L as per the WHO (2000) and UK guidelines (Pavord et al., 
2012). Severe postpartum anaemia is defined by Breymann et al. (2010) as Hb 
<85g/L, although international guidelines do not categorise postpartum anaemia 
according to severity (Table 1).  
Serum ferritin was the key variable that defined iron deficiency. The cut-off for iron 
deficiency was ferritin <20µg/L, and absent iron stores was ferritin <12µg/L. These 
parameters are lower than UK guidelines of ferritin <30µg/L (Pavord et al., 2012), but 
utilised in an often cited study by Walsh et al. (2011); and consistent with the  local 
DHB guideline with parameters for maternal for iron status (on intravenous iron use 
in pregnancy and postpartum).  
The study cut-off for iron deficiency, in the presence of inflammation (i.e. CRP >5mg), 
was serum ferritin <50µg/L, also consistent with the local DHB guideline. This 
parameter is between the ferritin <30µg/L parameter proposed by WHO (2011) and 
Thurnham et al., (2010), and the ferritin <70µg/L cut-off proposed by Wang et al. 
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(2010). Serum ferritin parameters for defining iron deficiency, in the presence of 
inflammation, have not been clearly established (Gartner et al., 2013; Nel et al., 
2015; Thurnham et al., 2010). 
Data from the clinical notes after each trimester’s blood tests, recorded up to three 
of the midwife’s actions, as some midwives had more than one strategy to manage 
iron status, e.g. dietary advice and an iron prescription. Management actions were 
categorised as main and secondary actions, according to how midwives prioritised 
their strategies in the clinical notes. There were six options or strategies: no action, 
dietary advice, over the counter iron, iron prescription, general practitioner referral, 
or obstetric referral. The scope of the study limited the amount of detail regarding 
management, simply describing that a clinical strategy had been advised, or not.  
Over the counter iron included all non-prescribed iron preparations, ranging from 
herbal preparations to supermarket bought supplements, including multivitamins 
and minerals. The variable for prescribed oral iron recorded the binary action of 
prescribing (yes/no), not the dose or frequency of the dose. Information on 
compliance or tolerance of oral iron supplements was not recorded. Oral iron 
supplements were operationalised primarily as outcome variables, because the 
action of prescribing or recommending iron was presumably influenced by changes in 
the predictor variables i.e. Hb, serum ferritin and gestation. 
Data measurement 
The details of measurements of the variables are described below to strengthen the 
validity and reliability of the study, especially where there was a potential for 
measurement error. The STROBE recommends giving sources of data, details of 
methods of measurement for the variables, as well as clear definition of the types of 
variable, to strengthen study validity (Vandenbrouke et al., 2007).   Accordingly, 
measurement error or bias was minimised with consistent decisions at the data entry 
level by the researcher.  
Iron status was the most challenging to categorise in order to minimise measurement 
error. This was due to inconsistent testing of serum ferritin, and inconsistent testing 
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of CRP alongside serum ferritin to adjust for the presence of inflammation.  For 
example, anaemia without a measure of serum ferritin for iron stores was 
categorised as ‘anaemic with unknown stores’, rather than IDA, which was probable.  
Without a concurrent CRP, serum ferritin may show as a false high/normal result. The 
decision was therefore made to operationalise iron sufficiency as ‘confirmed’ or 
‘unconfirmed’. Confirmed iron sufficiency was non-anaemic and ferritin ≥ 20µg/L 
with CRP<5mg/L, or ferritin ≥50µg/L with no CRP. Unconfirmed iron sufficiency was 
non-anaemic and ferritin 20-49µg/L with no CRP to correct for inflammation. So the 
decision was made early in the study, to interpret blood test results at face value,  
and to make minimal assumptions about iron status based on incomplete results. 
Information on methods of blood test analysis was sought from the two laboratories 
where midwives obtained the majority of test results, to minimise the potential for 
measurement error due to different analysis methods. Haematological analysis of the 
CBC at the DHB laboratory was automated on the Sysmex XE2100 analyser. The 
private laboratory used an updated version of the same method on the Sysmex 
XE5000. Serum ferritin was analysed at the DHB laboratory by a chemi-luminescent 
microparticle immuno assay (CMIA), on an Architect C8000 analyser, and via Hitashi 
Cobas instruments and an ECLIA method at the private laboratory. The DHB and 
private laboratory both tested CRP via an immune-turbidometric method on an 
Architect (C8000) analyser. Methods of testing are available on the website 
(www.labnet.health.nz/siqag).  Importantly, the reported reference ranges for all the 
tests are standardised by the South Island Quality Assurance Group.  
Measurement of blood loss as a postpartum variable was entered from recorded 
blood loss on women’s delivery summaries. Blood loss is usually estimated, and 
sometimes measured when loss is significant. Estimations of peri-partum blood loss is 
however, notoriously inaccurate. Of primary interest in this study was midwives’ 
management of anaemia following significant blood loss, defined as >500mls. 
A difficulty in measuring midwives’ management of maternal anaemia and iron 
deficiency was the documentation of clinical practice. The dictum “if it isn’t written 
down, it didn’t happen” posed challenges, because what some midwives told me 
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they were doing, was not necessarily evident in their documentation. For example 
one midwife explained that she always dedicated a first trimester antenatal visit to 
dietary advice, including iron intake, however this was not documented in the clinical 
notes, and therefore not entered. This highlighted the fact that clinical information 
from a chart review is at least two steps removed from the patient, as clinicians 
examine and document, then abstract the information (Allison et al., 2000).  
Consistent data entry was important for collection of data on iron supplementation, 
as the midwives’ documentation varied widely. For example, where midwives 
documented “taking iron supplements” or “taking iron tabs”, this was entered as 
over the counter iron, not prescription iron, unless stated as such. Doses or 
frequency of oral iron were not recorded. In the antenatal summary of the primary 
care notes where ‘minerals prescribed’ was ticked, but not distinguishable between 
iodine or iron, iron wasn’t entered as having been prescribed unless clarified in the 
clinical notes.  
Iron supplements were not presumed to have been continued once started. Unless 
midwives documented comments about the women taking oral iron in subsequent 
visits, it was presumed to have been stopped.  Conversely, if there was documented 
evidence of continuing to take oral iron, subsequent to the initial prescription or 
recommendation, data was re-entered as ‘oral prescription’ or ‘OTC iron’.  
Missing data 
The internal and external validity of this study was strengthened by addressing how 
‘missing’ laboratory results were managed for the main variables of interest (Hb and 
serum ferritin). There was no missing data, as all laboratory tests not undertaken 
were all accounted for by cross checking documentation with hard copies, and online 
laboratory results. All tests not undertaken were accurately coded according to why 
the tests were not undertaken.  
Whole groups of first, second or third trimester antenatal blood tests were not 
undertaken for some women. These data fields were coded as ‘tests not done’ when 
they were not requested by the LMC midwife. Other reasons for missing groups of 
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blood tests results were due to women booking later in pregnancy, declining blood 
tests, or birthing prematurely. These were coded separately.  
Because serum ferritin is not a routine test, missing ferritin results were coded as 
‘ferritin not requested alongside CBC’. Missing CRP results were coded according to 
the type of laboratory where the ferritin test was analysed, as concurrent testing of 
CRP with ferritin is based on laboratory practice. Information on laboratory types (i.e. 
DHB or private), was obtained from the online laboratory results. The analysis of the 
reasons why blood tests were not undertaken was, therefore, an important part of 
the study. 
Data Analysis 
The focus of analysis in this study was to describe midwifery decision making and 
management of maternal iron status, by analysing the frequency and results of 
laboratory tests, and the frequency of over the counter or prescribed iron, at each 
trimester and postpartum. This analysis included changes in iron status, and 
midwives’ response to this.  
Analysis of data was systematically approached in several phases following data entry 
and data cleaning. Data cleaning was a lengthy phase, as many laboratory results 
were not recorded, or incomplete, in the primary care notes. Therefore, almost all of 
the women’s results were cross-checked with on-line results. At this stage, the tests 
not undertaken were coded as to why they were not undertaken. Results were also 
coded as to which laboratory had undertaken the testing. Data cleaning occurred 
through every phase of analysis, and outliers and unusual or inconsistent results were 
investigated. Occasional data entry errors were found, and corrected, especially 
where continuous data was re-code or categorized.  
Data was initially entered on Microsoft Office Excel worksheet, then imported and 
analysed by SPSS (Version 22). Analysis of baseline data was the first phase. 
Demographic characteristics of the midwives and the cohort of women were 
analysed with descriptive statistics, to ascertain the representativeness of the study 
groups. The midwives were compared to 2910 midwives with annual practicing 
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certificates (APCs) in 2012 (MCNZ, 2012). The study women were compared to the 
62,321 women who gave birth in New Zealand in 2012 (MOH, 2015).   
Analysis of continuous variables in the demographic data included measuring 
distributions, to ascertain the appropriate measures of central tendencies for the 
normally distributed (mean and standard deviation (SD)) and skewed (median and 
inter-quartile range ) data.  Normally distributed variables that could have parametric 
statistical tests, included the midwives’ age in years, years in practice and caseload. 
The skewed variables that could have non-parametric statistical tests included the 
women’s age, BMI, time since last pregnancy, and gestation at birth.  
Following input from the Victoria University statistician, 95% confidence intervals of 
proportions were calculated to compare differences between the cohort of women, 
and comparative data from MOH (2015). The confidence intervals were calculated on 
https://www.mccallum-layton.co.uk/tools/statistic-calculators/confidence-interval-
for-proportions.  Confidence intervals were not calculated on midwives’ demographic 
data as the sample size was too small.  
The second phase was a descriptive analysis of the frequency of tests undertaken, 
categories of iron status, and midwives management strategies. This included 
categorising continuous demographic and clinical data into categorical variables. 
Initial analysis of this data resulted in the development of decision trees (Appendices 
D, E & F) that tracked the testing and iron status of each woman, for each trimester 
and postpartum. Women were grouped according to whether they had serum ferritin 
tested at booking, or not, as this was the main difference in practice. The decision 
trees provided an overview of testing and iron status, and provided a means of 
tracking individual cases throughout pregnancy and postpartum, which was unable to 
be achieved through the basic descriptive analysis. 
The research question, the distribution of the data, and the types of variables 
directed the choice of inferential statistical tests used to explore relationships 
between the variables.  Associations between midwives’ caseloads, or years of 
practice, and practices of testing for iron deficiency, and prescribing iron were 
analysed by Pearson chi-square tests of independence. A Mann-Whitney U-test was 
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also used to test the difference between third trimester ferritin levels for women 
who had ferritin tested at booking or not.  
Measures of effect were reported alongside the statistical level of significance (p 
value), to enable readers to interpret the research findings without over-reliance on 
p values (Field, 2013). As well as the 95% confidence intervals of proportions in the 
descriptive analysis, Cramer’s V and Cohen’s d values were the other reported 
measures of effect size, or strength of association, in the chi-square analysis (for the 
three by two, and two by two tables respectively).  Reporting the strength of the 
associations allows the reader to interpret the clinical significance of the study’s 
findings, especially where the study is too undersized to demonstrate statistical 
significance (Peat, 2002).  
Secondary analyses, that were not pre-determined, were undertaken to determine 
any differences between BMI and low iron status. A Mann-Whitney U-test was used 
to test the difference between third trimester ferritin levels (as continuous, skewed 
data) and normal/low-weight or over-weight/obese BMI. A Pearson’s chi-square test 
for independence was used to test the relationship between low iron status and BMI, 
in a 3 x 2 table. BMI was categorised to low/normal BMI (<25), and overweight/obese 
BMI (≥25). Iron status had three categories: low iron status, iron sufficiency 
(confirmed and unconfirmed), or unknown status. These categories for iron status 
were flawed due to the difficulty in categorising iron status because of incomplete 
blood tests results. These factors were not controlled for in the analysis. 
Another secondary analysis was undertaken because high BMI is a pro-inflammatory 
state that may mask iron deficiency, with false normal/high ferritin levels, 
uncorrected for inflammation by an absence of concurrent CRP testing. All women 
with ferritin testing at booking, but with no CRP, were analysed for each trimester. 
The women were categorised according to iron status and BMI: low/normal 
(BMI<25), overweight (BMI 25-29), and obese (BMI≥30). The basic descriptive 
analysis of proportions was repeated with the different serum ferritin parameters at 
booking of <20µg/L, <30µg/L and <50µg/L; the latter two parameters are two 
proposed for iron deficiency in the presence of inflammation. The small size of the 
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sub-groups, precluded statistical analysis, or use of confidence intervals, but may be 
clinically interesting.  
Validity, reliability and bias 
The validity and reliability of the study was strengthened by the methodological 
rigour and minimisation of bias, in the study’s planning phase. The methods section 
above outlines how potential sources of bias were minimised, and measurement 
errors were avoided, with careful explanation of conceptual and operational 
variables. Particular attention was given to developing an instrument or tool that had 
good internal and external validity in the collection of high quality data for analysis.   
Face, content and construct validity are types of internal validity relevant to this 
study. Face validity is the extent to which the instrument measured what it was 
supposed to measure (Cluett & Bluff, 2006; Peat 2002). Content validity is the extent 
to which the instrument covered the research area of interest, and construct validity 
the extent to which the tool encompassed the concept, or construct being measured 
(Cluett & Bluff, 2006; Peat 2002). Because a new instrument or tool was devised for 
this study, the internal validity of the tool is yet to be verified. Nonetheless, every 
effort was made to develop a tool that is highly valid and reliable.  
External validity or generalisability of the results was sought by maximising the 
sample size of midwives and women. Although the sample size of midwives was small 
and statistically underpowered, the results may still be of clinical interest. A 
recognised limitation of the study relates to differing ethnic demographics in the two 
main geographical islands of New Zealand. Validity and reliability in this study was 
achieved with the richness of the data collection, with no missing data which resulted 
in high quality data for the descriptive and inferential statistical analysis. 
Ethics, and the Treaty of Waitangi 
This study respected the Treaty of Waitangi principles of partnership, participation 
and protection, as the foundations for the ethical code of conduct for practice and 
research for New Zealand midwives. The NZCOM (2005) upholds “each women’s 
rights to free and informed choice and consent ... ensuring the advancement of 
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midwifery knowledge [and research] is based on activities that protect the rights of 
women” (p. 8). Accordingly, the participant information sheet clearly explained the 
purpose of this study including: an invitation to participate, what the midwives’ role 
in the study would be, potential risks and benefits, how privacy was protected, and 
how the information was to be collected and used (Appendix C).  
Ethics approval was granted by Victoria University of Wellington (Appendix A), and 
the DHB (Appendix B). The DHB ethics process involved a consultation process with 
Te Komiti Whakarite (DHB Maori Research Committee), and a commitment to submit 
a final report to Te Komiti Whakarite when the research is complete.  
The specific ethical issues that needed to be considered in this study were principally 
related to protecting the privacy and identity of the participating midwives; the 
safekeeping and protection of the information in the clinical documentation; and 
ensuring that the diagnostic tests and midwifery treatment decisions were not 
identifiable.  
The midwives were de-identified by allocating them a number, linked to the group of 
women in their care. The women were never named. The women’s NHIs were 
changed to case numbers after the initial data entry phase was completed. The 
participating midwives, and the women’s data, were de-identified and became 
anonymous very early in the research process. Therefore the midwives’ treatment 
strategies and the women’s test results also became anonymous early on. 
The clinical notes were held by the researcher for the minimal time possible, and 
locked away when not in use. The data was entered on a password protected 
computer, and hard-drive back-ups were also locked away. Only clinical information 
relevant to maternal iron status was studied in the notes, and recorded on the 
spreadsheet.  
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Chapter four: Results 
Introduction 
This chapter presents the results of the study of 21 New Zealand LMC midwives’ 
management of maternal anaemia and iron deficiency throughout pregnancy and 
postpartum. Section one of the results begins with the demographic and professional 
characteristics of the midwives and the demographic details of the cohort of 189 
women whose clinical details (related to anaemia and iron deficiency) provided data 
for this study. Section two presents the results of the LMC midwives’ practice around 
diagnosis and management of women’s Hb<110g/L and /or serum ferritin <20µg/L, 
during pregnancy and postpartum. Section three outlines results of additional 
analyses undertaken on iron status of women with a high BMI, as the presence of 
inflammation related to high BMI, may have confounded interpretation of laboratory 
results for midwives. 
Section One: Demographics 
Twenty-one self employed, ‘case-loading’ LMC midwives participated in this study. 
The sample of midwives is comparable to the Health Workforce Survey of 2910 
midwives with annual practising certificates in 2012 (MCNZ, 2012), in terms of mean 
age and years in practice (Table 3). However, Maori midwives were under-
represented in the study with no study midwives identifying as Maori. A higher 
proportion of the study midwives had larger caseloads. The urban setting also did not 
represent rural midwifery practice.  
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Table 3: Characteristics of Lead Maternity Carer Midwife participants compared 
with those with a practicing certificate in 2012 
Characteristic  Study midwives 
n (%) 
Midwives with 2012 APC 
n (%) 
Midwives age in years  
mean + / - SD 
                 
47.2 +/- 10.425 
                      
46.8 (no SD)  
Years in Practice  
mean +/- SD  
1-10 
11-20 
21-30 
31-40 
41+ 
Not stated 
     
15.5  +/-  12.695   
11 (52.4) 
2 (9.5) 
5 (23.8) 
3 (14.3) 
- 
- 
 
14.7 (no SD) 
1237 (42.5) 
865 (29.7) 
506 (17.4) 
255 (8.8) 
42 (1.4) 
5 (0.2) 
Caseload 2013  
mean +/- SD 
11-20 
21-30 
31-40 
41-50 
51-60 
61-70 
 
46.3  +/-  14.242     
1 (4.8) 
1 (4.8) 
6 (28.6) 
7 (33.3) 
2 (9.5) 
4 (19.0) 
 
42.0 (no SD)   
77 (7.2) 
89 (8.4) 
152 (14.3) 
198 (18.6) 
180 (16.9) 
101 (9.5) 
Ethnicity  
Maori 
New Zealand and other European 
Other 
 
0 (0) 
20 (95.2) 
1 (4.8) 
 
150 (5.2) 
2587 (88.9) 
44 (1.5) 
Practice arrangement 
Works alone 
Works with one other  
Works with two or more 
         
        0 (0) 
4 (19) 
17 (81) 
- 
- 
- 
Postgraduate study 
Completed qualification 
Currently studying 
 
1 (4.8) 
0 (0) 
 
 84 (2.9)* 
191 (6.6) 
Totals 21 2910 
* Only reports postgraduate qualification completed in previous year, therefore overall number of midwives with 
postgraduate qualifications will be higher 
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In the study group, and the population of all New Zealand midwives with annual 
practicing certificates, the largest proportion practiced for 1-10 years, 52.4% and 
42.5% respectively. Both groups had annual caseloads of 31-50. In the study, 19% of 
LMC midwives had larger caseloads of 61-70, compared to 9.5% of LMCs in the 
general population (MCNZ, 2012). The MCNZ (2012) did not survey practice 
arrangements. However 81% (n=17) of study midwives worked with two or more 
other midwives.  
Similar representativeness was present in the women for whom this group of 
midwives provided care. The women were similar to the target population of 62,321 
women who gave birth in New Zealand in 2012 (MOH, 2015) in terms of age, 
gestation at birth and parity (Table 4). However they did differ with respect to 
ethnicity and smoking behaviour. The study women included a high proportion (76%, 
n=143) of New Zealand or other European ethnicities compared to under half (48%, 
n= 28,894) in the general population. There was a small proportion of Maori (8.5%, 
n=16) compared to 25% (n=15,694) nationally.  Nationally more women in 2012 
smoked (15%) (MOH, 2015),  than in the study group (9%). The combined proportion 
of study women with overweight or obese BMIs was less than birthing women in 
New Zealand in 2012 (44% vs. 51%).   
The descriptive analysis, including the measures of central tendency, did not 
necessarily match comparative demographic data from the MOH (2015) and MCNZ 
(2012). For example MCNZ (2012) data did not include standard deviation (SD) with 
the mean, although this measurement is included in Table 3 to demonstrate 
statistical accuracy of the study midwives. Similarly, MOH (2015) data did not include 
inter-quartile range (IQR) for the non-parametric demographic data on women, but 
this is included in Table 4 to demonstrate statistical accuracy of the study cohort. 
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Table 4: Characteristics of women in study, compared to birthing population of 
women in 2012 
Characteristic  Study women  
median (IQR)* 
Women giving birth 2012§ 
median (IQR) 
Women’s age in years 
 
31.0 (27-35)  29.0 (-¶)  
Time since previous 
pregnancy in months  
29.0 (22-41.5) - (-) 
Gestation at birth  39.0 (38.0-40.0)   39.0 (-) 
Characteristic  Study women 
n (%), 95% CI’s¥ 
Women giving birth 2012  
n (%)¤, 95% CI’s  
Ethnicity  
NZ and other European 
Maori 
Asian 
Pacific 
Other 
                 
143 (75.7), 70-82 
16 (8.5), 5-14 
12 (6.3), 3-10 
5 (2.6), 0-5 
13 (6.9), 3-11 
                      
28,894 (48.0), 47.6-48.4 
15,694 (25.2), 24.9-25.5 
8,532 (13.7), 13.4-14.0 
6,975 (11.2), 11.0-11.4 
1,245 (2.0), 1.9-2.1  
Parity at booking 
0 
1 
2 
3 or more 
                  
 73 (38.6), 32-46 
65 (34.4), 28-41 
36 (19.0), 13-25 
15 (8.0), 4-12 
                      
22,691 (41.2), 40.8-41.6 
- (33.3), 32.9-33.7 
- (14.9), 14.6-15.2 
                           -(10.6), 10.4-10.8 
Pregnancy  
Singleton 
Multiple 
 
184 (97.4), 95-100 
5 (2.6), 3-5 
 
- (-) 
- (-) 
Smoking at booking 16 (8.5), 5-12 - (15.25), 15-16 
Body Mass Index† 
Underweight BMI<19 
Healthy BMI 19-24 
Overweight BMI 25-29 
Obese BMI>30  
 
9 (4.8), 2-8 
97 (51.1), 44-58 
49 (25.9), 20-32 
34 (18.2), 13-24 
                                   
- (2.8), 2.7-2.9 
                         - (46.6), 46.2-47.0 
15,507 (28.1), 27.8-28.4 
                   12,412 (22.5), 22.2-22.8 
Totals 189 62,321 
* Inter-quartile range 
§ MOH, 2015 
¶ Indicates no data provided 
¥ 95% Confidence Intervals of proportions presented as percentages for consistency. 
¤ Maternity Report 2012 percentages add up to more than 100% as some selected more than one ethnicity value 
† Body Mass Index (BMI) in kg/m² 
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Section Two: Diagnostic tests and treatments 
Testing for iron status in pregnancy 
The total combined LMC’s caseload was 974 women. Of these, 19.4% of women met 
the inclusion criteria of Hb<110g/L and/or serum ferritin <20µg/L at any point in 
pregnancy or postpartum. Haemoglobin was almost always tested in the first (98.4%) 
and second (95.8%) trimesters, but this decreased in the third trimester (82%). Across 
the three trimesters haemoglobin was tested at least once for all women. Serum 
ferritin was more commonly tested in the second trimester (83.6%), and third 
trimester (67.7%) than at the first trimester booking (52.4%) (Table 5). 
Table 5: Testing for iron status in pregnancy by trimester. 
Testing for Hb or ferritin 
N=189 
First trimester 
n (%) 
Second trimester 
n (%) 
Third trimester 
n (%) 
Total number of complete blood 
counts undertaken as routine 
antenatal testing (including  Hb)  
186 (98.4) 181 (95.8) 155 (82.0) 
No tests undertaken 3 (1.6) 7 (3.7) 34 (18.0) 
Ferritin tested alone without Hb - 1 (0.5) - 
Ferritin tested with Hb 99 (52.4) 158 (83.6) 128 (67.7) 
 
Almost half (47.6%, n=90) of the woman did not have serum ferritin tested at 
booking (Table 5). Serum ferritin was not requested alongside the routine request for 
the complete blood count and haemoglobin for 46.0% of women in the first, 12.2% of 
women in the second, and 14.3% of women in the third trimester.  The blood testing 
and iron status of individual women was tracked through each trimester, and 
represented in the decision trees (Appendices D, E & F), in a way that the aggregated 
results represented in the table could not. For example, five women had no ferritin 
tested at all (Appendix E), although this is not evident in Table 6. One midwife did not 
request any serum ferritin tests for four of her eight clients in the study. An 
additional 13.8% of women (n=26) had no third trimester bloods requested at all by 
midwives.   
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Table 6:  Reasons antenatal tests were not undertaken  
Reasons tests not 
undertaken 
N=189 (%) 
Antenatal 
tests  not 
requested 
n (%) 
Ferritin not 
requested  
with CBC* 
n (%) 
Late 
Booking 
 
n (%) 
Woman 
declined 
tests 
n (%) 
Woman 
away 
for tests 
n (%) 
Birthed 
Pre-
maturely 
n (%) 
No haemoglobin 
tested  
First trimester:   
3 (1.6) 
 
 
 
0 (0.0) 
 
 
 
0 (0.0) 
 
 
 
1(33.3) 
 
 
 
2 (66.7) 
 
 
 
0 (0.0) 
 
 
 
0 (0.0) 
No haemoglobin 
tested  
Second trimester:   
8 (4.2) 
 
 
 
6 (75.0) 
 
 
 
0 (0.0) 
 
 
 
1 (12.5) 
 
 
 
0 (0.0) 
 
 
 
1 (12.5) 
 
 
 
0 (0.0) 
No haemoglobin 
tested  
Third trimester:   
34 (18.0) 
 
 
 
26 (76.5) 
 
 
 
0 (0.0) 
 
 
 
0 (0.0) 
 
 
 
1 (2.9) 
 
 
 
0 (0.0) 
 
 
 
7 (20.6) 
No serum ferritin 
tested  
First trimester:   
90 (47.6) 
 
 
 
0 (0.0) 
 
 
 
87 (96.7) 
 
 
 
1 (1.1) 
 
 
 
2 (2.2) 
 
 
 
0 (0.0) 
 
 
 
0 (0.0) 
No serum ferritin 
tested  
Second trimester:  
31 (16.4) 
 
 
 
6 (19.4) 
 
 
 
23 (74.2) 
 
 
 
1 (3.2) 
 
 
 
0 (0.0) 
 
 
 
1 (3.2) 
 
 
 
0 (0.0) 
No serum ferritin 
tested   
Third trimester:  
61 (32.3) 
 
 
 
26 (42.6) 
 
 
 
27 (44.2) 
 
 
 
0 (0.0) 
 
 
 
1 (1.6) 
 
 
 
0 (0.0) 
 
 
 
7 (11.6) 
*Complete blood count including haemoglobin (Hb) 
Iron Status 
The findings on iron status at each trimester are presented throughout the results in 
relation to when the midwives tested, gave dietary advice, prescribed or 
recommended iron. Because of incomplete antenatal test results for iron stores, 
either due to serum ferritin not  tested, or ferritin not tested with CRP, the ‘sufficient’ 
iron status group was categorised as ‘confirmed’ or ‘unconfirmed’ (Table 7).  
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Table 7: Iron status in pregnancy 
Iron Status First  
trimester 
n (%) 
Second 
trimester 
n (%) 
Third 
trimester 
n (%) 
Confirmed Iron Sufficiency* 51 (27.0) 2 (1.1) 12 (6.3) 
Unconfirmed Iron Sufficiency§ 31 (16.4) 17 (9.0) 30 (15.9) 
Non-anaemic: 
 (ferritin not tested, iron stores 
unknown) 
86 (45.5) 23 (12.2) 24 (12.7) 
Non-anaemic iron deficiency:  
ferritin 12-19 µg/L (or SF <50 µg/L 
with CRP >5)  
13 (6.9) 46 (24.3) 42 (22.2) 
Non-anaemic absent iron stores: 
ferritin<12µg/L 
2 (1.1) 77 (40.7) 29 (15.3) 
Anaemic:¶  
(ferritin not tested, iron stores 
unknown) 
1(0.5) 1(0.5) 3 (1.6) 
Iron deficiency anaemia¥ 1 (0.5) 14 (7.4) 11 (5.8) 
Possible anaemia of inflammation or 
thalassaemia ¤ 
1 (0.5) 2 (1.1) 4 (2.1) 
Iron status unknown: 
 (not tested) 
3 (1.6) 7 (3.7) 34 (18.0) 
Total study women 189 (100) 189 (100) 189 (100) 
* Confirmed iron sufficiency: non-anaemiac, and ferritin ≥20 µg/L with CRP<5mg/L, or ferritin ≥50 µg/L with no 
CRP 
§ Unconfirmed iron sufficiency: non-anaemic, ferritin 20-49 µg/L with no CRP to correct for inflammation. 
¶ First trimester anaemia Hb<110g/L, second and third trimester anaemia Hb<105g/L as per NICE Guidelines 
(2014) 
¥ Anaemia with iron deficiency or absent iron stores 
¤ Anaemic and ferritin ≥20 µg/L, without CRP: possible anaemia of inflammation, or thalassaemia.       
 
Confirmed iron sufficiency included: Hb ≥ 110 g/L (first trimester) or Hb ≥ 105 g/L 
(second and third trimester) with ferritin ≥ 20µg/L with CRP ≤ 5mg/L; or ferritin ≥ 
50µg/L if CRP >5mg/L (ferritin parameter adjusted as inflammation present); or 
ferritin ≥ 50 µg/L with no CRP (presence of inflammation assumed). Unconfirmed iron 
sufficiency included: Hb ≥ 110 g/L (first trimester) or Hb ≥ 105 g/L (second and third 
trimester, or postpartum) with serum ferritin 20-49 µg/L with no CRP.   Six antenatal 
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tests with no concurrent CRP with ferritin, resulted in anaemia with normal or high 
ferritin (≥ 20 µg/L) (Table 7). These tests possibly indicated anaemia of inflammation, 
or thalassaemia.  
There was a decline in iron status from booking to late pregnancy, with the largest 
decline from the first to second trimester: 9.5% (n=18) had low iron status with either 
anaemia, non-anaemic iron deficiency (NAID) including absent iron stores, iron 
deficiency anaemia (IDA), or possible anaemia of inflammation (or thalassaemia) in 
the first trimester, 74.0% (n=140) in the second trimester, and 47.0% (n=89) in the 
third trimester (Table 7).  This meant that nearly half of this population of women 
approached childbirth with a low iron status. A large proportion of women at 
booking, 45.5% (n=86), were non-anaemic with unknown iron stores. 
A Mann-Whitney U Test comparing third trimester ferritin levels, between women 
who had serum ferritin tested at booking (n=99), and women who did not (n=90), 
showed no statistically significant difference (Z= -1.05, p=.294).  
Laboratory analysis of iron status 
Difficulty in categorising iron status was confounded by variance in laboratory 
analysis of ferritin, when CRP was not concurrently tested with serum ferritin. This 
study showed 86% (n=331) of serum ferritin results were not tested with CRP (Table 
8). The DHB laboratory routinely tested CRP with serum ferritin, whereas the private 
laboratory did not. Despite undertaking 84.7% of all antenatal serum ferritin analyses 
in this study, the private laboratory only tested CRP three times out of 326, as part of 
other biochemical tests requested for reasons other than iron status.   
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Table 8: Laboratory type and analyses of serum ferritin and C-reactive protein (CRP) 
Serum Ferritin 
Testing 
 
District Health 
Board Laboratory 
n (%) 
Private 
Laboratory 
n (%) 
Laboratory 
Unknown  
n (%) 
Total 
 
N = 385 (%) 
Serum ferritin 
tested  
51 (13.2) 326 (84.7) 8 (2.1) 385 (100) 
Serum ferritin 
tested with CRP* 
51 (94.4) 3 (5.6) - 54 (14.0) 
Serum ferritin 
tested without  
CRP 
- 323 (97.6) 8 (2.4) 331 (86.0) 
* C-reactive protein, an inflammatory marker: if CRP >5mg/L, serum ferritin may give false normal or false high 
result. 
Antenatal prevention and treatment of anaemia and iron deficiency 
Table 9 shows the total number of strategies to prevent or treat anaemia or iron 
deficiency, given that some women had multiple approaches e.g. dietary advice and 
prescribed iron. Dietary advice was the least common documented strategy with 
10.1% women receiving advice in early pregnancy, compared to 3.2% in late 
pregnancy (Table 9). Almost half the women (48.7%) were prescribed oral iron by 
LMC midwives in the second trimester, considerably more than at booking (4.8%) or 
in late pregnancy (27.0%). This trend was the same for documented dietary advice 
and over the counter iron recommendations. The women with documented evidence 
of continuing to take iron after the initial prescription, or recommendation, were 
included in subsequent trimesters as having iron prescribed, or recommended. 
Otherwise they were presumed to have stopped taking iron. One woman received a 
third trimester intravenous iron infusion for severe IDA.   
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Table 9: Antenatal prevention and treatment of anaemia and iron deficiency 
Management First trimester 
N=189 (%) 
Second trimester 
N=189 (%) 
Third trimester 
N=189 (%) 
Total oral iron 
prescriptions 
9 (4.8) 92 (48.7) 51 (27.0) 
Total OTC* iron 12 (6.3) 32 (16.9) 14 (7.4) 
Total dietary advice 19 (10.1) 25 (13.2) 6 (3.2) 
Antenatal intravenous 
iron 
0 (0) 0 (0) 1 (0.5) 
* OTC: Over the counter includes liquid/tablet iron supplements, multivitamins and minerals, and herbal 
preparations 
 
It was not determined whether midwives prescribed based on haemoglobin or serum 
ferritin results, or both. The mean haemoglobin and ferritin when iron was 
prescribed, was lowest in the second trimester and highest in the first trimester 
(Table 10). The ranges of haemoglobin and ferritin where iron was prescribed were 
wide, from 106-141 g/L and 13-36 µg/L in the first, 95-133 g/L and 3-67 µg/L in the 
second, and 84-138 g/L and 6-90 µg/L in the third trimester. Midwives prescribed 
iron with an Hb of >130g/L for 1.1% (n=2), 1.6% (n=3), and 2.6% (n=5) of first, second 
and third trimester women. For 70% (n=7) of these oral iron prescriptions where Hb 
>130g/L, the women had absent (serum ferritin <12µg/L) or deficient iron stores 
(serum ferritin 13-20µg/L). All the women with high haemoglobins (Hb >130g/L) were 
normocytic with MCV > 80 fL, and high haematocrits ≥ 0.38, indicating a degree of 
haemoconcentration. 
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Table 10:  Comparison of antenatal haemoglobin and serum ferritin when dietary 
advice offered, over the counter iron recommended or prescribed  
Laboratory Tests First line management First 
trimester 
Second 
trimester 
Third 
trimester 
Haemoglobin 
Mean (range) 
Where iron prescribed 121.3 g/L  
(106-141g/L) 
113.9 g/L 
(95-133 g/L) 
116.0 g/L 
(84-138 g/L) 
 Where OTC* iron  
Recommended 
126.7 g/L 
(115-140g/L) 
114.3 g/L 
(103-130g/L) 
109.8 g/L  
(94-124g/L) 
 Where dietary advice 
given 
130.8 g/L 
(118-144g/L)  
117.8 g/L 
(104-126g/L) 
142g/L§  
Ferritin  
Mean (range)  
Where iron prescribed 22.8 µg/L  
(13-36 µg/L) 
12.3 µg/L  
(3-67 µg/L) 
17.2 µg/L  
(6-90 µg/L) 
 Where OTC iron  
Recommended 
30.0 µg/L  
(7-67 µg/L) 
10.8 µg/L  
(5-20 µg/L) 
11.0 µg/L  
(5-18 µg/L) 
 Where dietary advice  
Given 
41.9 µg/L 
(11-73  µg/L) 
12.6 µg/L  
(4-22  µg/L) 
69 µg/L§ 
* OTC: Over the counter includes liquid/tablet iron supplements, multivitamins and minerals, and herbal iron 
preparations 
§ Single value therefore no range 
 
The mean haemoglobin where over the counter iron was recommended, was higher 
compared to prescribed iron, in the first (126.7 g/L  vs 121.3 g/L) and second 
trimester (114.3 vs 113.9 g/L), but not in the third trimester (109.8 g/L vs 116.0 g/L) 
(Table 10). The mean serum ferritin where over the counter iron was recommended 
was higher, compared to prescribed iron only in the first trimester (30.0µg/L vs 22.8 
µg/L).  
Table 11 shows the one main strategy of midwives per woman, whereas Table 9 
showed all the strategies. The midwives prescribed and recommended iron most 
commonly for NAID and absent iron stores, throughout pregnancy (Table 11). 
Midwives prescribed iron for 38.5%, and recommended over the counter iron for 
23.1% of the 13 women with NAID in the first trimester, 45.7% and 21.7% (of the 46) 
in the second, and 23.8% and 7.1% (of the 42) in the third trimester respectively. 
Similarly, midwives prescribed iron and recommended iron, for 67.5% and 15.6% of 
(the 77) women with absent iron stores in the second trimester, and 55.2% and 
10.3% (of the 29) in the third trimester respectively. Only one of the two women with 
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absent iron stores at booking were managed, with over the counter iron. Midwives 
did not prescribe or recommend iron for six of the 15 women (40%) with NAID or 
absent iron stores in the first trimester, 28 of 123 (22.8%) in the second, and 39 of 
the 71 (54.9%) in the third trimester. 
Table 11:  Main documented approach to management of iron status in pregnancy 
Iron status when main documented 
approach occurred 
 First 
trimester 
n (% of iron 
status)  
Second 
trimester 
n (% of iron 
status) 
Third 
trimester 
n (% of iron 
status) 
Prescribed Iron (n=151) 9 92 50 
Confirmed Iron Sufficiency*  1 (2.0) 0 (0) 3 (25.0) 
Unconfirmed Iron Sufficiency§  0 (0)      4 (23.5) 6 (20.0) 
Non-anaemic 
(ferritin not tested, iron stores unknown)  
1 (1.2) 3 (13.0)  3 (12.5) 
Non-anaemic iron deficiency  
ferritin 12-19 µg/L (or SF <50 µg/L with CRP 
>5)  
 
5 (38.5) 
      
21 (45.7) 
 
10 (23.8) 
Non-anaemic absent iron stores 
ferritin<12µg/L  
0 (0) 52 (67.5) 16 (55.2) 
Anaemic¶  
(ferritin not tested, iron stores unknown)  
0 (0) 0 (0) 0 (0) 
Iron deficiency anaemia¥  0 (0) 10 (71.4) 7 (63.6) 
Possible anaemia of inflammation or 
thalassaemia¤  
1 (100.0) 2 (100.0) 2 (50.0) 
Iron status unknown (not tested)  1 (33.3) 0 (0) 3 (8.8) 
Over the counter iron (OTC)† Iron (n=47) 12 27 8 
Confirmed Iron Sufficiency  1 (2.0) 0 (0) 0 (0) 
Unconfirmed Iron Sufficiency  3 (9.7) 1 (5.9) 0 (0) 
Non-anaemic 
(ferritin not tested, iron stores unknown)  
4 (4.7) 3 (13.0) 0 (0) 
Non-anaemic iron deficiency 
ferritin 12-19 µg/L (or SF <50 µg/L with CRP 
>5)  
3 (23.1) 10 (21.7) 3 (7.1) 
Non-anaemic absent iron stores 
ferritin<12µg/L  
1 (50.0) 12 (15.6) 3 (10.3) 
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Iron status when main documented 
approach occurred 
 First 
trimester 
n (% of iron 
status)  
Second 
trimester 
n (% of iron 
status) 
Third 
trimester 
n (% of iron 
status) 
Anaemic   
(ferritin not tested, iron stores unknown)  
0 (0) 0 (0) 0 (0) 
Iron deficiency anaemia  0 (0) 1 (7.1) 1 (9.1) 
Possible anaemia of inflammation or 
thalassaemia  
0 (0) 0 (0) 0 (0) 
Iron status unknown (not tested)  0 (0) 0 (0) 1 (2.9) 
Dietary Advice (n=24) 17 6 1 
Confirmed Iron Sufficiency  2 (3.9) 1 (50.0) 0 (0) 
Unconfirmed Iron Sufficiency  7 (22.6) 0 (0) 1 (3.3) 
Non-anaemic  
(ferritin not tested, iron stores  unknown)  
5 (5.8) 1 (4.3) 0 (0) 
Non-anaemic iron deficiency  
ferritin 12-19 µg/L (or SF <50 µg/L with CRP 
>5)  
1 (7.7) 2 (4.3) 0 (0) 
Non-anaemic absent iron stores 
ferritin<12µg/L  
0 (0) 1 (1.3) 0 (0) 
Anaemic   
(ferritin not tested, iron stores unknown)  
1 (100.0) 0 (0) 0 (0) 
Iron deficiency anaemia  0 (0) 1 (7.1) 0 (0) 
Possible anaemia of inflammation or 
thalassaemia  
0 (0) 0 (0) 0 (0) 
Iron status unknown  (not tested)  1 (33.3) 0 (0) 0 (0) 
* Confirmed iron sufficiency: non-anaemiac, and ferritin ≥20 µg/L with CRP<5mg/L, or ferritin ≥50 µg/L with no 
CRP 
§ Unconfirmed iron sufficiency: non-anaemic, ferritin 20-49 µg/L with no CRP to correct for inflammation. 
¶ First trimester anaemia Hb<110g/L, second and third trimester anaemia Hb<105g/L as per NICE Guidelines 
(2014) 
¥ Anaemia with iron deficiency or absent iron stores 
¤ Anaemic and ferritin ≥20 µg/L, without CRP: possible anaemia of inflammation, or thalassaemia.    
† OTC: Over the counter includes liquid/tablet iron supplements, multivitamins and minerals, and herbal 
preparations 
    
  
 Page 76 
 
In the one case of IDA at booking where iron was neither prescribed nor 
recommended in the first trimester, an intravenous iron infusion was required in the 
third trimester. For women with known IDA in the second and third trimesters, the 
midwives prescribed iron 71.4% (10 of 14), and 63.6% (7 of 11) of the time, 
respectively (Table 11). None of the anaemic women, with unknown ferritin levels, 
were prescribed or recommended iron in the first (n=1), second (n=1), and third (n=3) 
trimesters (Tables 7 & 11). Midwives prescribed iron unnecessarily for four women 
with unknown iron status and 21 women who were either non-anaemic (ferritin 
unknown), or had confirmed or unconfirmed iron sufficiency during pregnancy (Table 
11). 
Seven antenatal study women were anaemic with a normal-high, or high serum 
ferritin ≥ 20 µg/L, and no CRP to adjust for inflammation, indicating possible anaemia 
of inflammation or thalassaemia. Five of these women were prescribed oral iron, 
although none of the five had microcytic red cells (i.e. MCV <80 fL). The second 
trimester blood test results of one woman who was prescribed iron, highlighted the 
difficulty in interpreting iron status without a concurrent measure of inflammation: 
Hb 98 g/L, Hct 0.30 L/L, MCV 94 fL, serum ferritin 41 µg/L, and no CRP.   
Iron status was most frequently managed by midwives in the second trimester, 
prescribing and recommending to 48.7% and 16.9% of 140 women with recognised 
low iron status, respectively. In the first trimester 17 women had recognised low iron 
status and midwives did not prescribe or recommend for 47.1%, compared to 23.6% 
of 140 women in the second trimester, and 51.7% of 89 women in the third 
trimester. Approaching birth, 47.0% of women still had low iron status, and 18.0% 
had unknown iron status.  
Midwives’ years in practice, caseloads and testing for iron deficiency in pregnancy  
Testing for haemoglobin was more consistently undertaken throughout pregnancy, 
than testing of serum ferritin for iron deficiency (Table 5), therefore analysis focused 
on ferritin testing. Midwives were grouped according to years in practice or 
caseloads, aligned with the 2012 Workforce Survey of midwives with annual 
practicing certificates (MCNZ, 2012).  
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The highest proportion of women with serum ferritin tested throughout pregnancy, 
were cared for by midwives with either 11-20 or 31-40 years in practice, although the 
number of midwives (and women) in each group was small: two (n=16) and three 
(n=33) (Table 12). Eleven midwives with 1-10 years in practice, caring for the largest 
group of 80 women, were least likely to have tested serum ferritin throughout 
pregnancy. For example 76.3% (n=80) had second trimester ferritin testing, 
compared to 100% (n=16) of women with midwives with 11-20 years in practice, and 
94.0% (n=31) of women with midwives with 31-40 years in practice.  
Table 12: Midwives’ years in practice and ferritin testing 
Midwives years in 
practice (%)  
Number of 
women (%) 
First  
trimester 
ferritin testing 
n (% ) 
Second 
trimester 
ferritin testing 
n (%) 
Third 
trimester 
ferritin testing 
n (%) 
1-10 years   
11 (52.4) 
 
80 (42.3) 
 
38 (47.5) 
 
61 (76.3) 
 
50 (62.5) 
11-20 years   
2 (9.5) 
 
16 (8.5) 
 
10 (62.5) 
 
16 (100) 
 
13 (81.3) 
21-30 years   
5 (23.8) 
 
60 (31.7) 
 
30 (50.0) 
 
50 (83.3) 
 
39 (65.0) 
31-40 years   
3 (14.3) 
 
33 (17.5) 
 
21 (63.6) 
 
31 (94.0) 
 
26 (78.8) 
21 (100) 189 (100) 99 158 128 
 
Midwives were regrouped for Pearson’s chi-square test of independence (Table 13). 
Categories were 1-20 and 21-40 years in practice, and ferritin testing yes/no, for each 
trimester separately. In the 2 x 2 table chi-square analysis of midwives’ years in 
practice and frequency of ferritin testing, 0% of cells had an expected count < 5 for 
each trimester. There was no statistical association, or effect of association, between 
LMC midwives years in practice and ferritin testing in the first (X²(1,N=189)=.271, 
p=.603, phi=-.048), second (X²(1,N=189) =1.171, p=.279, phi=-.093), or third 
trimesters (X²(1,N=189) =.223, p=.637, phi=-.046). The 95% confidence intervals of 
 Page 78 
 
proportions for years in practice and ferritin testing also showed no difference 
between the groupings (Table 13).  
Table 13: Midwives’ years in practice (regrouped) and ferritin testing 
Midwives years in 
practice (%)  
Number of 
women (%) 
First  
trimester 
ferritin testing  
n (%) 
95% CI* 
Second 
trimester 
ferritin testing 
n (%) 
95% CI* 
Third  
trimester 
ferritin testing 
n (%) 
95% CI* 
1-20 years in practice  
13 (61.9) 
96 (50.8) 48 (50.0) 
40.0-60.0 
77 (80.2) 
72.2-88.2 
63 (65.6) 
56.1-75.1 
21-40 years in practice  
8 (38.1) 
93 (49.2) 51 (54.8) 
44.7-64.9 
81 (87.1) 
80.3-93.9 
65 (69.9) 
60.6-79.2 
21 (100) 189 (100) 99 158 128 
* 95% Confidence Interval of proportions presented as percentages for consistency. 
Thirteen midwives with higher annual caseloads (i.e. 41-50 or >50) cared for most 
women (n=146) (Table 14). Midwives with the highest caseload (>50) tested more 
serum ferritin proportionately, than those with other caseloads, in the first (58.2%) 
and second (92.4%) trimester, ranking third with 77.2% in the third trimester.  The 
two midwives with the smallest annual caseloads of ≤ 30 consistently ranked second 
highest (in each trimester) with regard to the proportion of women having ferritin 
tested.  
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Table 14: Midwives’ annual caseloads and ferritin testing 
Midwives annual 
caseloads (%)  
Number of 
women (%) 
First  
trimester 
ferritin testing 
n (%) 
Second  
trimester 
ferritin testing 
n (%) 
Third  
trimester 
ferritin testing 
n (%) 
Caseload ≤30 
2 (9.5) 
 
14 (7.4) 
 
8 (57.1) 
 
12 (85.7) 
 
11 (78.6) 
Caseload 31-40 
6 (28.6) 
 
29 (15.3) 
 
15 (51.7) 
 
22 (75.9) 
 
23 (79.3) 
Caseload  41-50  
7 (33.3) 
 
67 (35.5) 
 
30 (44.8) 
 
51 (76.1) 
 
33 (49.3) 
Caseload >50 
6 (28.6) 
 
79 (41.8) 
 
46 (58.2) 
 
73 (92.4) 
 
61 (77.2) 
21 (100) 189 (100) 99 158 128 
 
 
Midwives were regrouped for Pearson’s chi-square test of independence (Table 15). 
Categories were 1-40 (small), 41-50 (medium), and 51-70 (large) caseloads, and 
ferritin testing yes/no, for each trimester separately. In the 3 x 2 table, chi-square 
analysis of midwives’ caseloads and ferritin testing, 0% of cells had an expected count 
< 5, for each trimester.  
There was no statistically significant association or effect, between LMC midwives’ 
caseloads, and proportion of ferritin testing in the first trimester (X²(1, N=189) =2.7, 
p=.265, Cramer’s V = .12).  There was a significant association, and a small measure of 
effect, between LMC midwives’ caseloads, and frequency of ferritin testing in the 
second trimester (X²(1, N=189) =7.845, p=.02, Cramer’s V = .20). The association 
between LMC midwives’ caseloads, and frequency of ferritin testing in the third 
trimester, was strongly significant with a moderately strong measure of effect (X²(1, 
N=189) =16.245, p=.0003, Cramer’s V = .293). The 95% confidence interval of 
proportions for ferritin testing also showed significant differences between caseloads 
for the second and third trimester (Table 15). 
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Table 15: Midwives’ annual caseload (regrouped) and ferritin testing 
Midwives annual 
caseloads (%)  
Number of 
women (%) 
First  
trimester 
ferritin testing  
n (%) 
95% CI* 
Second  
trimester  
ferritin testing 
n (%) 
95% CI* 
Third  
trimester  
ferritin testing 
n (%) 
95% CI* 
Caseload 1-40  
8 (38.1) 
43 (22.8) 23 (53.5) 
38.6-68.4 
34 (79.1) 
67.0-91.3 
34 (79.1) 
67.0-91.3 
Caseload 41-50  
7 (33.3) 
67 (35.5) 30 (44.8) 
32.9-56.7 
51 (76.1) 
65.9-86.3 
33 (49.3) 
37.3-61.3 
Caseload >50  
6 (28.6) 
79 (41.7) 46 (58.2) 
47.3-69.0 
73 (92.4) 
86.6-98.2 
61 (77.2) 
67.8-86.5 
21 (100) 189 (100) 99 158 128 
* 95% Confidence Interval of proportions in presented as percentages for consistency. 
Midwives’ years in practice, caseloads and iron supplementation in pregnancy 
Midwives with 31-40 years in practice prescribed more iron (66.7%) and offered 
more dietary advice (60.6%) in the second trimester, compared to midwives with 21-
30 years practice who prescribed iron (35.0%) and gave dietary advice (3.3%) the 
least (Table 16). Conversely midwives with 21-30 years practice recommended more 
over the counter iron (including liquid/tablet iron supplements, herbal preparations, 
multivitamins and minerals) in the second and third trimester, whilst they prescribed 
iron the least.  
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Table 16: Midwives’ years in practice and management of antenatal iron status 
Midwives years in 
practice (%)  
Number of 
women (%) 
Strategy First 
trimester  
n (%) 
Second 
trimester 
n (%) 
Third 
trimester 
n (%) 
1-10 years  
11 (52.4)  
 
80 (42.3) 
Oral iron 
prescription 
 
4 (5.0) 
 
40 (50.0) 
 
20 (25.0) 
  OTC* iron 2 (2.5) 9 (11.3) 4 (5.0) 
  Dietary 
advice 
6  (7.5) 12 (15.0) 0 (0) 
11-20 years  
2 (9.5) 
 
16 (8.5) 
Oral iron 
prescription 
 
0 (0) 
 
9 (56.3) 
 
9 (56.3) 
  OTC iron 4 (25.0) 5 (31.3) 2 (12.5) 
  Dietary 
advice 
      1 (6.3) 5 (31.3) 0 (0) 
21-30 years  
5 (23.8) 
 
60 (31.7) 
Oral iron 
prescription 
 
4 (6.7) 
 
21 (35.0) 
 
13 (21.7) 
  OTC iron 6 (10.0) 13 (36.7) 8 (13.3) 
  Dietary 
advice 
9 (15.0) 2 (3.3) 2 (3.3) 
31-40 years  
3 (14.3) 
 
33 (17.5) 
Oral iron 
prescription 
 
1 (3.0) 
 
22 (66.7) 
 
9 (27.3) 
  OTC iron 0 (0) 2 (6.1) 0 (0) 
  Dietary 
advice 
2 (6.1) 20 (60.6) 3 (9.1) 
21 (100) 189 (100)     
 
Midwives were regrouped for Pearson’s chi-square test of independence (Table 17). 
Categories were 1-20 and 21-40 years in practice, and iron prescription yes/no, for 
each trimester separately. In the 2 x 2 table, chi-square analysis of midwives’ years in 
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practice and frequency of oral iron prescriptions for each trimester, two cells (50%) 
had an expected count < 5 in the first trimester, and 0% of cells had < 5 in the second 
and third trimesters. 
There was no statistically significant association, or measure of effect, between 
midwives’ years in practice and prescribing of iron in the first trimester (X²(1, N=189) 
=.002, p=.961, phi=-.028). In the second (X²(1, N=189) =.265, p=.606, phi=-.48) and 
third (X²(1, N=189) =.273, p=.601, phi=-.50) trimesters, there was no statistically 
significant association, between midwives’ years in practice and prescribing of iron, 
although there was a medium effect (Table 17). 
Table 17: Midwives’ years in practice (regrouped) and oral iron prescriptions 
Midwives years in 
practice (%)  
Number of 
women (%) 
First  
trimester 
iron  
prescriptions  
n (%) 
95% CI* 
Second  
trimester  
iron  
prescriptions 
n (%) 
95% CI* 
Third  
trimester  
iron  
prescriptions 
n (%) 
95% CI* 
1-20 years in practice  
13 (61.9) 
96 (50.8) 4 (4.2) 
0.2-8.2 
49 (51.0) 
41.0-61.0 
28 (29.2) 
20.1-38.3 
21-40 years in practice  
8 (38.1) 
93 (49.2)  5 (5.4) 
8.1-10.0 
43 (46.2) 
32.9-53.1 
23 (22.6) 
14.1-31.1 
21 (100) 189 (100) 9 92 51 
* 95% Confidence Interval of proportions presented as percentages for consistency. 
 
Only a small proportion of women (4.8%) were prescribed or recommended OTC iron 
(6.3%) in the first trimester (Table 9). In the second trimester, the proportion of iron 
prescribed was highest (54.4%) from midwives with annual caseloads >50, and lowest 
(42.9%) from midwives with caseloads of ≤30 (Table 18). Although in the third 
trimester, midwives with caseloads of ≤30, prescribed the most (50.0%) for their 
proportion of women. 
  
 Page 83 
 
Table 18: Midwives’ annual caseloads and management of antenatal iron status 
Midwives annual 
caseloads (%)  
Number of 
women (%) 
Strategy First 
trimester 
n (%) 
Second 
trimester 
n (%) 
Third 
trimester 
n (%) 
Caseload ≤30  
2 (9.5) 
 
14 (7.4) 
Oral iron 
prescription 
 
1 (7.1) 
 
6 (42.9) 
 
7 (50.0) 
  OTC* iron 0 (0) 2 (14.3) 0 (0) 
  Dietary 
advice 
 
0 (0) 
 
3 (21.4) 
 
0 (0) 
Caseload 31-40 
6 (28.6) 
 
29 (15.3) 
Oral iron 
prescription 
 
2 (6.9) 
 
14 (48.3) 
 
4 (13.8) 
  OTC iron 3 (10.3) 6 (20.7) 4 (13.8) 
  Dietary 
advice 
 
2 (6.9) 
 
3 (10.3) 
 
0 (0) 
Caseload  41-50  
7 (33.3) 
 
67 (35.5) 
Oral iron 
prescription 
 
2 (3.0) 
 
29 (46.5) 
 
14 (20.9) 
  OTC iron 1 (1.5) 12 (17.9) 9 (13.4) 
  Dietary 
advice 
 
4 (6.0) 
 
14 (48.3) 
 
1 (1.5) 
Caseload >50 
6 (28.6) 
 
79 (41.8) 
Oral iron 
prescription 
 
4 (5.1) 
 
43 (54.4) 
 
26 (32.9) 
  OTC iron 9 (11.4) 13 (16.5) 5 (6.3) 
  Dietary 
advice 
 
12 (15.2) 
 
17 (21.5) 
 
1 (1.3) 
21 (100) 189 (100)     
 
Midwives were regrouped for Pearson’s chi-square test of independence (Table 19). 
Categories were 1-40, 41-50, and 51-70, and iron prescription yes/no, for each 
trimester separately. In the 3 x 2 table chi-square analysis of midwives’ caseloads and 
frequency of oral iron prescriptions, three cells (50%) had an expected count < 5 in 
the first trimester, and 0% of cells had < 5 in the second and third trimesters.  
There was no statistical association, or measure of effect, between midwives’ 
caseload and oral iron prescribing in the first (X²(1, N=189) =.947, p=.623, Cramer’s 
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V=.07), second (X²(1, N=189) =1.908, p=.385, Cramer’s V=.10), or third (X²(1, N=189) 
=2.712, p=.258, Cramer’s V=.12) trimesters. The 95% confidence intervals of 
proportions, for caseloads and iron prescriptions, showed no difference between the 
groupings (Table 19).  
Table 19: Midwives’ caseload (regrouped) and oral iron prescriptions 
Midwives annual 
caseloads (%)  
Number of 
women (%) 
First  
trimester 
iron  
prescriptions  
n (%) 
95% CI* 
Second  
trimester  
iron  
prescriptions 
n (%) 
95% CI* 
Third  
trimester  
iron  
prescriptions 
n (%) 
95% CI* 
Caseload 1-40  
8 (38.1) 
43 (22.8) 3 (7.0) 
0.6-14.6 
20 (46.5) 
31.6-61.4 
11 (25.6) 
12.6-38.6 
Caseload 41-50  
7 (33.3) 
67 (35.4) 2 (3.0) 
1.0-7.0 
29 (43.3) 
31.4-55.2 
14 (20.9) 
11.2-30.6 
Caseload >50  
6 (28.6) 
79 (41.8) 4 (5.1) 
0.3-10.0 
43 (54.4) 
43.4-65.4 
26 (32.9) 
22.5-43.3 
21 (100) 189 (100) 9 92 51 
* 95% Confidence Interval of proportions presented as percentages for consistency. 
Postpartum management of anaemia  
Estimated blood loss (EBL) was documented on every delivery summary in the 
primary care notes: 20.1% of women had EBL >500 mls (Table 20). Midwives 
management of postpartum anaemia was analysed in relation to late pregnancy iron 
status, and blood loss (>500 mls) around the time of birth.  
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Table 20: Late pregnancy iron status, peri-partum blood loss, and management of 
postnatal anaemia 
Clinical Status Total 
women 
 
N=189  
n (%) 
Hb tested 
within 72 hrs 
postpartum 
N=43  
n (%) 
Hb tested  
≥ 10 days 
postpartum 
N = 9 
n (%) 
Oral iron 
prescription  
 
N = 20 
n (%) 
OTC* 
Iron 
 
N=1  
n (%) 
Estimated blood loss 
(EBL) mls 
EBL ≤ 500 mls 
EBL 501-750 mls 
EBL 751-1000 mls 
EBL 1001-1500 mls 
EBL 1501-2000 mls 
EBL 2001-3000 mls 
 
 
151 (79.9) 
17 (9.0) 
15 (7.9) 
1 (0.5) 
3 (1.6) 
2 (1.1) 
 
 
15 (34.9) 
9 (20.9) 
13 (30.2) 
1 (2.3) 
3 (7.0) 
2 (4.7) 
blood  
 
3 (33.3) 
2 (22.2) 
2 (22.2) 
0 (0) 
1 (1.1) 
1 (1.1) 
blood lo 
 
6 (30.0) 
2 (10.0) 
6 (30.0) 
1 (5.0) 
3(15.0) 
2 (10.0) 
 
 
1(100) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
Total EBL 501-
3000mls 
38 (20.1) 28 (65.1) 6 (66.7) 14(70.0) 0 (0) 
 
Third trimester iron 
status unknown 
with EBL > 500mls 
7 (3.7) 5 (11.6) 3 (33.3) 5 (25.0) 0 (0) 
Third trimester 
ferritin <20µg/L or 
IDA§, and EBL 
>500mls 
16 (8.5) 11 (25.6) 4 (44.4) 6 (30.0) 0 (0) 
Postpartum 
anaemia  
Hb <100g/L¶ 
21 (11.1) 21 (48.8) 4 (44.4) 7 (35.0) 0 (0) 
Severe postpartum 
anaemia  
Hb <85g/L¥ 
3 (1.6) 3 (7.0) 2 (22.2) 2 (10.0) 0 (0) 
* OTC: Over the counter includes liquid/tablet iron supplements, multivitamins and minerals, and herbal 
preparations 
§ Iron deficiency anaemia (IDA): anaemia with iron deficiency or absent iron stores 
¶ UK Guidelines for postpartum anaemia parameters (Pavord et al., 2012) 
¥ Postpartum anaemia categorization by Breymann et al. (2010) 
 
Forty-three women (22.8%) had their haemoglobin tested after birth. The midwives 
did not test serum ferritin to measure iron stores postpartum. Of the 38 women with 
EBL > 500 mls, 73.6% (n=28) had haemoglobin tested by the LMC midwife or staff in 
the birthing facility, in the 72 hours after birth; 14 (36.9%) were prescribed oral iron 
(Table 13). All five women with EBL > 1500 mls had Hb testing within 72 hours of 
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birth and oral iron prescriptions, with two of the five showing as non-anaemic when 
haemoglobin was re-tested after 10 days postpartum (Table 20 & Appendix F). For an 
overview of postnatal management and tracking of individual cases refer to the 
Postnatal Decision Tree (Appendix F). 
Seven women with EBL >500 mls had unknown iron status in late pregnancy, but 
most were followed up postpartum. Five (71.4%) of these women had haemoglobin 
tested within 72 hours postpartum, two were anaemic and one was severely anaemic 
and received a blood transfusion. Five (71.4%) were prescribed iron, three (42.9%) 
had haemoglobin re-tested after 10 days and were found to be non-anaemic (Table 
20 & Appendix F). One woman with unknown iron status in late pregnancy, with a 
postpartum haemorrhage of 3000 mls, was prescribed oral iron for anaemia after 
birth with Hb 90g/L, but did not have subsequent testing or follow-up for iron status.  
Sixteen women (42.1%) with EBL > 500 mls at birth had low iron status (NAID or IDA) 
in late pregnancy. Yet only eleven of these sixteen women (68.75%) had early 
postpartum haemoglobin testing (Table 20).  Within case analysis of the data showed 
five were anaemic (Hb 86-100g/L), another two severely anaemic (Hb <85g/L). Six 
(37.5%) were prescribed iron, and two (12.5%) were tested later and were non-
anaemic (Appendix F).  
Midwives did not request haemoglobin testing after birth, for five of the sixteen 
women with low iron status in late pregnancy, and EBL > 500mls. Three of these 
women with EBL 501-750mls, had no documented follow-up, and only one of the two 
women with EBL 751-1000mls were prescribed iron with no other follow-up 
(Appendix F). 
Overall, almost half of the women tested in the early postpartum (48.8% of 43) were 
anaemic with Hb < 100g/L, yet only seven of these (33.3% of 21) were prescribed iron 
or had documented evidence of oral iron supplementation. Of the three severely 
anaemic (Hb< 85g/L) postpartum women (14.3% or 1.6% of the cohort), two were 
prescribed iron (Table 13) and one also received a blood transfusion (Appendix F). 
 Page 87 
 
Midwives’ years in practice, caseloads and management of postnatal iron status 
The overall number of postpartum women tested, and treated for anaemia was 
small. This precluded inferential statistical analysis of postpartum management of 
anaemia in relation to midwives caseloads or years in practice. Midwives with 11-20 
years in practice tested less haemoglobin (12.5%) in the early postpartum period, 
compared to other groups of midwives (Table 21). The proportion of iron 
prescriptions was similar for all years in practice, ranging from 9.1-12.5%. 
Table 21: Midwives’ years in practice and postpartum management of iron status 
Midwives years in 
practice (%)  
Number of 
women (%) 
Hb tested 
early* 
n (%) 
Hb tested 
later§ 
n (%) 
Oral iron 
prescription 
n (%) 
OTC¶ 
iron  
n (%)  
1-10 years   
11 (52.4)  
 
80 (42.3) 
 
19 (23.8) 
 
2 (2.5) 
 
9 (11.25) 
 
1 (1.25) 
11-20 years 
2 (9.5)   
 
16 (8.5) 
 
2 (12.5) 
 
1 (6.25) 
 
2 (12.5) 
 
0 (0) 
21-30 years 
 5 (23.8)  
 
60 (31.7) 
 
15 (25.0) 
 
3 (5.0) 
 
6 (10.0) 
 
0 (0) 
31-40 years 
3 (14.3)   
 
33 (17.5) 
 
7 (21.2) 
 
3 (9.1) 
 
3 (9.1) 
 
0 (0) 
21 (100) 189 (100) 43 9 20 1 
* Hb tested within 72 hours postpartum 
§ Hb tested ≥ 10 days postpartum 
¶ OTC: Over the counter includes liquid/tablet iron supplements, multivitamins and minerals, and herbal 
preparations 
 
When grouped according to caseload, the range of proportions for women being 
prescribed postpartum iron was 6.9–14.3% (Table 22). Midwives with smaller (≤ 30) 
and larger (> 50) caseloads tested more haemoglobin in the early postpartum, as well 
as after 10 days, and prescribed oral iron more than midwives with moderate 
caseloads (31-50), although numbers were small. 
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Table 22: Midwives’ caseloads and postpartum management of iron status 
Midwives annual 
caseloads (%)  
Number of 
women (%) 
Hb tested 
early*  
n (%) 
Hb tested 
later§ 
n (%) 
Oral iron 
prescription 
n (%) 
OTC¶ 
iron  
n (%) 
Caseload ≤30  
2 (9.5)  
 
14 (7.4) 
 
5 (35.7) 
 
2 (14.3) 
 
2 (14.3) 
 
0 (0) 
Caseload 31-40 
6 (28.6)  
 
29 (15.3) 
 
8 (27.6) 
 
0 (0) 
 
2 (6.9) 
 
1 (3.4) 
Caseload  41-50  
7 (33.3)  
 
67 (35.5) 
 
8 (11.9) 
 
0 (0) 
 
5 (7.5) 
 
0 (0) 
Caseload >50 
6 (28.6)   
 
79 (41.8) 
 
22 (27.8) 
 
7 (8.9) 
 
11 (13.9) 
 
0 (0) 
21 (100) 189 (100) 43  9  20 1 
* Hb tested within 72 hours postpartum 
§ Hb tested ≥ 10 days postpartum 
¶ OTC: Over the counter includes liquid/tablet iron supplements, multivitamins and minerals, and herbal 
preparations 
Section Three: Other analyses 
BMI and iron status 
The proportion of study woman with high BMI (>25 kg/m²) was 44.1% (95% CI 36.8-
51.0%), compared to 50.6% (95% CI 50.2-51.0%) of women giving birth in 2012 (Table 
4). Because obesity is a pro-inflammatory state that may mask true iron deficiency, all 
women with first trimester serum ferritin testing, without CRP to correct for 
inflammation (n=77), were analysed according to BMI categories and their 
subsequent second and third trimester iron status (Table 23).  
Three different first trimester serum ferritin parameters were used to categorise and 
compare groups: <20µg/L as highly specific for iron deficiency (Wang et al., 2010); 
<30µg/L (Thurnham et al., 2010; WHO, 2011) and <50µg/L (as per the local DHB IV 
iron policy), as suggested parameters for iron deficiency in the presence of 
inflammation. Sizes of the BMI sub-groups were small ranging from 4-21. In the 
entire group, presence of inflammation was unknown where ferritin <30µg/L or 
<50µg/L, and no CRP, therefore iron sufficiency was unconfirmed. 
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The greatest drop in proportion of unconfirmed iron sufficiency from the first to 
second trimester occurred in women with BMI ≥ 30 (Table 23). In the first trimester 
ferritin <30µg/L and BMI ≥ 30 group (n=4), the proportion of unconfirmed iron 
sufficiency dropped from 50.0% (n=2) in the first, to 0% in the second trimester. The 
greatest drop was in the ferritin <50µg/L and BMI ≥ 30 group (n=9), where 
unconfirmed iron sufficiency dropped from 77.8% (n=7) in the first to 0% in the 
second trimester. This group appeared more iron replete at booking with serum 
ferritin levels up to 50µg/L, but more had low iron status subsequently. The 
proportion of all women with low iron status increased most markedly from the first 
to second trimesters for all BMI groups (Table 23).  
Women were regrouped for a Pearson’s chi-square test of independence. Categories 
were low/normal BMI <25, and overweight/obese BMI ≥25; and low iron status, 
confirmed and unconfirmed iron sufficiency. In the 2 x 3 table, chi-square analysis of 
BMI and iron status, 50% (2) of cells had an expected count of <5 in the first 
trimester. Zero cells had an expected count of <5 in the second and third trimesters. 
There was no statistically significant association or effect, between BMI groups and 
frequencies of iron status in the first (X² (1, n=186) = 1.057, p= .590, Cramer’s V = 
.075), second (X² (1, n=182) = 1.881, p= .390, Cramer’s V = .102) and third (X² (1, 
n=155) = 1.406, p= .495, Cramer’s V = .95) trimesters. 
A Mann-Whitney U Test comparing third trimester ferritin levels, between women 
with low/normal BMI <25 (n=71, median SF= 18 µg/L), and overweight/obese BMI 
≥25 (n=57, median =14 µg/L), and third trimester ferritin levels showed some 
statistical difference (U=1618, Z=-1.95, p=.05). 
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Table 23:  Comparison of Body Mass Index (BMI)* and subsequent iron status of women with serum ferritin <20µg/L, <30µg/L, and <50µg/L 
uncorrected§ for inflammation (no CRP) in the first trimester. 
 First trimester  ferritin <20µg/L (no CRP)  
n=11 (%) 
First trimester ferritin <30µg/L (no CRP)  
n=21 (%) 
First trimester ferritin <50µg/L (no CRP) 
n=45 (%) 
 All BMIs 
N=11 (%) 
BMI <25 
n=4 (%) 
BMI 25-29 
n=5 (%) 
BMI ≥30 
n=2 (%) 
All BMIs 
N=21 (%) 
BMI <25 
n=9 (%)  
BMI 25-29 
n=8 (%) 
BMI ≥30 
n=4 (%) 
All BMIs 
N=45 (%) 
BMI <25 
 n=18 (%) 
BMI 25-29 
n=18 (%) 
BMI ≥30  
n=9 (%) 
Unconfirmed Iron  
sufficiency
¶
 
First trimester 
Second trimester 
Third trimester 
 
 
0 (0) 
2 (18.2) 
1 (9.1) 
 
 
0 (0) 
1 (25.0) 
0 (0) 
 
 
0 (0) 
1 (20.0) 
1 (20.0) 
 
 
0 (0) 
0 (0) 
0 (0) 
 
 
10 (47.6) 
2 (9.5) 
3 (14.3) 
 
 
5 (55.6) 
1 (11.1) 
1 (11.1) 
 
 
3 (37.5) 
1 (12.5) 
1 (12.5) 
 
 
2 (50.0) 
0 (0) 
1 (25.0) 
 
 
33 (73.3) 
3 (6.7) 
11 (24.4) 
 
 
13 (72.2) 
2 (11.1) 
5 (27.8) 
 
 
13 (72.2) 
1 (5.6) 
3 (16.7) 
 
 
7 (77.8) 
0 (0) 
3 (33.3) 
Non-anaemic iron 
deficiency 
First trimester 
Second trimester 
Third trimester 
 
 
9 (81.8) 
1 (9.1) 
5 (45.5) 
 
 
3 (75.0) 
0 (0) 
1 (25.0) 
 
 
4 (80.0) 
0 (0) 
3 (60.0) 
 
 
2 (100) 
1 (50.0) 
1 (50.0) 
 
 
9 (42.9) 
3 (14.3) 
9 (42.9) 
 
 
3 (33.3) 
1 (11.1) 
5 (55.6) 
 
 
4 (50.0) 
1 (12.5) 
3 (37.5) 
 
 
2 (50.0) 
1 (25.0) 
2 (50.0) 
 
 
9 (20.0) 
8 (17.8) 
 13 (28.9) 
 
 
3 (16.7) 
2 (11.1) 
6 (33.3) 
 
 
4 (22.2) 
4 (22.2) 
5 (27.8) 
 
 
2 (22.2) 
2 (22.2) 
2 (22.2) 
Absent iron stores 
First trimester 
Second trimester 
Third trimester 
 
1 (9.1) 
4 (36.6) 
1 (9.1) 
 
1 (25.0) 
2 (50.0) 
1 (25.0) 
 
1 (20.0) 
2 (40.0) 
0 (0) 
 
0 (0) 
0 (0) 
0 (0) 
 
1 (4.8) 
10 (47.6) 
2 (9.5) 
 
1 (11.1) 
6 (66.7) 
1 (11.1) 
 
0 (0) 
3 (37.5) 
1 (12.5) 
 
0 (0) 
1 (25.0) 
0 (0) 
 
1 (2.2) 
24 (53.3) 
6 (13.3) 
 
1(5.6) 
11 (61.1) 
2 (11.1) 
 
0 (0) 
8 (44.4) 
3 (16.7) 
 
0 (0) 
5 (55.6) 
1 (11.1) 
Iron deficiency  
Anaemia 
First trimester 
Second trimester 
Third trimester 
 
 
1 (9.1) 
2 (18.2) 
0 (0) 
 
 
0 (0) 
0 (0) 
0 (0) 
 
 
0 (0) 
2 (40.0) 
0 (0) 
 
 
0 (0) 
0 (0) 
0 (0) 
 
 
1 (4.8) 
2 (9.5) 
1 (4.8) 
 
 
0 (0) 
0 (0) 
0 (0) 
 
 
1 (12.5) 
2 (25.0) 
1 (12.5) 
 
 
0 (0) 
0 (0) 
0 (0) 
 
 
1 (2.2) 
4 (8.9) 
3 (6.7) 
 
 
0 (0) 
1 (5.6) 
1 (5.6) 
 
 
1(5.6) 
3 (16.7) 
1(5.6) 
 
 
0 (0) 
0 (0) 
0 (0) 
Non-anaemic  
(ferritin unknown) 
First trimester 
Second trimester 
Third trimester 
 
 
0 (0) 
2 (18.2) 
0 (0) 
 
 
0 (0) 
1 (25.0) 
0 (0) 
 
 
0 (0) 
0 (0) 
0 (0) 
 
 
0 (0) 
1 (50.0) 
0 (0) 
 
 
0 (0) 
3 (14.3) 
0 (0) 
 
 
0 (0) 
1 (11.1) 
0 (0) 
 
 
0 (0) 
0 (0) 
0 (0) 
 
 
0 (0) 
2 (50.0) 
0 (0) 
 
 
0 (0) 
4 (8.9) 
3 (6.7) 
 
 
0 (0) 
1 (5.6) 
2 (11.1) 
 
 
0 (0) 
1(5.6) 
2 (11.1) 
 
 
0 (0) 
2 (22.2) 
0 (0) 
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 First trimester  ferritin <20µg/L (no CRP)  
n=11 (%) 
First trimester ferritin <30µg/L (no CRP)  
n=21 (%) 
First trimester ferritin <50µg/L (no CRP) 
n=45 (%) 
 All BMIs 
N=11 (%) 
BMI <25 
n=4 (%) 
BMI 25-29 
n=5 (%) 
BMI ≥30 
n=2 (%) 
All BMIs 
N=21 (%) 
BMI <25 
n=9 (%)  
BMI 25-29 
n=8 (%) 
BMI ≥30 
n=4 (%) 
All BMIs 
n=45 (%) 
BMI <25 
 n=18 (%) 
BMI 25-29 
n=18 (%) 
BMI ≥30  
n=9 (%) 
Anaemic (ferritin 
unknown) 
First trimester 
Second trimester 
Third trimester 
 
 
0 (0) 
0 (0) 
1 (9.1) 
 
 
0 (0) 
0 (0) 
0 (0) 
 
 
0 (0) 
0 (0) 
1 (20.0) 
 
 
0 (0) 
0 (0) 
0 (0) 
 
 
0 (0) 
1 (4.8) 
1 (4.8) 
 
 
0 (0) 
0 (0) 
0 (0) 
 
 
0 (0) 
1 (12.5) 
1 (12.5) 
 
 
0 (0) 
0 (0) 
0 (0) 
 
 
0 (0) 
1 (2.2) 
1 (2.2) 
 
 
0 (0) 
0 (0) 
0 (0) 
 
 
0 (0) 
1(5.6) 
1(5.6) 
 
 
0 (0) 
0 (0) 
0 (0) 
Possible anaemia 
of inflammation
¥
 
First trimester 
Second trimester 
Third trimester 
 
 
 
0 (0) 
0 (0) 
1 (9.1) 
 
 
 
0 (0) 
0 (0) 
1 (25.0) 
 
 
 
0 (0) 
0 (0) 
0 (0) 
 
 
 
0 (0) 
0 (0) 
0 (0) 
 
 
 
0 (0) 
0 (0) 
2 (9.5) 
 
 
 
0 (0) 
0 (0) 
1 (11.1) 
 
 
 
0 (0) 
0 (0) 
1 (12.5) 
 
 
 
0 (0) 
0 (0) 
0 (0) 
 
 
 
1 (2.2) 
0 (0) 
2 (4.4) 
 
 
 
0 (0) 
0 (0) 
1 (5.6) 
 
 
 
0 (0) 
0 (0) 
1 (5.6) 
 
 
 
0 (0) 
0 (0) 
0 (0) 
Iron status 
unknown 
First trimester 
Second trimester 
Third trimester 
 
 
0 (0) 
0 (0) 
2 (18.2) 
 
 
0 (0) 
0 (0) 
1 (25.0) 
 
 
0 (0) 
0 (0) 
0 (0) 
 
 
0 (0) 
0 (0) 
1 (50.0) 
 
 
0 (0) 
0 (0) 
3 (14.3) 
 
 
0 (0) 
0 (0) 
1 (11.1) 
 
 
0 (0) 
0 (0) 
0 (0) 
 
 
0 (0) 
0 (0) 
1 (25.0) 
 
 
0 (0) 
1 (2.2) 
6 (13.3) 
 
 
1(5.6) 
1 (5.6) 
1 (5.6) 
 
 
0 (0) 
0 (0) 
2 (11.1) 
 
 
0 (0) 
0 (0) 
3 (33.3) 
Total low iron 
status 
First trimester 
Second trimester 
Third trimester 
 
 
11 (100) 
7 (63.6) 
7 (63.6) 
 
 
4 (100) 
2 (50.0) 
2 (50.0) 
 
 
5 (100) 
4 (80.0) 
4 (80.0) 
 
 
2(100) 
1 (50.0) 
1 (50.0) 
 
 
11 (52.4) 
16 (76.2) 
13 (61.9) 
 
 
4 (44.4) 
7 (77.8) 
6 (66.7) 
 
 
5 (62.5) 
7 (87.5) 
6 (75.0) 
 
 
2 (50.0) 
2 (50.0) 
1 (25.0) 
 
 
11 (24.4) 
37 (82.2) 
23 (51.1) 
 
 
4 (22.2) 
14 (77.8) 
10 (55.6) 
 
 
5 (27.8) 
16 (88.9) 
10 (55.6) 
 
 
2 (22.2) 
7 (77.8) 
3 (33.3) 
* Body Mass Index (BMI) in kg/m² 
§ Uncorrected serum ferritin i.e. without C-reactive protein (CRP). CRP is a marker of acute and chronic inflammation, and correcting test alongside serum ferritin for diagnosing iron 
deficiency: if CRP >5, serum ferritin may indicate false normal or false high result, therefore the ferritin parameter for diagnosing iron deficiency increases  from ferritin < 20 µg/L to < 30 µg/L 
(WHO, 2011), or <50 µg/L (Thurnham et al., 2010). In the absence of CRP, uncorrected serum ferritin ≥20 µg/L may indicate false positive or false normal iron stores, therefore not detecting 
iron deficiency. 
¶ Unconfirmed iron sufficiency: no CRP with serum ferritin to correct for inflammation, possible false positive or false normal indication of iron stores. 
¥ Low Hb and ferritin ≥20 µg/L, without CRP: possible anaemia of inflammation, or functional iron deficiency  
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Summary of results 
In this descriptive study of LMC midwives management of maternal anaemia and iron 
deficiency, the main difference in practice was in testing of serum ferritin, especially 
in the first trimester where almost half of the women did not have their iron stores 
measured. Haemoglobin testing was shown to be consistently undertaken 
throughout pregnancy. There was no statistical association between testing, or not 
testing serum ferritin at booking, and subsequent low iron status, although the 
results may be clinically significant. 
There was a wide range in LMC practice throughout pregnancy and postpartum in 
testing for iron status, in prescribing or recommending over the counter iron, and in 
offering dietary advice. There was a statistically significant difference in ferritin 
testing according to midwives’ caseloads, but not according to years in practice, 
although there was evidence of effect. 
Iron status was difficult to categorise as iron stores were frequently not measured, or 
serum ferritin was not tested with CRP in order to adjust for inflammation. A private 
laboratory undertook most of the serum ferritin testing, and almost all were not 
analysed with CRP. Confirmed and unconfirmed categories of iron status were 
analysed in relation to midwives response and management of women’s iron status. 
There was no missing data, as all tests not undertaken were accounted for.   
The proportions of iron deficiency and absent iron stores were probably 
underestimated, especially in the first trimester with just under half of the women 
presenting as non-anaemic, with no measure of ferritin. The most common 
documented strategy for first trimester management of iron status was dietary 
advice, for one in 10 women.   The largest decline in iron status was in the second 
trimester, when almost half of the women (48.7%) were prescribed iron. 
Subsequently, almost half of the women (47.1%) still had low iron status in late 
pregnancy. The range of haemoglobin and serum ferritin where iron was prescribed 
or recommended throughout pregnancy, was wide.  
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Overall, midwives tested 22.8% of the women’s haemoglobins postpartum. Only 
three quarters of women with EBL > 500mls (n=38) had their haemoglobin tested 
early in the postpartum period. Over half of these women had had either low or 
unknown iron status in the third trimester. Over half of all women tested postpartum 
had anaemia or severe anaemia, most had no documented evidence of prescribed or 
recommended oral iron intake. 
Results of secondary analysis of BMI and iron status, using different serum ferritin 
parameters to adjust for inflammation throughout pregnancy, showed no statistical 
significance. However there was statistically significant association between 
overweight/obese BMI and lower ferritin levels in the third trimester.  
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Chapter five: Discussion 
Introduction 
This study described and examined primary care midwives’ management of iron 
status in pregnancy and postpartum, as little is known about practice in New 
Zealand. Even in countries where guidelines and recommendations exist, the actual 
practice of identifying and managing maternal iron status has not been well 
described (Barrosso et al., 2011). The five key findings that will be discussed in this 
chapter are: 
 Testing for iron stores by maternity primary care providers was inconsistent, 
especially at booking when under half of the women who had their Hb tested 
(46.0% of  98.4%), did not have serum ferritin tested. 
 Of the 385 serum ferritin tests undertaken, only 14% were tested with CRP to 
allow for adjustment of ferritin parameters, in the presence of inflammation. 
 Despite midwives prescribing iron for 48.7% of second trimester women, and 
recommending OTC iron for 16.9%, 47.1%  of women still had low iron status, 
and 18.0% unknown iron status as they approached birth.  
 Despite the high proportion (65.1%) of  low or unknown iron status, and 20.1% 
with EBL>500mls at birth, midwives tested only 22.8% of haemoglobins in the 
early postpartum period. Only 10.6% of women had documented evidence of 
prescribed oral iron intake, and 0.5% had evidence of OTC iron supplementation, 
in the postpartum period. 
 Women who appeared to be iron sufficient at booking, with ferritin up to 50 
µg/L (and no CRP to adjust for inflammation) (n=45), had the largest decline to 
low iron status in the second trimester, especially for women with BMI ≥25 
(n=27). The largest drop in iron status was in women with BMI ≥30 and ferritin 
up to 50 µg/L (n=9), with 77.8% unconfirmed iron sufficiency at booking, and 0% 
being iron sufficient in the second trimester. There was a significant difference 
(p=.05) between third trimester ferritin levels in women with BMI ≥ 25 (Md SF 14 
µg/L) and BMI < 25 (Md SF 18 µg/L). 
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Consistencies and inconsistencies when testing for iron status 
Haemoglobin has been used for decades as the primary measure of iron status, and 
proxy measure for iron deficiency (Goonewardene et al., 2012; Milman, 2006). Most 
of the 189 women in the study did have haemoglobin testing at booking (98.4%), and 
in the second (95.8%) and third trimesters (82.0%). This was comparably higher than 
haemoglobin testing of 2013 women in a UK study by Barrosso et al. (2011) (88.7%, 
83.8% & 72.4% respectively). However, haemoglobin alone is a poor measure of iron 
status as the Hb is the last red cell indice to drop before end stage iron deficiency 
anaemia (Mei et al., 2005; Pasricha, 2012; Walsh et al., 2011).  
The WHO and CDC anaemia parameters used in the study were Hb <110 g/L for the 
first, and Hb <105 g/L for the second and third trimesters.   In the first trimester 
45.5% of women (N=189), 12.2% in the second trimester, and 12.7% third trimester 
women were non-anaemic with unknown iron stores. Without a measure of serum 
ferritin for iron stores, it could not be discerned where women sat on the spectrum 
from iron sufficiency to deficiency, or depletion, before iron deficiency anaemia. 
Therefore iron deficiency was probably undetected by the study midwives, especially 
at booking when an Hb cut-off value of 110g/L has been demonstrated to miss over 
90% of NAID (Walsh et al., 2011). Although there was no statistical association 
between testing, or not testing serum ferritin at booking, and third trimester ferritin 
levels, results were likely to be confounded by the variability of iron 
supplementation, which was not controlled for. Although this was a study limitation, 
the results may still be clinically relevant. Given current available technologies, 
haemoglobin and serum ferritin are the most efficient combination of tests in 
detecting changes to iron status in populations (Mei et al., 2005).  
A recent UK study (Daru et al., 2015) examined the views and opinions of multi-
disciplinary maternity clinicians, finding that all clinicians were interested in testing 
for NAID as a target condition, if proven to be effective at improving maternal and 
neonatal outcomes. In this study, the main difference in primary maternity care was 
inconsistent testing of serum ferritin, especially at booking. Just over half of the 
women (52.4%, n= 99) had serum ferritin testing in the first trimester, with 83.6% 
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and 67.7% in the second and third trimesters. Only five women had no serum ferritin 
testing at all during pregnancy, with four of these cared for by one midwife. 
However, the rate of serum ferritin testing was notably higher than in Barrosso et 
al.’s (2011) UK study of 2013 women where ferritin was tested 10.2%, 7.2% and 3.8% 
at the first, second and third trimesters, respectively. 
Antenatal serum ferritin testing in pregnancy is not routinely undertaken in New 
Zealand, especially at booking. There are no national guidelines for testing of 
maternal iron status for New Zealand midwives. However, the results show that 
testing for iron deficiency is very common; 97.4% of women did get tested at some 
stage. Authors in a prominent New Zealand midwifery text book (Hunter & Gunn, 
2015) do not offer clear recommendations for midwives, saying serum ferritin can be 
done at booking, and repeated with second trimester bloods. Hunter and Gunn 
(2015) suggest that if serum ferritin is not tested at booking, midwives may discuss 
the option of an additional early pregnancy test or undertake second trimester 
bloods earlier at 24 weeks gestation.  
The most common reason for not testing serum ferritin in the study, was that it was 
not requested alongside other routine antenatal bloods for 46.0% of women (n=87) 
in the first, 12.2% (n=23) in the second, and 14.3% (n=27) in the third trimester. 
Importantly, many of the first antenatal bloods may have been requested by general 
practitioners when pregnancy was confirmed, although there was no way of knowing 
this proportion, within the study. General practitioners refer to the online Health 
Pathways (2015) primary care resource, which does not recommend testing serum 
ferritin unless MCV<80. So it is not only LMC midwives who request blood tests, 
especially at booking.  
An additional 13.7% (n=26) of women did not have any third trimester blood tests 
(including haemoglobin or ferritin) requested by midwives, excluding the seven 
women who birthed prematurely. Although NZCOM (2005) suggests considering CBC 
at 36 weeks, and Grigg and Tracy (2015) state there is no debate regarding routine 
screening of women for anaemia, no specific recommendations around timing of 
haemoglobin testing are made.      
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Given the recent focus on maternal iron deficiency (Grigg, 2015) it was surprising 
that recently educated midwives with 1-10 years in practice were least likely to test 
serum ferritin throughout pregnancy, although no statistical significance was 
demonstrated. This may have been due to the small sample size. Midwives with 
larger annual caseloads of 41-50, or >50 appeared to test serum ferritin more 
throughout pregnancy, with a statistical significance p=0.02, and p=.0003 
demonstrated in the second and third trimesters, respectively. These findings might 
indicate a more pro-active, risk-averse approach to managing iron status in 
pregnancy, by midwives with more years in practice and higher caseloads.   
Limited testing and understanding of C-reactive protein 
This study demonstrated that in the DHB area, current testing of CRP alongside 
serum ferritin relies on individual laboratory practices. According to the Laboratory 
Test Schedule (DHBSS, 2013) midwives are able to request CRP, but none of the study 
midwives requested CRP alongside serum ferritin. Of the 385 ferritin tests 
undertaken, only 14% were tested with CRP, and 94.4% of these were tested in the 
DHB laboratory. Of the 326 (84.7%) serum ferritin tests analysed in the private 
laboratory, 99.1% (n=323) were not tested with CRP to adjust for inflammation. As a 
result, a large and unknown proportion of women may have had false normal or high 
ferritin results, potentially misleading midwives with the appearance of a normal iron 
store result.   
Studies show that serum ferritin unadjusted for inflammation is associated with a 
14% (Thurnham et al., 2010) to 17.2% (Nel et al., 2015) underestimation of iron 
deficiency. In New Zealand, Midwifery: preparation for practice acknowledges the 
value of checking CRP with ferritin (Hunter & Gunn, 2015), but no practice 
recommendations are made. Anecdotally midwives in New Zealand do not appear to 
understand the significance of CRP testing with serum ferritin, or how to interpret 
the results.  
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Prescribing in relation to iron status in pregnancy 
There was a significant decline in iron status of women in the study from booking to 
late pregnancy. Low iron status included anaemia (with unknown ferritin levels), IDA, 
NAID, absent iron stores and possible anaemia of inflammation. The largest decline 
in iron status was from the first to second trimester, most likely due to normal 
physiological haemodilution. However, despite midwives prescribing iron for 48.7% 
of second trimester women, and recommending over the counter iron for 16.9%, 
47.1%  of women still had low iron status, and 18.0% had unknown iron status as 
they approached birth.  
The reasons why many women in late pregnancy had low iron status were not clear, 
but maybe due to many factors or a combination of factors, including: the normal 
increased demand for iron in late pregnancy, poor dietary habits, other risk factors 
(e.g. short time interval between births, multiple pregnancy, multi-parity, poor socio-
economic status), midwives’ under-recognition of low iron status, delay in 
management, under-prescribing, or unnecessary prescribing, or women’s non-
compliance with iron supplementation.  
Studies show that compliance of oral iron supplements is low, often around 50% in 
clinical trials (NBA, 2015), and likely to be less in real life. It is recommended that all 
pregnant women should have good dietary advice including discussion on inhibiters 
(e.g. tannins) and promoters (e.g. vitamin C) of iron absorption (Hunter & Gunn, 
2015; Pavord et al., 2012). However midwives’ documented dietary advice, including 
how to maximise iron absorption from supplements and minimise side effects, was 
limited with only 10.1%, 13.2% and 3.2% of women receiving documented advice 
from the first to third trimesters, respectively. 
The overall proportion of women receiving iron prescriptions for each trimester 
(4.8%, 48.7%, and 26.5%) exceeded iron prescriptions observed (8.5%, 19.0% and 
14.5%) in Barroso et al.’s (2011) study. Still, more women in this study had low iron 
status, than were prescribed or recommended OTC oral iron, throughout pregnancy. 
Midwives did not prescribe or recommend iron for 47.1% (8/17) of women with 
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recognised low iron status in the first trimester, 23.6% (33/140) in the second 
trimester, and 51.7% (46/89) in the third trimester.  
The study demonstrated a very wide range of practice with likely under-recognition 
of low iron status, and under or over prescribing. Midwives prescribed unnecessarily 
for a few women with unknown iron status (n=4), or for women who were either 
non-anaemic (ferritin unknown), or who were iron sufficient during pregnancy 
(n=21). It could not be determined whether midwives prescribed based on 
haemoglobin or ferritin results, or both; or if midwives based iron prescriptions on 
reported symptoms, and/or their clinical experience. However, the ranges of 
haemoglobin and serum ferritin where iron was prescribed were wide, from 106-141 
g/L and 13-36 µg/L (respectively) in the first, 95-133 g/L and 3-67 µg/L in the second, 
and 84-138 g/L and 6-90 µg/L in the third trimester. 
In the UK, clinicians have expressed concern about raising haemoglobin levels in 
pregnancy too high, with iron supplementation (Daru et al., 2015), due to potential 
risks of increased maternal blood viscosity, hypertension and decreased placental 
perfusion (Pena-Rosas et al., 2012). In New Zealand, the Ministry of Health (2006) 
recommends prescribing iron only when anaemia is diagnosed. Some midwives in 
this study prescribed iron with an Hb of >130g/L for 1.1%, 1.6% and 2.6% of first, 
second and third trimester women. All of these women had a degree of 
haemoconcentration (Hct ≥0.38 L/L), and were normocytic (MCV >80 fL); although 
72.7% were iron deficient or with absent iron stores. These findings suggest that 
midwives may not recognise the clinical significance of interpreting Hb with other red 
cell indices such as MCV and haematocrit, rather than in isolation. It is recommended 
that NZ midwives assess the CBC and serum ferritin two to four weeks after 
commencing oral iron therapy to avoid risks of iron overload and ensure correct 
diagnosis of iron deficiency or IDA (Hunter & Gunn, 2015). This was inconsistently 
undertaken in the study. 
Because of a lack of CRP testing in the study, some results of iron status were 
interpreted cautiously, but considered clinically significant. The seven anaemic 
antenatal women with normal, or high serum ferritin ≥ 20 µg/L levels, and no CRP to 
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adjust for inflammation, were suggestive of functional iron deficiency (anaemia of 
inflammation or chronic disease), or thalassaemia. Five of these women (71.4%) 
were prescribed oral iron, which is recommended only if there is evidence of 
microcytic iron deficiency (MCV<80 fL) (Thomas et al., 2013), yet all five women had 
MCV values ≥80 fL.  
Midwives’ management of possible anaemia of inflammation implied a lack of 
practitioner understanding of current evidence, and knowledge of hepcidin-mediated 
iron metabolism and sequestering, in the presence of inflammation. The blood test 
results of one case highlighted the clinically significant challenge of interpreting iron 
status without a concurrent measure of inflammation: Hb 98 g/L, Hct 0.30 L/L, MCV 
94 fL, SF 41 µg/L, and no CRP.  Anaemia of chronic disease  is more challenging to 
treat than iron deficiency, and should begin with treatment of the underlying cause 
of infection/inflammation once confirmed (Friedman et al., 2012; Koenig et al., 
2014). The use of iron in ACD is also controversial because of poor intestinal 
absorption, and it may increase growth of microorganisms and the risk of bacteremia 
(Friedman et al., 2012). Furthermore, women may have both IDA and ACD (Friedman 
et al., 2012), requiring a very considered interpretation of laboratory tests, and 
treatment approach. 
Chi-square statistical analysis of the association between midwives years in practice, 
annual caseloads, and prescribing of iron showed no statistical association, although 
there was some small-medium evidence of effect. There appeared to be an inverse 
relationship between prescribing and recommending OTC iron. For example, in the 
second trimester midwives with 31-40 years practice gave more dietary advice and 
prescribed more iron, but recommended OTC iron less. Similarly, midwives with 
annual caseloads >50 prescribed more but recommended less OTC iron in the second 
trimester. It is unclear why midwives with more experience and higher caseloads 
may be  more pro-active and risk-averse in their management of maternal iron 
status.  This  is a question that could be posed in future research.    
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Limited testing and management of postnatal iron status 
Although midwifery educators in New Zealand acknowledge that postpartum iron 
deficit and IDA is undertreated, resulting in poorer outcomes for women (Hunter & 
Gunn, 2015), there are no clear recommendations on how midwives should manage 
iron status appropriately. In this study midwives management of postpartum iron 
status was infrequent and inconsistent. Only 10.6% of women had documented 
evidence of prescribed oral iron intake, and 0.5% had evidence of over the counter 
iron supplementation. Despite the high proportion (65.1%) of third trimester women 
with low or unknown iron status, and 20.1% with EBL>500mls at birth, only 22.8% of 
women had haemoglobin tested in the early postpartum period. Yet it is well known 
that the development of postpartum anaemia is a reflection of pre-partum anaemia 
as well as the magnitude of blood loss (Milman, 2012a). 
Peri-partum anaemia and blood loss are strongly associated with 20% of global 
maternal mortality (Pena-Rosas et al., 2012). In New Zealand blood loss >1999mls is 
the leading cause of preventable severe acute maternal morbidity (SAMM) (Lawton 
et al., 2014). Just over 20% of the women in this study had an estimated blood loss 
>500mls. When comparing the proportion of women with excessive blood loss, 
defined as >1000mls (MOH, 2011), fewer women in the study (0.5%) lost 1000-
1500mls, compared to 3.6% at the local DHB for all births in 2014. A slightly larger 
proportion (2.7%) of women in the study had an EBL > 1500mls, compared to 2.1% in 
the DHB in 2014. The study incidence of blood transfusion was small (0.5%), less than 
2.4% in the local tertiary level hospital, and not associated with any SAMM.  
None of the study women were given IV iron in the postnatal period, although two 
women had severe anaemia (Hb <85g/L) even 10 days after birth. Although these 
women were prescribed oral iron, IV iron may have been underutilised then as a 
more effective and appropriate treatment than oral iron for moderate-severe 
postpartum anaemia (Breymann et al., 2007; Breymann et al., 2010; McMahon, 
2010; Van Wyck et al., 2007). Barrosso et al. (2011) also found that IV iron was 
underutilised despite there being guidelines for use. One explanation in this study is 
that in 2013, iron polymaltose was in use but with limited utilisation due to the five 
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hour infusion time. Anecdotally, more (third generation) IV iron is being used now, 
with the advantage of carboxymaltose’s total dose and rapid infusion time, especially 
in the postpartum period. With over three quarters of women with unknown iron 
status in the postpartum period, an unknown number of women may have 
benefitted from IV iron, especially since many had low iron status before birth. 
The overall proportion of women with Hb tested around the time of birth (22.8%) 
was small, and less than 30.0% cited in a UK study on the   management of anaemia 
(Barroso et al., 2011). It was concerning that almost half (48.8%, n=21) of the study 
women who had Hb tested were anaemic, yet only 33.3% (n=7) of these women had 
evidence of prescribed or recommended oral iron intake and follow up from their 
midwives. Although the study midwives did test postpartum Hb for women who had 
both low iron status in the third trimester, and EBL >500mls, a considerable 31.3% 
did not have their iron status checked at all.  
Very few women had follow up for iron status after the early postpartum period. Of 
particular concern was the   one woman with unknown iron status in late pregnancy, 
with a postpartum haemorrhage of 3000 mls, who was prescribed oral iron for 
anaemia after birth with Hb 90g/L, but did not have subsequent testing or follow-up 
for iron status. These findings reflect Barroso et al.’s (2011) study that identified no 
consistent policy for postnatal screening, discrepant practice, and the suggestion of 
uncertainty amongst health professionals regarding appropriate management. 
In the study by Daru et al. (2015), ‘Hb levels prior to birth’ was identified as the most 
important outcome measure for research in to iron supplementation, in the opinion 
of 55.9% midwives, obstetricians and anaesthetists. This is not reflected in this study, 
where a high proportion of poor/unknown iron status in late pregnancy was a 
preventable clinical factor for postpartum anaemia, related primarily to inactions by 
the health care providers. 
Physiologically, postpartum intravascular fluid volumes and iron levels revert to pre-
pregnant steady states over four to six weeks (Milman, 2012b). However, the effects 
of maternal postpartum anaemia and iron deficiency are often underestimated, 
despite the evidence of adverse outcomes for women and babies (Bodnar et al., 
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2005; Milman, 2011). These outcomes of fatigue, lethargy, irritability, poor wound 
healing, decreased lactation, increased risk of postnatal depression, and poor 
maternal-infant bonding will be familiar to many midwives and other health 
professionals. Yet, the findings from this study suggest that these (often) subjective, 
yet significant costs to women may be underestimated by LMC midwives in New 
Zealand.  The importance of postpartum iron status appears to also be 
underestimated in a UK study (Daru et al., 2015) with only 17.2% and 15.2% of 
midwives, obstetricians and anaesthetists considering ‘postpartum Hb’ and ‘maternal 
quality of life’ as important outcome measures. 
BMI, unconfirmed iron sufficiency, and subsequent low iron status 
The 44.1% proportion of high BMI women (>25 kg/m²) in the study was less than the 
50.6% of high BMI women in the population of 62,321 women giving birth in New 
Zealand in 2012 (MOH, 2015) (Table 3). This proportion is nonetheless high, and 
reflects the global obesity epidemic. Obesity is a pro-inflammatory state and 
associated with lower iron status, due to hepcidin mediated sequestering and down-
regulation of iron uptake, (Gartner et al., 2013; Koenig et al., 2014).  
The iron status of women who had ferritin tested at booking without CRP (n=77), was 
analysed in relation to BMI, because without concurrent measures of CRP to indicate 
inflammation, serum ferritin levels can appear misleadingly normal or high (Nel et al, 
2015; Pasricha et al., 2013; Thurnham et al., 2010). The study found that in the first 
trimester, the proportion of obese women (BMI ≥ 30) who appeared to be iron 
sufficient, but had low iron status subsequently, was greater than women with lower 
BMIs. The drop in second trimester iron status was greatest for the women with BMI 
≥ 30 (n=9) with serum ferritin levels up to 50µg/L at booking. (Serum ferritin <50µg/L 
was the study parameter for iron deficiency in the presence of inflammation.) Of 
these women, 77.8% appeared iron sufficient in the first trimester, but none were 
iron sufficient in the second trimester.  
Although the study size was small, there was a statistically significant association 
(p=.05) between third trimester ferritin levels of women with BMI <25 (median SF 18 
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µg/L), and BMI ≥25 (median SF 14 µg/L). This result may be clinically significant. 
Women with higher BMIs may have lower iron status in pregnancy because the pro-
inflammatory state may lead to functional iron deficiencies, and/or masking of true 
iron deficiencies, resulting in a lack of recognition and under-treatment by health 
professionals.  
These observational findings reflect results in other studies where obesity is 
statistically associated with low iron status in non-pregnant populations (Gartner et 
al., 2013; Moschonis et al., 2012; Nel et al., 2015; Thurnham et al., 2010). Although 
reviews (Friedman et al., 2012; Koenig et al., 2014, Wang et al., 2010) state obesity in 
pregnancy is associated with low iron status, there are no published clinical trials to 
date which demonstrate this. Mor et al. (2011) propose that the implantation of 
pregnancy causes maternal inflammation. Theoretically this may exacerbate the 
possible obesity related inflammation observed in this study, especially in the first 
trimester. 
Study strengths and limitations 
The study population  
The study population of 21 midwives is comparable to midwives with annual 
practicing certificates in 2012 (MCNZ, 2012), although Maori midwives were under-
represented in the study. LMC midwives who did not network via local NZCOM 
meetings or newsletters, or who were not conveniently accessible to the researcher 
in the tertiary level birthing unit, or rural midwives, did not participate in the study. 
The small accessible study populations of midwives and women were not necessarily 
generalisable to New Zealand LMC midwives and birthing women, but they were well 
defined and overall representative groups.  
In terms of age, gestation at birth and parity, the cohort of 189 women was 
representative of women giving birth in New Zealand. Maori women were under-
represented however, compared to the population of birthing women (MOH, 2015). 
Fewer women smoked in the study, and although the proportion of overweight and 
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obese women was high, it was less than the national birthing population (MOH, 
2015).  
Study strengths 
Polit and Beck (2008) describe generalisability as an almost impossible ideal that 
researchers’ must strive for. The validity, integrity and applicability of this study, was 
enhanced by the representativeness of the sample, the vigorous research methods, 
no missing data, and the extensive literature review.  
The extensive literature review and synthesis of the evidence and meta-analyses are 
cornerstones of evidence-based practice (Polit & Beck, 2010). However the literature 
review outlined the limitations of meta-analyses, where data on iron status and 
supplementation could not be pooled due to heterogeneity of study populations, 
parameters, interventions and outcome measures. From a New Zealand perspective 
this study highlighted that ‘no evidence of an effect’ is distinct from ‘evidence of no 
effect’ (Pasricha, 2010). 
The external validity of this study was enhanced by being immersed in, and knowing 
the data very well. There was no missing data, as all tests not undertaken were 
accounted for in terms of the reasons the tests were not done. As researcher I 
collected, inputted (twice) and analysed the data, and was able to scrutinize the data 
to look within cases (Appendices D-F), as well as having the overview of the 
aggregated data. This enabled the recognition of extreme cases, and sub-groups. 
Immersion in the data in this way is known as “qualitizing of quantitative data” (Polit 
& Beck, 2010, p. 1456).   
Study limitations 
A significant study limitation was the documentation of midwives practice. Data on 
midwives’ management of iron status relied on documentation in the primary care 
notes. Midwives may not have documented all strategies to improve women’s iron 
status therefore these strategies may have been underestimated in the study. The 
study also did not distinguish who ordered the first trimester blood tests, with many 
women booking with LMCs after the initial antenatal blood tests were requested by 
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general practitioner doctors. This reflects the complexity of primary care 
arrangements in New Zealand (MOH, 2015). 
The study described midwives practice, but the reasons for poor iron status are 
multi-factorial and complex, including the role of women in improving their own 
health and well being. This was not investigated in this study as was any exploration 
of the partnership between women and midwives in working together to improve 
maternal iron status.   
Analysis of data was mostly limited to descriptive statistics because the study sample 
size was small. Inferential statistical tests that were undertaken were underpowered, 
but still the findings have implications in informing further research. Although there 
was no statistical association between testing or not testing serum ferritin at 
booking, and third trimester ferritin levels, other variables such as iron 
supplementation were not controlled for. This was a study limitation. 
Implications for education, practice and research 
Implications for education  
 This study suggests similar findings to Daru et al.’s (2015) survey, that maternity 
health care professionals have a lack of understanding of the natural history of 
non-anaemic iron deficiency (NAID) and iron deficiency anaemia (IDA). This lack 
of understanding is complicated by recent evidence on the effects of 
inflammation on iron status. 
 Consistent, evidence based education is required for student midwives, practising 
midwives and other primary health care providers (e.g. general practitioners) to 
fill the gaps between knowledge and practice, regarding: 
o  Recognition of low iron status. This includes education on the timing of 
tests for iron stores, the importance of concurrent CRP testing with 
serum ferritin, the interpretation of all lab results (including MCV and 
Hct), especially in the presence of inflammation.  
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o Alternative approaches to oral iron prophylaxis and treatment, such as 
low dose iron started early in pregnancy, or intermittent dosing of higher 
dose oral iron, are likely to improve women’s compliance by reducing 
side effects, if advice on improving absorption is included.    
Implications for primary care midwifery practice 
 A clear national midwifery or multi-disciplinary evidence-based guideline for the 
management of maternal iron status should be developed. The aim of the 
guideline would be for midwives and primary health care providers to provide 
consistent care to improve outcomes for mothers and babies, and reduce adverse 
outcomes associated with anaemia and iron deficiency, especially around the 
time of birth and postpartum. The current lack of a national, or even local 
guideline, reflects the problematic lack of guidelines in many countries (Milman, 
2012b), that leads to discrepant practice and uncertainty by health professionals 
(Barosso et al., 2011), as indicated in this study.  
 Primary maternity care providers should undertake first trimester testing of 
serum ferritin with CRP, as well as haemoglobin, either for all women, or 
alternatively as a risk-based approach, to maximise treatment time with oral iron.  
 Midwives and primary maternity care providers should identify and pro-actively 
manage women at high risk of low iron status in pregnancy: short time interval 
between births (≤ 12 months), multiparity, multiple pregnancy, obesity, 
teenagers, smokers, poor diet, poor SES, certain ethnicities (e.g. Indian) including 
screening for haemoglobinopathies (in high risk ethnicities), chronic 
inflammation, and poor socio-economic status. 
 More emphasis should be placed by midwives and primary maternity care 
providers on prevention and treatment of postpartum anaemia and iron 
deficiency, including follow up of at risk women with low iron status in 
pregnancy, or where there has been significant blood loss > 1000mls, as per the 
revised Dutch midwives guideline (Beentje & Jans, 2012). 
 Development of consistent laboratory practices around concurrent testing of CRP 
alongside serum ferritin to allow for adjustment of the threshold for iron 
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deficiency, in the presence of inflammation. For example, serum ferritin and CRP 
ought to be printed on the ‘midwife only’ laboratory request forms. 
Recommendations for future research 
This was the first such study on management of maternal anaemia in New Zealand. 
As a result of this study, and in view of the global evidence and gaps in knowledge, 
there are multiple recommendations for future research to be undertaken in New 
Zealand: 
 A large scale study to determine the prevalence of maternal anaemia and iron 
deficiency in NZ; to determine the optimal statistical and functional cut-offs for 
defining anaemia in this population, as described by Pasricha et al. (2013).  
 A larger replication of this study on midwives management of maternal iron 
status, in a different geographical area with greater ethnic representation of 
Maori in particular, to verify the findings in this study.  
 A multi-disciplinary study of New Zealand clinicians’ opinions and priorities 
towards different levels of maternal anaemia and iron deficiency, similar to Daru 
et al. (2015), although from a sociological perspective to explore different 
professional frameworks and philosophies that might affect management.  
 A large scale intervention or observational study (e.g. oral vs. IV iron, for 
moderate-severe postpartum anaemia) including functional maternal outcome 
measures (i.e. quality and duration of breastfeeding, quality of life, physical and 
psychological well-being), as well as laboratory indices.  
Conclusion 
The aim of this research was to describe New Zealand LMC midwives management of 
maternal anaemia and iron deficiency, by retrospectively gathering clinical data from 
women in their care in 2013. This study was a snapshot of 21 midwives’ management 
included testing, diagnosis, dietary advice, recommending or prescribing iron in 
relation to maternal iron status and gestation. This research begins to fill the gap 
between knowledge and practice about midwives primary care management of 
anaemia and iron deficiency in pregnancy and postpartum, as little is known about 
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actual practice in New Zealand, or overseas. The specific aims of this research were 
met. This research also adds to the small international body of midwifery research, 
mostly from midwives in the Netherlands, from a unique New Zealand perspective.  
The main conclusion is that this research suggests a need for a comprehensive 
evidence-based midwifery, or multi-disciplinary guideline, on the primary-care 
management of maternal iron status. Although midwives consistently tested 
haemoglobin levels, testing of serum ferritin was inconsistent especially in the first 
trimester when almost half of the woman did not have a measure of iron stores. 
General practitioners may also have requested some of the antenatal blood tests on 
confirmation of pregnancy. Without a measure of iron stores, midwives could not 
discern where women sat on the spectrum from iron sufficiency to non-anaemic iron 
deficiency, before end-stage iron deficiency anaemia.  
Despite international recommendations for either routine, or a risk-based approach 
to serum ferritin testing, measurement of maternal iron stores appears to be ad hoc 
in New Zealand. However the literature suggests that this is a global issue. Clinical 
guidance on the management of maternal iron deficiency should address concurrent 
testing of serum ferritin with C-reactive protein; to avoid misleading false-positive 
results, and to enable accurate interpretation of iron stores, in the presence of acute 
or chronic infection or inflammation.  This study indicated that women with high 
BMIs may have lower iron stores possibly due to the pro-inflammatory state, 
although the study was small and the results should be interpreted cautiously. Given 
the worldwide obesity epidemic, more research is required to examine the 
association between high BMI, and low maternal iron status in New Zealand. 
There was a very wide range of midwives’ practice in prescribing iron, with some 
midwives not prescribing for low iron status, and some midwives over-prescribing for 
unknown iron status or unknown iron stores. Despite midwives prescribing iron for 
almost half of the second trimester women, over half still had low iron status or 
unknown iron status as they approached birth. This potentially had implications for 
women in terms of lowered tolerance to blood loss, and increased likelihood of blood 
transfusion and IV iron, although this was not evident in the study.  
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Low iron status in the postnatal period is associated with fatigue and lethargy, 
impaired maternal-infant interactions, poor breastfeeding and postnatal depression. 
Yet midwives only tested haemoglobin levels of under a quarter of postpartum 
women, and only a tenth of women had evidence of postnatal iron supplementation. 
These results indicate a short-fall in practice, with potential implications for women. 
Given the insidious nature of adverse effects related to anaemia and iron deficiency, 
research is required in New Zealand on maternal outcomes, especially in the 
postpartum period 
Although this study was small, and even without further research, these results point 
to the second main conclusion that midwives need more education on the 
complexities of maternal anaemia and iron deficiency. The line between normal 
physiological anaemia of pregnancy, and anaemia associated with pathology remains 
blurred. Like Barroso et al.’s (2011) UK study, the study’s results indicate that 
midwives in New Zealand, may not understand the natural progression from iron 
deficiency to iron deficiency anaemia. However with improved education, there is 
sufficient knowledge and evidence so midwives can interpret other red cell indices 
(i.e. MCV, MCH and Hct) as well as haemoglobin, serum ferritin and CRP, to more 
accurately recognise and diagnose anaemia and iron deficiency in pregnancy and in 
the postpartum period.    
Finally, until a large population and prevalence study is undertaken in New Zealand 
on haemoglobin parameters throughout pregnancy, the ‘normal’ haemoglobin 
parameters for our population of birthing women will remain unclear. Until then 
midwives walk a fine line between ‘abnormalising’ normal physiological anaemia of 
pregnancy, and ‘normalising’ low maternal iron status.   
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